<link rel="stylesheet" href="https://bootswatch.com/4/flatly/bootstrap.min.css"><link rel="stylesheet" href="style.css"><script src="https://ajax.googleapis.com/ajax/libs/jquery/3.5.1/jquery.min.js"></script>
<script src="https://cdnjs.cloudflare.com/ajax/libs/popper.js/1.16.0/umd/popper.min.js"></script>
<script src="https://maxcdn.bootstrapcdn.com/bootstrap/4.5.2/js/bootstrap.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1">
<div class="header"><div class="top_text"><p id="home">02/14/23</p><p class="summary"><strong> <em>Summary: New data in 12 studies; Expedited timeline in 12 studies; 26 new studies; 1 new IND acceptance; 1 new FDA approval.</em> </strong></p></div><div id="images" class="logos"><img src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAcAAAABwCAMAAAC+RlCAAAAA5FBMVEX///9QW3aJ3fR7maq+1jpHU3BOWXVLVnJEUG76+vvW2d6qrrl4gJSHrcH29vhGUm9jbITCxc6FjJ7Z5OqfpbOUmqqZuMlrc4jw8fM+S2qRs8Xp7/NaZH6lwNB0lKbGytG80Nvc5uy71CyuxtS6ztrD7fmOlabQ3eWsxdOQ3/XH1+H9/vi61Cfh7K3n+P2q5veRqrjX8/uou8aEoLD0+OC0uMOj5Pbj9vz6/PDD2Uzu9M/O8Pp7g5bn8Lu36vigtcHI3FzQ4XfY5pDT44XM3mrj7bPd6Z32+ebV5Yrr8sjx9tfR4XthxIevAAAa60lEQVR4nO1da1vbuBJOAnbiQG6EJI6dQBwCDmmgFAqUhQK9bNm2////HGlGsiVZMnZwlj57mA8tdnR/NaOZ0UgulXJR0+8uDh7OLjYoXZydz8Kgma+EN3o18sNzAtze3t5GTPTh4rz7BuIfT+7ibEOCTkLx4iF8w/BPJv98QwVP5ETy997FgfvarXwjA4VnMu9RvM4OFmHgNptN1/eD7uKcJNl78F+7pW+kofBCQW/jPNQxm7942DtbGUKnCfSCdr6QsP6sUuS1W5ud/DMZvo2HrmNM7IQPDysK0q3yiNCduew1k7NN6x/ZQbbkd5C6vt42FUDOTFr79i5mMj7vKElv/PPuSjVt1Wzbrm6/HoCDKmmAPcwI4DZNXf3jAQwuZPjCeHyffp58/fbl++Pj4/ffP05+fooz+cEqKGxZ5XL5NQHctkkDypkBpKntPx3AhWzxLfj7j3//3lwup4Q2KZH/l8ubf/5+4r+/AfhHUPNBWv1mbGyfTm6WDDmJCIqPf39KLzKF3gAsmlxRe4nUy19fNjXgRSDefH1KL9VIbwAWTL64/O0x9vvri473JAg3f39cqb7XB7D6nwLQl7wuuPp9+r18Bj4UpV/fPVO4jl4bwGZOLfQPB1DEb+8CxedJFvgQwp/5a3xtAEtNFyhj6j8cQP9CxA8cDk+PSwkjqnkKmqhMy2+5mfDVAcxHfzaATVF/Qfz+uomAmi43H798Pfn788+/fn7+8fXLzWaSNaePeVfCNwALJAk/ECqfOUTTzccfv54k/vr09Pnbo8qI05tf+ep8A7A4OhftP1jUPy+Z4Lw5MXDWz4R+Ov0rV6VvABZGXdF+COmbkyWKzu9pmHz6oUC4/Jyn1jcAiyJXVGAm9M0JALP88tyy9u6HbORP8yD4BmBRJAjQvQf6Ata/6WMWifj0TWZChuBphqxvABZEogDdoAroL8DvR0a74KfEhFN0rJ1+eD7jG4Avp2s6ehfKAvjuhiKRXaX89Cgi+IgvD5/nwTcAX0zAJzNVgBKhOH3MtcnwVbD4p//AK+fq2VxvAL6YYJBFAUo9aMSAmH7JuUl0IiKIS+fh4XOZVgGwWb/cPQLavayvNUAl2Kc19bY6ddbAwgB06/tbPejAM148d/+yh53duqzrhunwlvwzERhwRp4/3WxOf+d2i4kIPkJup/IcMvkBDI7a1ZpVBbJaVvtIHU5/sE1osK/LXMffBNf1Pn0z2NWkdbcG5VqL1GRZNavdgzwygJeQ99LY1OYOSTDY9nnqHnvv1HukDy3oQKu9o20pJty/G7VaUWft9m4C7tMKTSesgBs0ydfp9IuxVDP9iNfB6Q948/79M1nyAuge2ZYNW3iM7Gp1R4mJO6JxNtZAw5vONslst3aEV52h+ob/0K5V41psq7zlqADWa1Xbro6MjYXfrQF72q3VMKO/Q9/HHahtG1i6fteqin0t262yCuH7e/JPKDDgOXn+OJ3erLI3VPpH0GRAAF9XntFEcwJYL1vlBFVr8hx2YeBrGs7oDGHzTwS8U6MlJAB0t4e2Uk2t7SoA4mZizShRdy2xHbuW3ab/X9pVpeTqcEuXvTNUE1II29J0va5QRfFBUEEpwN+nNysGSXyJfd9f4cXxcTo2+QC8jEeV7uJFD8oAbLVoglFC3LhtmsOS5KUewGBUFevBmqrl+p28Bl62EuUJ5NDq7BEfcAJniyTdHarl0g5oREBvKPeVpbWH4oS5oiqMr6igT8tVdvaAPt3ELjXg4dvKbWqGXADu1zjLVUcDQiObSTm71hHTNRGonpp/VwOsFkCf4VetldsDqMmyKBjtUVkC0K1BgYbm1qn8i4um/GjVL6G+mi2WS6iVbGzUWRs7a3GRXouX8GsYXtGGoDbg1+XXtGFMpb9iFjyhz6eV49T0eQAMRjbOx52O60I8tbvfK0Ov7LIkxwCVclXZZvchf0sWrVoAB1iotc0qarr+VtsqMyYQtNA7mnBokKE9kKCReKcA2iNtueWkxN9nU6jcq/POdnaYJGhHU/AKJOiZoMKQx3fTzdWjzIj+IyuiV+ksmAfAHQubL41XgEEt1YH4EhcnFZYjmt8eyHXpAATJWK6OJLZ2dy0uxOIGdNJkKKQdRbrULlu+7bJaLry2ZImPk9WSFbQ6SoYar/C0AhJUWAGpCvM5336CQu8iAJfgxzlMZ8EcANYZUmraI2C3ljQqddRWZKgh3VBR2jUAOsjobfXAR2eYALBZA8mqNUbrLVmOcwATgd1YrjwNYBmPkYrqayNjsqbdV6gOKhqBND7+y6OuOZnp72gT+Bt9PK1UrlNS5wAQuEo3WCDH7LL07qiaYEvkyjslswbArZqy0nBiEIiG/I5ZhvaUn1huTeItFC0iC+Kbo0RSFzjTwh+cCij5ggSlcRRPm/m2ZBP0yFkQVFnnGGaJibID6KKg0Vi9gSYy0AV9VdRtUANK6PxJAJn8TWgVZP6zRVgoY98ypEU+RsMBCQFMqlYlJi/FxqIEsTRemo6gN91WwFEirIBUB/35qKkhD8UsCDuJ7yuVlMTZAezoVjAkYLeWbErAcAn86gxs7ZxOAujDfGjpTszh4igCCAqv3daMNEwYS2gU40BdAOOlpTRi1zgvwBRi52uuEksgdaP9s6oJwSkyJdAbc1hJU2OyAwh9svQWbyupiKCsqUXpQX3XzOkkgPWawjoxBQkRyiaPRoaCBG0JcOGUGiRTUv9EWZoGzEOg9bFhuVRnJasTdXQJR1n2aHX5faAqRYrod/r0AasxUHYAYaWTVRVOPhU49rb88hJlDRsUtOFbSX0xCSBaarrZz0qRAAS4TYuVNA2Qq5IpS9xwjUx+9jzU+rkvI84mrEE3Cw6EnQiS4+OJLlcueuJObTAkyDxJcWlnBxBEoN5t1QQAR3IhDhhzbLkv9VoGDSgJYAqrO8ndiObAlowFqVxpvmG5epNjIJfbRHVHm3Q/avAVyjbBj3ZGmvFr1WMqMb37zrUYuggSLSbFIZodwJEZwJIOQOypjcpkANpHTcO/SQDB/m5pAdRtJyEuCWlH1VPZ6ZMyMRBAK/bwDM0A1nmDT9nACjsRZ+Tx4wuMeE58V2IKluBVmgxdI4Co4qPdgH/qqnkxgIHWmQpeH/lt0QCStQn8MMpOxMsZkHAxk6HoESAAmm35dQLILPc618q1mV8MIKq36mBDsbIWUjSA92xtUgAshDgHwnr6ns0ULa0TQISCum60njWkFwOIThNVOtMaFeuiaACJBKUGmqtsxhdC30U7gs4U4yK4VgCbFq58+zgeWqXu5QDCaCuzwwebRdZk1wSguJc00eZYgdgiiHuCFECjM2atADIfVduwuwT0cgCRv2ULEyxzpbEFA0i1+7UByA7FoDeUmCsVY3jaegFEewp2geyyPnqoAAARLUmGgm2heI0KBvBDJSlCJ9ocK9BPlQONWkxOAO3tHR1VDQCyjcGyGZEiAHRttQgAQMUqN4BVbV+3WW23DMCmAOCBvo/56ddUWQONWkxOAGkMk4bKJgBRvNFf24YqCgCQbYcIzlPwlgwVb2puAMvavuKe7g4INvAyr0ML/SgqMe+LBNBMegDrjAX1fsVSMQDuUz1U3OkHHVT1euYH0EykwcAX6zIjPop2IABoUkNzc6CRqmVtIUfVsoqQREUACC7SauyL9cFdqUbF5QfQ3Flrh5rXyBfKblIh9MQ4EHYWrwoE0G6bSbvTxLYBW8bo2yIAZLMk2nnAqDhVacoNYFpnezisdK9cdKUVdUSBcSAcjqG+UPOOUm4tlN1PqSNttjtcIPXolgoCEAR1FJYEm0GJrf9VtFBzX51SNKzCwcCLoi7f/cWc2dQv51QKBTBnS/bZaqIL8wUqBEDckuB7RwGNfmolFt2CzAhOACDdThJDYoq6epeZEY/0bzA4K6ZTLmsGkBmC2jBfpEIAZHt99fhBs0m/DgDVuPowNUt2QkMe7fgPrwkgBndRMjhiCgIwEA0/ioamunUAqIsqLILQlYZK6OErAohxFSwcVi9eigGwJMjQOuz9G7i0OABBiVGDms5Ss2QnPCKBJ63fv+Ia2MMwFO680FFBAAKrY2AcSFDN2ai1AKgcbdkoaBHEsKbvNKICldDXATBg24C6MF9OBQEoOM9oQ3U4FQzg+0iyiVFNi9Q8WenTMvbDoA5TlB1oANCgoNzxbUAM893WpSkIQCZDHRZAXtNwQkEA8hv2EUAa6+AXLkNRh1lCcMbtvwGgPTja2k8EXNajoBg/EeYbUVEARhtIFCftXCkIwMvRdo8ezEbd4lg53LJXiCUI5zynEFTIJkpRvlDTdpJdtYaqK02MsO4pYb4xFQUgBI7TmDO6eaW1OosCsFattoY7ImdMCt5ReoeOUAgQZkvgugEsa5zZuJVUgynpluUwXyVVAQCCvLYHDqy3Q51XqDAAscHXFa0MvdBmykd4R94N/I1WYBH7gdtmAKG/6oYRC+VlA4ZhvppN3ZfGhUYETtda3ShB8wDYHD0H4C5XLuAE9EOxtjwYEeyQL5OgBezI75ijzUHbVEdNPhxhOhqhi8xuRZJXJU1ktvxb9QiseG0rcwDoYGS21ruLx7q3ItlG9Xvxnq2XqzG4m/uID1hJETExaWcjNOHtEFYkhEZjmG/Svk4CiCm1ZxgCKNRwT8wRyNCRNk77mQ4kAEy5PQE0aqqPHQvCTVRjVvuEjkBw8x276YettEVEpXXMKXei8x7KOzH5nfZ4oAZAPMemPZ20lTidJBAovSM9n1PKAWBKGH4sBO4rsXoRiiz4wj2lp9gNyt0FhcSFuhgdr5FOdTj7LEcwJG13gzWvOeC5Yzof6CTPBwoUOc4t/e95AMTGVjWczG7gKEXqBS5PictCV6fvU362M7LiK+a7RnKc0MXIk6R4wlMsyl0Rg2QoL8iexMagBsCO9ix2iSFrBDA6wGvYe8wDYKlq8P6xlYHyJh/cBAu+zJ8GO0lLdsbwvThJtMQAzFJyHX3S2wqCDt59ICsOeI5V9oe4GOarmGi6Sw5QSpVVnLZYfI0JQPTcGe88yAUg+AWSx+Hwog28e4ZrMXjy5KEgPQauqVziPVvcVDHvRTAA7UFn30hxWu0tFXV2S4U0B5qaG30ivVQ2JXQAIgvao0uRldyexS7bMV52h8C3DB8RyQUglqXeUrEv3VLBF0HQMKRPfrzAI0oPd0b3rF2JTK4njJ22WzUjxYPosyWotXPpOkBu56iquyeG8Ypi9eERd2VWa++JwUlh1wa8IifYHVEDD276MQKYvh7kA5DfE1Pt7bM2+Jd3NRRCbKuDL4KoiM7EO89XFqLUhp8+sjO+UQUp14YigGkkDEedxUdUa8Ma/ZIm+Y+tSkP56hXleDUnPGZdlnqnBdAd8RughjZ8s9MaUkWpOnLp1DACCDceGIM38gFY2oo7W6VNGA5bvLOsA05FknDJr0bkp1/gA+VntI+l8vWUC0BiosXBocJVafZQHjTtjT6lyDsqmRL6u9LctiVVhDOfLj1EOzICiCaa6QbTnABGCMp9JTwZJXtfEUWcKwrR1WwJer1BjN+9VLyB8gFYqrdbyRSWom7gjUDJqCIeYyiZEsbbCoW5goNY26bTOqjZJgAdS1sUp7wAljpVzW2FNeGy00jEoRAVNdG9VUJE3z1OyfrH8Ys0mDQJSqaZNn48IquqeDh3y5Y4svQizyNFa9iukYy1hMlOaQd+EnmzQxtQS46602m3xPtCayM29Fs13Z0UUFTiWLxEu7Qm/cWSpTa9/TXheQl2qup9oaMtkcGjIUYhJ366ZYXwmHfEApxG1+RFSm6qBC3tH/WeIVUW+LujanSJba066iXipKHIxEW+QAH+JqyCdXijW7eal9tlq9WyLKtVq7YveR5nt2dQEdABYJRdHVrTkT7Ef/doZ+duO6m+1ndGVtzZxI29sZBDKffwEgTpvfXL+IqLWD4/e+1ybqp3tnp3d3fbR1udvHGi+cjd72zt7u5uXWapxjVfI/ICcvY7u0fbpLc9TWdP40FGX8kLEPy1OV0+/ooeD+Oi027a+i8RdXL9258oF9gEFirpA3R7DzluhD/ZnG7+iB9vhamR5QMu/wFyoqiYf5FiRYM5ZBwJwYus9uDT7+X0e8x+gnr0/8OAcD+v8frldZHAgqhrSAjyr+g+RyebS+kbS+K8SLMh/lPUE6Pr/zU6FYcaYzelzwhG3yFPoZ+by2/SDZVSof8vDAhbTdm88oXSvTjYqO8vJB7knyI30Mcfm7+j6w0VF916VNA/lMCNZj6GuDYSzLUIweBCYsKLhRGEp5OTv6LLDf0Q0t1K+GX4gFnJ9Qmxv5t+Vs3JcVPnRvaCGPlIq37KBzf8uZnmZPJFNtNSZe2AzC8o8JoPMhOeLQxlCfeq+ee4Xsr4Pf/1q1Jz5jUaDW+MEE4aWbdCQi/12++LxiRjQawZYw+oP8/4SXklu3zbTzjOInkmXsoClbkDV/KIY8XhhQzhxnn6Whg+sMVSEslZNJjmuDEOg/CggZ3JAWAjNXonN4D9/oxS3/NWCcy7lO/bOmhkUeCLAdCRh5yZbc5sT4Zw7+LcMGBOeL7HthBPj+XC0j/6ATRjiHUbMGn9blbTRQugM+bXhWUvCKnZH+MfgefpJNtknCrRMIwsemx4WeahBkDngN/1kr0D1/Kgc9dl83xDgpBguHE26fqibGj63dkZec8UnVulpOe+fEUb7LFxI5M2n+zSA9hY9a6bCEBS8ETz+7ifBiDcGRzHQQWNqFtppAEwbkYOOlTGnftO3JksSBHEi7OH89ns4Pz84ezigrzYu5hh106v1HIyrAO+N2F/hY18omttADa1g58OIG4VRUbgxBtr2VihogCUzHnUZdjQNxdnGyqGACMlFKwPIXbMUadB+vciOPleJPMW0OVomJpBAH+7fsCjq1mrHHiOAHT8IHBZAtc7oNEHkN+Jf+Zb2LSawNcOrQBgv6/mJCWO+77DG0CaJgkifu9y9Dzud6PWYZ1CYEicGQB0op+aNG6CNMPcgcQTJ5V3KsfR6uVPzjb2NCCiSA35YNweJ/DLsAAmp3vXox0PZmRtbMBCckD/R96c97FLC5i4HMCgT1I0QArMUZEEpsaCyP/w8xza2V1AcQ2daZsE0B/TtKAdT1jBcxhC2rSGpOpATG/sRmuS5nhMFMx9n7agz/B05zRzH1cLAHDMFdauF/B6aN6A9S/EDrBJvICng4Q0SA5/DGGpGdKFTqGNh0kYFfMhmT+rC2Ysq50IS9AY98OgO27M5v0u/R/SjD0GYEMA0G+QlMGsQYd/MZl5/clsRse2ixI5pD93Jw0QgF2vPybFzXRyNgGgT+YPyenRQe7OJn1vNplBM+aNg24QjkUJjiGnkQSlTZt7rH99bxIEBAVI3vQas2534eF6DwCGfO0nQjqcxR0IsAML6MAMO0BVPehtX22+qj4CSR+hdoNwdv7w8HBOaBYGwhRwNNyX3YXm9hsHgkjgACKzzT1sKa4o474GQLbYsBU0XgMRQAKGgz9PsPvw20yjLyUAnOMCFTRQxkdrYIA6jsOnU4l/YiA+TTFvOKSRAWs6NgwbssBmuih3AECX8aoLi0ncDMaBntgB/rRI6gtaBCvvPzyrh5ze63M+ly8iIqm8ecDr4QBy24L/T9/qAOSIMZGlAsh1JJTUfGHyNUp+AkAPRZszZnOIAzhhJt4iNvU68mV3UJTPdFmeD5OPPXw6APRRiWG8GkICFUC3IXagyZ7cRvJyZT2CleNUDE8PE6tnXvxoU+cekRMl1g0EEB/5iKcAyFb0JlufVADZDHD6MoDJ/idFKHJQAkC3y3wdMYD0y7zVOFoRpp2aDxvts8yTBn2LAHaRV3EtVAHk88CZ0441G3N8CjQqsaNHkNDV/W3So+J8OHxvzJELP9pMsirMmajIByAnEweuDiAnFUBO3QhAt90eDNpxLMUMcJkBRlG+UPLNzAQAHQ+xWcjNkAHkjUl1VBm4ifPi1f394eHt7eHh/f2VETqgVbaQZji5VgCwO5nP5+M1ABhMCM36CQCdBf1hbvKWOZiD9UEF0IfMYwFA0nXolCs3Qwug7zW8idlDc58KS2ZKi0Iz01iAJQeAzrgxp+NcPIAHjTE4R1UAiS5LFNLJ2AQgLx2bogA4gUJlAAGq8VhphhZAMnnG1LwyLWuqL2wVOs6ygyS0iP+BiktuAFFerUGEck1PFaGkJiduhYYW3pi5xZslFcCQtUdcA4m+dEDUklBphh5AQi4xYYybHdfpsjEDXeULoQj6XKNHhTG3EsP0seIBZCZHUgv1ElqoTGOvjwTKiQwg78JMAnDiOYuGozRDAdAR/o12AHT0QjGad/mLVREfIMgLIE/JAGwWASBo7A5X/1QA51IrkkSys9NEMLdkAFFXVjmQdIJJULMWOqYd67Lp7qR5THVelTWxHzSTjziKrDQA58yImggAcoS46yryzHEAJ+zn7AAusEjG2gkADyS7IElhxB1gSSoAskqkNbBU6vc97jqNVGDFDmQzMJQaZaCkWzojZfJ+KsQ8FaXAg56mAci8EU1PXAMxGwEVATzgPkrsq8Ms50kjLGUD0Fkwb8cYR7fL3FbR/ipzLrh9A4DxXu6M/iUDOMMwAr8hA8jrhEysA8wT0+/7WD10pzFmHrX0rySdJrYnMtDx/bNeGx2RgZgvFouZh11TARSBJArnQdhdeHPRmd1tjBdB92A8RuHk973xeBFnJfNi0Q1nuOqnA0gyEupzT7NPcgbdWX+OAJLKx7hbTH2h3UXftOkeYwFQy4a8Sz2jtAsygEKDXNoOwRcaNGgHDphfKCRPQTjz+s9tVl3nhvAwt/Rk1CTYNTweE8N2IyK27Ir/Q/iMtyjNwIHBYmK6fZJ97PpMFPtE+5uIWfs0D25Z8ix+XwPgmKkeE24uBGOP7hs4fHWa9Nk6C62YYCsSFIhYkKxztpMfIlg+FBqWANZJnxURCs7ZJunAQuhAFzrA9x9CeJpn2Kw/zaPNHB++JHrQ8YM4AkvSthL/N5WNOCBf2SDD7TQn/jlyPDlSCqUVSM8XTB375ogxsQT6t6N2QS2U0lg2C+QxEDuAT1ljLW7TXTMR3WfZuX0jM7k5A7Cyk9FZHfPefT67/Y00xNxoayHn9IPR83l8dXj9/xJ4vVZaKQ4mD51e3xIUjyMcyZ8Eu9M38IohP2c418rkOKen19enpzoV4I1Wp1ljhQH9HzFE5cGhnZHbAAAAAElFTkSuQmCC" alt="Lexidyne Logo" width="150" class="lex"><p class="logos">           </p><p class="logos">           </p><p class="logos">           </p><p class="logos">           </p><img src="data:image/png;base64,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" alt="Janssen Logo" width="150" class="jj"> </div></div><h1>Clinical Trials Weekly Digest</h1><br>

<h4><a href="#clinical">Clinical Results Press Releases</a></h4>
<h4><a href="#new_lc">Lung Cancer</a></h4>
<h4><a href="#new_it">Intratumoral</a></h4>
<h4><a href="#new_ct">Cytotoxic</a></h4>
<h4><a href="#new_ia">Immune Activation</a></h4>
<h4><a href="#approvals">Drug Approvals / Applications</a></h4>

<form action="https://getform.io/f/387eb37d-4992-430e-99b3-0bd1f47d1fb2"method="POST" id="interest_form" enctype="multipart/form-data" name="interest_form"><div class="form-group"><br>
<!-- ############################### -->
<!-- ############################### -->
<!-- ###### CLINICAL RESULTS ####### -->
<!-- ############################### -->
<!-- ############################### -->

<h2 id="clinical">Clinical Results Press Releases</h2>
<h4><a href="#home">Home</a></h4>
<table border="1" summary="Long-term goals table" width="100%" cellspacing="0" cellpadding="0" class="fda">
  <thead>
    <tr>
      <th><h3>Company</h3></th>
      <th><h3>Update</h3></th>
      <th><h3>Trial ID</h3></th>
      <th><h3>Interest Level?</h3></th>
    </tr>
  </thead>
  <tbody>
  <tr>
    <td>Bicycle Therapeutics</td>
    <td>Bicycle Therapeutics Announces Phase I Dose Escalation Results from Ongoing Phase I/II Study of BT8009</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04561362" target="_blank">NCT04561362</a></td><td><select class="form-select" id="select_form_1" name="NCT04561362"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td>enGene</td>
    <td>enGene announces poster presentation containing interim Phase 1 clinical trial data at the 2023 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04752722" target="_blank">LEGEND (NCT04752722)</a></td><td><select class="form-select" id="select_form_2" name="NCT04752722"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td>MacroGenics</td>
    <td>MacroGenics Announces Preliminary Clinical Results from Single Arm Study of Lorigerlimab in Patients with Metastatic Castration-Resistant Prostate Cancer to be Presented at ASCO Genitourinary Cancers Symposium</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03761017" target="_blank">NCT03761017</a></td><td><select class="form-select" id="select_form_3" name="NCT03761017"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td>Alligator Bioscience & Aptevo Therapeutics</td>
    <td>Alligator Bioscience & Aptevo Therapeutics Announce Dosing of First Patient with ALG.APV-527 in Phase 1 Clinical Trial</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/" target="_blank"></a></td><td><select class="form-select" id="select_form_4" name=""><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td>Moleculin</td>
    <td>Moleculin Announces Final Topline Data from Successful European Phase 1 Trial Evaluating Annamycin as Single Agent Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML)</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/" target="_blank"></a></td><td><select class="form-select" id="select_form_5" name=""><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td>ESSA Pharma</td>
    <td>ESSA Pharma Announces Presentations at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU)</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04421222" target="_blank">NCT04421222</a></td><td><select class="form-select" id="select_form_6" name="NCT04421222"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td>MAIA Biotechnology</td>
    <td>MAIA Biotechnologys Telomere-targeting Agent THIO in Combination With Checkpoint Inhibitor Immune Therapies Atezolizumab (anti-PD-L1) or Pembrolizumab (anti-PD-1) Demonstrated Significantly Greater Tumor Inhibition</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05208944" target="_blank">NCT05208944</a></td><td><select class="form-select" id="select_form_7" name="NCT05208944"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td>BioXcel Therapeutics</td>
    <td>BioXcel Therapeutics Announces Positive Full Data from Phase 2 Trial of BXCL701 in Rare Aggressive Form of Prostate Cancer; to be Presented at 2023 ASCO Genitourinary Cancers Symposium</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03910660" target="_blank">NCT03910660</a></td><td><select class="form-select" id="select_form_8" name="NCT03910660"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td>Bristol-Myers Squibb</td>
    <td>Cabometyx in combination with nivolumab shows durable survival benefits at over three-years follow-up in first-line advanced renal cell carcinoma</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03141177" target="_blank">CheckMate 9ER (NCT03141177)</a></td><td><select class="form-select" id="select_form_9" name="NCT03141177"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td>Pfizer</td>
    <td>New Analyses Reinforce Survival Benefit of BAVENCIO First-Line Maintenance Treatment in Patients With Advanced Urothelial Carcinoma</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT02603432" target="_blank">JAVELIN Bladder 100 (NCT02603432)</a></td><td><select class="form-select" id="select_form_10" name="NCT02603432"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td>G1 Therapeutics</td>
    <td>G1 Therapeutics Announces Top Line Results from Pivotal Phase 3 Trial of Trilaciclib in Patients Receiving Triplet Therapy with FOLFOXIRI + Bevacizumab for Metastatic Colorectal Cancer (CRC) (PRESERVE 1)</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04607668" target="_blank">PRESERVE 1 (NCT04607668)</a></td><td><select class="form-select" id="select_form_11" name="NCT04607668"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td>Blue Earth Diagnostics</td>
    <td>Blue Earth Diagnostics Highlights Upcoming Presentation of Additional Results from Investigational Phase 3 LIGHTHOUSE Study of 18F-rhPSMA-7.3 in Newly Diagnosed Prostate Cancer</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04186819" target="_blank">LIGHTHOUSE (NCT04186819)</a></td><td><select class="form-select" id="select_form_12" name="NCT04186819"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr data-toggle="collapse" data-target="#demo1" class="accordion-toggle">    <td>IMV</td>
    <td>IMV reports positive data from Diffuse Large B Cell Lymphoma therapy trial</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05243524" target="_blank">NCT05243524</a></td><td><select class="form-select" id="select_form_13" name="NCT05243524"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  </tbody>
</table>

<!-- ############################### -->
<!-- ############################### -->
<!-- ########### NEW LC ############ -->
<!-- ############################### -->
<!-- ############################### -->

<br><h2 id="new_lc">New Trials - Lung Cancer</h2>
<h4><a href="#home">Home</a></h4>
<table border="1" summary="Long-term goals table" width="100%" cellspacing="0" cellpadding="0">
  <thead>
    <tr>
      <th><h3>Condition</h3></th>
      <th><h3>Sponsor</h3></th>
      <th><h3>Phase</h3></th>
      <th><h3>Intervention</h3></th>
      <th><h3>Trial ID</h3></th>
      <th><h3>Interest Level?</h3></th>
    </tr>
  </thead>
  <tbody>
  <tr>
    <td>NSCLC with a KRAS mutation</td>
    <td>Navire Pharma Inc. a BridgeBio company</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_1">Study Arms</button></td>
    <td><p>BBP-398 with nivolumab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_500">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05375084" target="_blank">NCT05375084</a></td><td><select class="form-select" id="select_form_14" name="NCT05375084"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td>Advanced solid tumors</td>
    <td>Kineta Inc.</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_2">Study Arms</button></td>
    <td><p>KVA12123 - Dose Escalation; KVA12123 Plus Pembrolizumab - Dose Escalation; KVA12123 - Dose Expansion; KVA12123 Plus Pembrolizumab - Dose Expansion</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_501">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05708950" target="_blank">NCT05708950</a></td><td><select class="form-select" id="select_form_15" name="NCT05708950"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td>Advanced melanoma or non-small cell lung cancer</td>
    <td>iOx Therapeutics</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_3">Study Arms</button></td>
    <td><p>IMM60; Pembrolizumab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_502">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05709821" target="_blank">NCT05709821</a></td><td><select class="form-select" id="select_form_16" name="NCT05709821"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td>Advanced solid tumors</td>
    <td>Vincerx Pharma Inc.</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_4">Study Arms</button></td>
    <td>VIP236</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05712889" target="_blank">NCT05712889</a></td><td><select class="form-select" id="select_form_17" name="NCT05712889"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td>Locally advanced or metastatic NSCLC carrying EGFR exon 20 insertion mutations</td>
    <td>Dizal Pharmaceuticals</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_5">Study Arms</button></td>
    <td>DZD9008</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05712902" target="_blank">NCT05712902</a></td><td><select class="form-select" id="select_form_18" name="NCT05712902"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td>Advanced NSCLC</td>
    <td>Shanghai Gopherwood Biotech Co. Ltd.</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_6">Study Arms</button></td>
    <td>BR790+anlotinib</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05715398" target="_blank">NCT05715398</a></td><td><select class="form-select" id="select_form_19" name="NCT05715398"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td>Locally advanced and metastatic or recurrent (Stage IV) squamous NSCLC</td>
    <td>Chia Tai Tianqing Pharmaceutical Group Co. Ltd.</td>
<td><p>Phase 3</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_7">Study Arms</button></td>
    <td>TQB2450; Anlotinib hydrochloride capsule; Tislelizumab injection</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05718167" target="_blank">NCT05718167</a></td><td><select class="form-select" id="select_form_20" name="NCT05718167"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td>Advanced ALK-positive NSCLC</td>
    <td>Instituto Nacional de Cancerologia de Mexico</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_8">Study Arms</button></td>
    <td>Alectinib Oral Product</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05713006" target="_blank">NCT05713006</a></td><td><select class="form-select" id="select_form_21" name="NCT05713006"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td>NSCLC</td>
    <td>Canadian Cancer Trials Group</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_9">Study Arms</button></td>
    <td>JDQ443</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05714891" target="_blank">NCT05714891</a></td><td><select class="form-select" id="select_form_22" name="NCT05714891"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td>NSCLC</td>
    <td>Hackensack Meridian Health</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_10">Study Arms</button></td>
    <td><p>Nivolumab; Ipilimumab; Carboplatin; Paclitaxel; Pemetrexed</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_509">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05715229" target="_blank">NCT05715229</a></td><td><select class="form-select" id="select_form_23" name="NCT05715229"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td>Non-small Cell Lung Cancer</td>
    <td>Pusan National University Hospital</td>
<td><p>N/A</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_11">Study Arms</button></td>
    <td>Lazertinib</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05716672" target="_blank">NCT05716672</a></td><td><select class="form-select" id="select_form_24" name="NCT05716672"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td>Unresectable stage III NSCLC and ALK-rearrangement</td>
    <td>ETOP IBCSG Partners Foundation</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_12">Study Arms</button></td>
    <td><p>Brigatinib; Durvalumab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_511">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05718297" target="_blank">NCT05718297</a></td><td><select class="form-select" id="select_form_25" name="NCT05718297"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td>SLFN11-positive ED-SCLC</td>
    <td>ETOP IBCSG Partners Foundation</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_13">Study Arms</button></td>
    <td>Niraparib</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05718323" target="_blank">NCT05718323</a></td><td><select class="form-select" id="select_form_26" name="NCT05718323"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td>Lung Cancer</td>
    <td>Mario Negri Institute for Pharmacological Research</td>
<td><p>Phase 3</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_14">Study Arms</button></td>
    <td><p>Canakinumab; Placebo</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_513">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05725343" target="_blank">NCT05725343</a></td><td><select class="form-select" id="select_form_27" name="NCT05725343"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr data-toggle="collapse" data-target="#demo2" class="accordion-toggle">  <td colspan="6"><button type="button" class="btn btn-large btn-outline-primary">VIEW LARGE COMPANY TRIALS</button></td>
  </tr>
 <tr>  <td colspan="12" class="hiddenRow"> <div class="accordian-body collapse" id="demo2"><table class="table table-striped"><thead>
    <tr>
      <th><h3>Condition</h3></th>
      <th><h3>Sponsor</h3></th>
      <th><h3>Phase</h3></th>
      <th><h3>Intervention</h3></th>
      <th><h3>Trial ID</h3></th>
      <th><h3>Interest Level?</h3></th>
    </tr>
  </thead>
  <tbody>
  <tr>
    <td>Advanced cancer in the biliary tract pancreas lung or bladder</td>
    <td>Boehringer Ingelheim</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_15">Study Arms</button></td>
    <td>BI 907828</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05512377" target="_blank">NCT05512377</a></td><td><select class="form-select" id="select_form_28" name="NCT05512377"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td>Non-small-cell lung cancer (NSCLC) diagnosed with having the anaplastic lymphoma kinase (ALK) gene</td>
    <td>Takeda</td>
<td><p>N/A</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_16">Study Arms</button></td>
    <td><p>Brigatinib</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_515">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05721950" target="_blank">NCT05721950</a></td><td><select class="form-select" id="select_form_29" name="NCT05721950"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td>Metastatic Non-small Cell Lung Cancer</td>
    <td>Merck Sharp & Dohme LLC</td>
<td><p>Phase 3</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_17">Study Arms</button></td>
    <td><p>Pembrolizumab coformulated with hyaluronidase; Pemetrexed; Cisplatin; Carboplatin; Paclitaxel; Nab-paclitaxel; Pembrolizumab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_516">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05722015" target="_blank">NCT05722015</a></td><td><select class="form-select" id="select_form_30" name="NCT05722015"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  </tbody>
</table>
</div></td></tr>  </tbody>
</table>
<!-- THE MODAL -->
<div class="modal fade" id="modal_1" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Level 1 oral capsules administered in combination with nivolumab|Level 2 oral capsules administered in combination with nivolumab|Level 3 oral capsules administered in combination with nivolumab|RP2D defined dose. Oral capsules administered in combination with nivolumab</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: BBP-398 with nivolumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Phase 1a Dose Escalation: Assess safety tolerability and recommended phase 2 dose (RP2D) of BBP-398 in combination with nivolumab|Phase 1b Dose Expansion: Assess antitumor activity of BBP-398 in combination with nivolumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Anti-tumor activity will be defined by objective response rate (ORR) according to RECIST v1.1</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Completion of 1 Cycle (28 days)</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_2" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Part A will consist of dose escalation with KVA12123 administered as a single agent in participants with advanced solid tumors.|Part B will consist of dose escalation with KVA12123 administered in combination with a fixed dose of pembrolizumab.|Part C will consist of dose expansion with KVA12123 administered as a single agent at the RP2D in participants with advanced solid tumors.|Part D will consist of dose expansion with KVA12123 administered at the RP2D in combination with a fixed dose of pembrolizumab.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: KVA12123 Plus Pembrolizumab - Dose Expansion; Drug: KVA12123 - Dose Expansion; Drug: KVA12123 Plus Pembrolizumab - Dose Escalation; Drug: KVA12123 - Dose Escalation</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Adverse Events|AEs related to study drug|Recommended Phase 2 dose (RP2D) or maximum tolerated dose (MTD)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Type and frequency of treatment related adverse events as assessed by CTCAE v4.0.; Type and frequency of adverse events as assessed by CTCAE v4.0.; Recommended Phase 2 dose (RP2D) or maximum tolerated dose (MTD) of KVA12123 when administered alone and in combination with pembrolizumab in participants with advanced solid tumors (milligrams or milligrams/kilogram).</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Through study completion an average of 1 year</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_3" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Active Comparator; Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>3 dose levels of IMM60 will be assessed (1 3 and 9 mg/m^2 administered IV every 3 weeks for up to 6 cycles)|Pembrolizumab 200 mg IV every 3 weeks for up to 35 cycles will be administered in combination with IMM60 IV every 3 weeks for up to 6 cycles. The IMM60 dose will be determined based on the results of the IMM60 dose escalation safety cohort.|Pembrolizumab 200 mg IV every 3 weeks for up to 35 cycles will be administered in combination with IMM60 IV every 3 weeks for up to 6 cycles. The IMM60 dose will be determined based on the results of the Phase 1 dose escalation safety cohorts.|Pembrolizumab 200 mg IV every 3 weeks for up to 35 cycles.|Participants will be treated with one cycle of IMM60 with a tumor biopsy before and after to determine any changes in PD-L1 expression. After this one cycle the participants will receive the combination of IMM60 IV for up to 6 total cycles + pembrolizumab 200 mg every 3 weeks administered IV. The IMM60 dose will be determined based on the results of the Phase 1 dose escalation cohorts.|IMM60 IV every 3 weeks for up to 6 cycles. The IMM60 dose will be determined based on the results of the Phase 1 dose escalation cohorts.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Pembrolizumab; Drug: IMM60</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Phase 1 Co-Primary Objective - Identify Maximum Tolerated Dose (MTD)|Phase 1 Co-Primary Objective - Safety|Phase 2 Primary Objective - Progression-free Survival</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>To compare the progression-free survival (PFS) rate at 12 months in the randomized arms comparing pembrolizumab alone versus IMM60 + pembrolizumab in patients with advanced PD-L1 â‰¥50% NSCLC; To confirm the maximum tolerated dose (MTD) of IMM60 alone and in combination with pembrolizumab defined as the highest dose level at which 2 out of 6 participants experience a dose-limiting toxicity; To characterize the safety of IMM60 alone and in combination with pembrolizumab as assessed by the frequency of Grade 3 or higher treatment-related adverse events</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Through Phase 1 completion an average of 1 year; 12 months after last participant enrolled; Assessed at the end of Cycle 1 for each patient (each Cycle is 28 days)</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_4" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Investigating VIP236 in a dose escalation cohort in subjects with advanced solid tumor cancer</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: VIP236</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Incidence of DLT (Dose limit toxicity) of VIP236|Number of participants with adverse events as a measure safety and tolerability</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Cycle 1 Day 1 up to 30 days after the last dose where each cycle is up to 21 days (up to approximately 10 months); Cycle 1 Day 1 through Cycle 2 Day 1 where each cycle is up to 21 days</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_5" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: DZD9008</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Objective Response Rate (ORR) according to RECIST 1.1 by an Independent Review Committee (IRC)</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>From first dosing until disease progression or intolerable adverse events</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_6" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>BR790 will be administered orally variable dose on Day 1 of each 21-day cycle Anlotinib will be administered as PO fixed dose on Day1-14 of each 21-day cycle</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: BR790+anlotinib</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Maximum tolerated dose/Recommended Phase â…¡ Dose(MTD/RP2D)|Objective Response Rate (ORR)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>To evaluate the MTD/RP2D of BR790 in combination with anlotinib (Part 1); To evaluate the objective response rate (ORR) of BR790 in combination with anlotinib. ORR is defined as the proportion of subjects who achieve a Complete Response (CR) or Partial Response (PR) as assessed by RECIST v1.1 (Part 2)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>2 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_7" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Active Comparator; Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>In the induction stage:||TQB2450 injection: 1200 mg Intravenous drip on d1; Carboplatin injection: Area Under Curve 5mg/mL/min Intravenous drip on d1; Paclitaxel injection: 175mg/m2 Intravenous drip on d1. The above schemes are repeated every three weeks.||In the maintenance stage:||TQB2450 injection: 1200 mg Intravenous drip on d1; Anlotinib Hydrochloride Capsules: 10mg orally administered every day from d1-d14.||The above schemes are repeated every three weeks.|In the induction stage:||Tislelizumab injection: 200 mg Intravenous drip; Carboplatin injection: Area Under Curve 5mg/mL/min Intravenous drip; Paclitaxel injection: 175mg/m2 Intravenous drip. The above schemes are repeated every three weeks.||In the maintenance stage:||Tislelizumab injection: 200 mg Intravenous drip on d1 Placebo capsule: 0mg orally administered every day from d1-d14. The above schemes are repeated every three weeks.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: TQB2450; Drug: Tislelizumab injection; Drug: Anlotinib hydrochloride capsule</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Progression Free Survival (PFS)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Progression Free Survival (PFS) assessed by Independent Review Committee (IRC)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Base line up to 2 years. The curative effect was evaluated every 6 weeks (42 days) in the first 54 weeks of treatment period; After 54 weeks the efficacy was evaluated every 9 weeks (63 days).</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_8" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: BI 907828</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Objective response (OR)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>OR is defined as a best overall response of confirmed complete response (CR) or confirmed partial response (PR) according to RECIST version 1.1.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 30 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_9" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Participants with ALK positive locally advanced or metastatic NSCLC will be observed ambispectively (retrospective plus prospective) after receiving recommended dose of brigatinib 90 mg orally once daily for first 7 days followed by 180 mg once daily for up to 36 months as their first line of treatment as part of routine medical care up to approximately 16 months. Data will be collected every 3 months after their first dose until the 36 month or participant death loss to follow-up or withdrawal from the study for any reason in the real-world setting from September 1 2022 and December 31 2026.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Brigatinib</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Real-World Time-to-Treatment Discontinuation (rwTDD)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>rwTTD is defined as the time from initiation of brigatinib to discontinuation of treatment for any reason including disease progression death serious adverse events or participant preference.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 52 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_10" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Active Comparator; Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Participants with treatment-naÃ¯ve metastatic NSCLC will receive MK 3475A SC in combination with platinum doublet chemotherapy.|Participants with treatment-naÃ¯ve metastatic NSCLC will receive Pembrolizumab IV in combination with platinum doublet chemotherapy.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: Pembrolizumab; Drug: Cisplatin; Drug: Pemetrexed; Drug: Carboplatin; Biological: Pembrolizumab coformulated with hyaluronidase; Drug: Paclitaxel; Drug: Nab-paclitaxel</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Area Under the Curve (AUC) of Pembrolizumab Measured After the First Dose|Trough Concentration (Ctrough) of Pembrolizumab Measured at Steady State</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Ctrough is defined as the trough concentration at steady-state.; AUC is defined as area under curve exposure.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>At pre-defined intervals from first administration of study drug up to treatment discontinuation visit (up to approximately 27 months)</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_11" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Alecensa 150 mg Roche</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Alectinib Oral Product</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>AUC|Cmax|Cmin|Tmax|ORR|Steady state</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Highest concentration of drug in blood (Serum) for each given dose (300 450 and 600 mg).; Lowest concentration of drug in blood (Serum) for each given dose (300 450 and 600 mg).; overall response rate is measured in phase two; Time in witch Cmax is reached in each dose of the drug (300450 and 600 mg); The amount of drug in the plasma has built up to a therapeutically effective concentration level and as long as regular doses are administered to balance the amount of drug being cleared the drug will continue to be active.; The area under the curve (AUC). Pharmacokinetic behavior of the initial alectinib for each given dose (300 450 and 600 mg).</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>From baseline control pre-dose 0.50 1.00 2.00 3.00 4.00 5.00 6.00 8.00 10.00 and 11.90 hours; From first dose administration through the following 12 hours (day 1); For phase two: between 2 and 4 months of treatment with investigators chosen dose.; Amount of drug concentration between 0 to 12 hours after first drug administration; From first dose administration up to disease progression by CT scan every 6 weeks through study completion.</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_12" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>If *MPR/cPR* - standard of care adjuvant treatment may be followed by experimental adjuvant therapy (JDQ443)||*Major Pathological Response (MPR)/ Complete Pathological Response (cPR)</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: JDQ443</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Identify promising neoadjuvant treatment regimens for NSCLC for later validation in randomized clinical trials by evaluating major pathological response rates (MPR)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>3 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_13" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Other; Active Comparator</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Arm A - Intervention arm (Immunotherapy and Chemotherapy)||Nivolumab 360 mg/kg every 3 weeks Ipilimumab 1 mg/kg every 6 weeks||Platinum- doublet Chemotherapy (Histology-based) 4 cycles depending on the investigator's discretion.||Carboplatin dosed at AUC 5 and either Paclitaxel 175 mg/m2 for squamous or Pemetrexed 500 mg/m2 for non-squamous|Arm B - control arm (Immunotherapy only)||Nivolumab 360 mg/kg every 3 weeks Ipilimumab 1 mg/kg every 6 weeks</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Ipilimumab; Drug: Pemetrexed; Drug: Nivolumab; Drug: Carboplatin; Drug: Paclitaxel</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Progression Free Survival (PFS)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>To compare progression free survival in patients with on-treatment-ctDNA guided therapy continuation or escalation by addition of platinum-doublet chemotherapy to therapy continuation with Nivolumab-Ipilimumab regardless of on-treatment-ctDNA results.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Time from randomization to objective disease progression or death from any cause whichever first up to 36 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_14" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Maintenance of the 240mg dose for 12 weeks after the first administration of Lazertinib|Reduction of the 160mg dose for 12 weeks after the first administration of Lazertinib</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Lazertinib</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Progression Free Survival(PFS)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Progression-free survival is defined as the period from the start of Lazertinib administration to the time when objective disease progression is confirmed or death from any cause during treatment whichever occurs first.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to approximately 3 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_15" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Active Comparator; Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Brigatinib 180 mg once daily p.o. with seven day lead-in at 90 mg once daily for 3 years or until progression of disease or unacceptable toxicities or withdrawal of consent|Patients in the control arm will be observational or as per investigators choice patients may receive durvalumab administered within the label in the respective country.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Brigatinib; Drug: Durvalumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Progression-free survival according to RECIST v1.1 evaluated in the ITT cohort. PFS will be compared between the two arms.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>defined as the time from the date of randomisation until documented progression (according to RECIST v1.1) or death if progression is not documented</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>From the date of enrolment until last tumour assessment (approximately 45-48 months after enrolment of the first patient)</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_16" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Niraparib</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Progression-free survival (PFS) rate at 3 months by investigator assessment (according to RECIST v1.1)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Defined as the rate of patients without a PFS event at 3 months after enrolment</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>From date of enrolment until 3 monhts post-enrolment</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_17" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental; Placebo Comparator</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Eligible subjects will be randomized in a 3:2 ratio to receive either canakinumab s.c. at 200 mg or placebo every two months.|Eligible subjects will be randomized in a 3:2 ratio to receive either canakinumab s.c. at 200 mg or placebo every two months.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Canakinumab; Drug: Placebo</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Time To Lung Cancer</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>TTLC will be measured from the date of randomization up to the date of lung cancer or for subjects free from disease the date of last contact.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>date of randomization up to the date of lung cancer or for subjects free from disease the date of last contact up to 48 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>


<!-- ############################### -->
<!-- ############################### -->
<!-- ######## EXISTING LC ########## -->
<!-- ############################### -->
<!-- ############################### -->

<br><h2 id="existing_lc">Existing Trials - Lung Cancer</h2>
<h4><a href="#home">Home</a></h4>
<table border="1" summary="Long-term goals table" width="100%" cellspacing="0" cellpadding="0">
  <thead>
    <tr>
      <th><h3>Update</h3></th>
      <th><h3>Condition</h3></th>
      <th><h3>Sponsor</h3></th>
      <th><h3>Phase</h3></th>
      <th><h3>Intervention</h3></th>
      <th><h3>Trial ID</h3></th>
      <th><h3>Interest Level?</h3></th>
    </tr>
  </thead>
  <tbody>
  <tr>
    <td><strong>Completion Date moved earlier by 1096 days; Enrollment decreased by: 421; Primary Completion Date moved earlier by 884 days</strong></td>
    <td>Advanced or metastatic solid tumors harboring RET mutations or alterations</td>
    <td>Turning Point Therapeutics Inc.</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_18">Study Arms</button></td>
    <td>TPX-0046</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04161391" target="_blank">NCT04161391</a></td><td><select class="form-select" id="select_form_31" name="NCT04161391"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Primary Completion Date moved earlier by 137 days</strong></td>
    <td>Locally advanced or metastatic Non-small Cell Lung Cancer (NSCLC) with EGFR mutations</td>
    <td>Yuhan Corporation</td>
<td><p>Phase 3</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_19">Study Arms</button></td>
    <td><p>Lazertinib 240 mg/160 mg; Gefitinib 250 mg; Lazertinib-matching placebo 240 mg/160 mg; Gefitinib-matching placebo 250 mg</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_518">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04248829" target="_blank">NCT04248829</a></td><td><select class="form-select" id="select_form_32" name="NCT04248829"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 1734 days; Changed status from recruiting to active; Primary Completion Date moved earlier by 91 days</strong></td>
    <td>High-risk resectable NSCLC</td>
    <td>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_20">Study Arms</button></td>
    <td><p>Nivolumab; Carboplatin; Paclitaxel</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_518">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT02259621" target="_blank">NCT02259621</a></td><td><select class="form-select" id="select_form_33" name="NCT02259621"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Enrollment decreased by: 19</strong></td>
    <td>Small Cell Lung Cancer</td>
    <td>Ipsen</td>
<td><p>Phase 3</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_21">Study Arms</button></td>
    <td>Irinotecan liposome injection; Topotecan</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03088813" target="_blank">NCT03088813</a></td><td><select class="form-select" id="select_form_34" name="NCT03088813"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date moved earlier by 295 days; Trial completed</strong></td>
    <td>Locally Advanced or Metastatic Epithelial Tumor</td>
    <td>Sichuan Baili Pharmaceutical Co. Ltd.</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_22">Study Arms</button></td>
    <td>SI-B001</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04603287" target="_blank">NCT04603287</a></td><td><select class="form-select" id="select_form_35" name="NCT04603287"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Trial terminated</strong></td>
    <td>Non Small Cell Lung Cancer</td>
    <td>Daiichi Sankyo Co. Ltd.</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_23">Study Arms</button></td>
    <td><p>DS-1205c; Gefitinib</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_520">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03599518" target="_blank">NCT03599518</a></td><td><select class="form-select" id="select_form_36" name="NCT03599518"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Enrollment decreased by: 70</strong></td>
    <td>Unresectable stage II-III non-small cell lung cancer</td>
    <td>Mayo Clinic</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_24">Study Arms</button></td>
    <td><p>Carboplatin; Cisplatin; Etoposide; Paclitaxel; Pemetrexed; Proton Beam Radiation Therapy; Quality-of-Life Assessment; Questionnaire Administration</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_520">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03132532" target="_blank">NCT03132532</a></td><td><select class="form-select" id="select_form_37" name="NCT03132532"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Now recruiting</strong></td>
    <td>Non-small cell lung cancer</td>
    <td>University of Southern California</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_25">Study Arms</button></td>
    <td><p>Atezolizumab and Recombinant Human Hyaluronidase; Survey Administration</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_520">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05340309" target="_blank">NCT05340309</a></td><td><select class="form-select" id="select_form_38" name="NCT05340309"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Trial completed</strong></td>
    <td>Locally advanced or metastatic NSCLC</td>
    <td>Chonnam National University Hospital</td>
<td><p>Phase 4</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_26">Study Arms</button></td>
    <td><p>Atezolizumab Injection [Tecentriq]</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_520">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04059887" target="_blank">NCT04059887</a></td><td><select class="form-select" id="select_form_39" name="NCT04059887"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Changed status from recruiting to active</strong></td>
    <td>Early resectable NSCLC</td>
    <td>Xiangya Hospital of Central South University</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_27">Study Arms</button></td>
    <td><p>nivolumab 4.5mg/kg+Paclitaxel (albumin-bound type) 260mg / m2+ Carboplatin AUC5</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_520">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04699721" target="_blank">NCT04699721</a></td><td><select class="form-select" id="select_form_40" name="NCT04699721"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Enrollment decreased by: 143; Changed status from recruiting to active</strong></td>
    <td>Non-small Cell Lung Cancer</td>
    <td>Roswell Park Cancer Institute</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_28">Study Arms</button></td>
    <td><p>Pembrolizumab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_520">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04032418" target="_blank">NCT04032418</a></td><td><select class="form-select" id="select_form_41" name="NCT04032418"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Changed status from recruiting to active</strong></td>
    <td>NSCLC</td>
    <td>Spectrum Pharmaceuticals Inc</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_29">Study Arms</button></td>
    <td>Poziotinib Once Daily Dosing; Poziotinib Twice Daily Dosing; Poziotinib Once Daily Dosing or Twice Daily Dosing as determined in Phase 1</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04402008" target="_blank">NCT04402008</a></td><td><select class="form-select" id="select_form_42" name="NCT04402008"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Now recruiting; Start Date moved earlier by 209 days</strong></td>
    <td>Stage 4 and recurrent non- small cell lung cancer</td>
    <td>University of Kansas Medical Center</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_30">Study Arms</button></td>
    <td><p>Atezolizumab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_521">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04467723" target="_blank">NCT04467723</a></td><td><select class="form-select" id="select_form_43" name="NCT04467723"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Enrollment increased by: 11</strong></td>
    <td>Solid tumors</td>
    <td>Genmab</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_31">Study Arms</button></td>
    <td>GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04424641" target="_blank">NCT04424641</a></td><td><select class="form-select" id="select_form_44" name="NCT04424641"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Now recruiting</strong></td>
    <td>Unresectable locally advanced Stage III non-small cell lung cancer</td>
    <td>Genfleet Therapeutics (Shanghai) Inc.</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_32">Study Arms</button></td>
    <td><p>GFH018; Toripalimab; Paclitaxel; Carboplatin; Cisplatin; Pemetrexed; Thoracic Radiation Therapy (TRT); Paclitaxel; Carboplatin; GFH018; Toripalimab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_522">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05386888" target="_blank">NCT05386888</a></td><td><select class="form-select" id="select_form_45" name="NCT05386888"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Changed status from recruiting to suspended</strong></td>
    <td>Locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring human epidermal growth factor receptor 2 (HER2) exon 20 mutations</td>
    <td>Spectrum Pharmaceuticals Inc</td>
<td><p>Phase 3</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_33">Study Arms</button></td>
    <td><p>Poziotinib; Docetaxel</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_522">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05378763" target="_blank">NCT05378763</a></td><td><select class="form-select" id="select_form_46" name="NCT05378763"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Now recruiting</strong></td>
    <td>Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations</td>
    <td>Allist Pharmaceuticals Inc.</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_34">Study Arms</button></td>
    <td>Furmonertinib</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05466149" target="_blank">NCT05466149</a></td><td><select class="form-select" id="select_form_47" name="NCT05466149"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Now recruiting</strong></td>
    <td>Advanced Solid Tumors</td>
    <td>Multitude Therapeutics Inc.</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_35">Study Arms</button></td>
    <td>AMT-151</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05498597" target="_blank">NCT05498597</a></td><td><select class="form-select" id="select_form_48" name="NCT05498597"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Enrollment increased by: 27</strong></td>
    <td>Advanced/recurrent solid tumors that express HER2</td>
    <td>Mersana Therapeutics</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_36">Study Arms</button></td>
    <td>XMT-2056</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05514717" target="_blank">NCT05514717</a></td><td><select class="form-select" id="select_form_49" name="NCT05514717"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Now recruiting</strong></td>
    <td>Advanced or metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion</td>
    <td>Prelude Therapeutics</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_37">Study Arms</button></td>
    <td>PRT3789</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05639751" target="_blank">NCT05639751</a></td><td><select class="form-select" id="select_form_50" name="NCT05639751"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Now recruiting</strong></td>
    <td>Locally advanced recurrent or metastatic NSCLC</td>
    <td>Mythic Therapeutics</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_38">Study Arms</button></td>
    <td>MYTX-011</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05652868" target="_blank">NCT05652868</a></td><td><select class="form-select" id="select_form_51" name="NCT05652868"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Now recruiting</strong></td>
    <td>NSCLC</td>
    <td>Affiliated Hospital of Jiangnan University</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_39">Study Arms</button></td>
    <td>Antitumor therapy guided by organoid drug sensitivity test</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05669586" target="_blank">NCT05669586</a></td><td><select class="form-select" id="select_form_52" name="NCT05669586"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 365 days</strong></td>
    <td>Non-small Cell Lung Cancer</td>
    <td>University of Rochester</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_40">Study Arms</button></td>
    <td><p>Pembrolizumab; Pemetrexed (Chemotherapy); Nab-paclitaxel (Chemotherapy)</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_528">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04297605" target="_blank">NCT04297605</a></td><td><select class="form-select" id="select_form_53" name="NCT04297605"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 365 days</strong></td>
    <td>ALK-positive non-small cell lung cancer</td>
    <td>Xcovery Holding Company LLC</td>
<td><p>Phase 3</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_41">Study Arms</button></td>
    <td><p>X-396 (ensartinib); crizotinib</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_528">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT02767804" target="_blank">NCT02767804</a></td><td><select class="form-select" id="select_form_54" name="NCT02767804"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 366 days</strong></td>
    <td>Small-cell Lung Cancer</td>
    <td>Case Comprehensive Cancer Center</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_42">Study Arms</button></td>
    <td><p>Abemaciclib</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_528">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04010357" target="_blank">NCT04010357</a></td><td><select class="form-select" id="select_form_55" name="NCT04010357"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 366 days; Primary Completion Date pushed later by 365 days</strong></td>
    <td>Solid tumors that have spread to other places in the body (advanced) and extensive-stage small cell lung cancer</td>
    <td>Jonsson Comprehensive Cancer Center</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_43">Study Arms</button></td>
    <td><p>Atezolizumab; Niraparib; Quality-of-Life Assessment; Questionnaire Administration; Temozolomide</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_528">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03830918" target="_blank">NCT03830918</a></td><td><select class="form-select" id="select_form_56" name="NCT03830918"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 567 days; Enrollment increased by: 15; Trial completed; Primary Completion Date pushed later by 504 days</strong></td>
    <td>Treatment-naive Advanced Non-small Cell Lung Cancer</td>
    <td>Shanghai Junshi Bioscience Co. Ltd.</td>
<td><p>Phase 3</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_44">Study Arms</button></td>
    <td>TORIPALIMAB INJECTION (JS001 ) combine with chemotherapy</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03856411" target="_blank">NCT03856411</a></td><td><select class="form-select" id="select_form_57" name="NCT03856411"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 182 days; Enrollment decreased by: 10; Changed status from recruiting to active</strong></td>
    <td>Lung Cancer</td>
    <td>EMD Serono Research & Development Institute Inc.</td>
<td><p>Phase 3</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_45">Study Arms</button></td>
    <td>Bintrafusp alfa</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05061823" target="_blank">NCT05061823</a></td><td><select class="form-select" id="select_form_58" name="NCT05061823"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 365 days</strong></td>
    <td>Malignant Pleural Effusion</td>
    <td>Memorial Sloan Kettering Cancer Center</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_46">Study Arms</button></td>
    <td>GL-ONC1</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT01766739" target="_blank">NCT01766739</a></td><td><select class="form-select" id="select_form_59" name="NCT01766739"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 365 days; Changed status from recruiting to active</strong></td>
    <td>Primary or cancer that has spread to the breast colorectal lung or pancreatic</td>
    <td>Julie L. Sutcliffe Ph.D</td>
<td><p>Early Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_47">Study Arms</button></td>
    <td>18F-v6-BP</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03164486" target="_blank">NCT03164486</a></td><td><select class="form-select" id="select_form_60" name="NCT03164486"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 214 days; Enrollment decreased by: 14; Changed status from recruiting to active</strong></td>
    <td>Relapsed mesothelioma</td>
    <td>University of Leicester</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_48">Study Arms</button></td>
    <td><p>Rucaparib; Abemaciclib; pembrolizumab & bemcentinib; Atezolizumab & Bevacizumab; Dostarlimab and Niraparib</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_532">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03654833" target="_blank">NCT03654833</a></td><td><select class="form-select" id="select_form_61" name="NCT03654833"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 1734 days; Changed status from recruiting to active; Primary Completion Date moved earlier by 91 days</strong></td>
    <td>High-risk resectable NSCLC</td>
    <td>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_49">Study Arms</button></td>
    <td><p>Nivolumab; Carboplatin; Paclitaxel</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_532">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT02259621" target="_blank">NCT02259621</a></td><td><select class="form-select" id="select_form_62" name="NCT02259621"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 517 days</strong></td>
    <td>Stage IIIB or IV non-small cell lung cancer with EGFR mutations</td>
    <td>M.D. Anderson Cancer Center</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_50">Study Arms</button></td>
    <td>Osimertinib; Radiation Therapy; Therapeutic Conventional Surgery</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03410043" target="_blank">NCT03410043</a></td><td><select class="form-select" id="select_form_63" name="NCT03410043"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 1005 days</strong></td>
    <td>Melanoma or genitourinary cancer</td>
    <td>M.D. Anderson Cancer Center</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_51">Study Arms</button></td>
    <td><p>Best Practice; Biospecimen Collection; Endoscopic Procedure; Fecal Microbiota Transplantation; Infliximab; Laboratory Biomarker Analysis; Prednisone; Vedolizumab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_533">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03819296" target="_blank">NCT03819296</a></td><td><select class="form-select" id="select_form_64" name="NCT03819296"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 365 days</strong></td>
    <td>Non-Small Cell Carcinoma of Lung TNM Stage 4</td>
    <td>Fox Chase Cancer Center</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_52">Study Arms</button></td>
    <td>Arm A; Arm B</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03786692" target="_blank">NCT03786692</a></td><td><select class="form-select" id="select_form_65" name="NCT03786692"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 694 days; Primary Completion Date pushed later by 698 days</strong></td>
    <td>RET fusion-positive non-squamous non-small cell lung cancer (NSCLC) that has spread to other parts of the body</td>
    <td>Loxo Oncology Inc.</td>
<td><p>Phase 3</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_53">Study Arms</button></td>
    <td><p>Selpercatinib; Carboplatin; Cisplatin; Pemetrexed; Pembrolizumab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_534">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04194944" target="_blank">NCT04194944</a></td><td><select class="form-select" id="select_form_66" name="NCT04194944"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 366 days</strong></td>
    <td>Stage IB-IIIA non-small cell lung cancer</td>
    <td>Roswell Park Cancer Institute</td>
<td><p>Early Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_54">Study Arms</button></td>
    <td>Quality-of-Life Assessment; Questionnaire Administration; Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04298606" target="_blank">NCT04298606</a></td><td><select class="form-select" id="select_form_67" name="NCT04298606"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Enrollment decreased by: 105; Changed status from recruiting to active; Primary Completion Date pushed later by 365 days</strong></td>
    <td>Advanced or metastatic non-small cell lung cancer microsatellite stable colorectal cancer pancreatic cancer and shared neoantigen-positive tumors</td>
    <td>Gritstone bio Inc.</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_55">Study Arms</button></td>
    <td><p>GRT-C903; GRT-R904; nivolumab; ipilimumab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_535">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03953235" target="_blank">NCT03953235</a></td><td><select class="form-select" id="select_form_68" name="NCT03953235"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Start Date pushed later by 90 days</strong></td>
    <td>Resectable Stage II to IIIA non-small cell lung cancer (NSCLC)</td>
    <td>BeiGene</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_56">Study Arms</button></td>
    <td>Tislelizumab; Ociperlimab; LBL-007</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05577702" target="_blank">NCT05577702</a></td><td><select class="form-select" id="select_form_69" name="NCT05577702"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Changed status from recruiting to active; Primary Completion Date pushed later by 365 days</strong></td>
    <td>Metastatic squamous cell carcinoma of head and neck lung or esophagus</td>
    <td>Gustave Roussy Cancer Campus Grand Paris</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_57">Study Arms</button></td>
    <td><p>Durvalumab; Tremelimumab; SBRT</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_536">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03212469" target="_blank">NCT03212469</a></td><td><select class="form-select" id="select_form_70" name="NCT03212469"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Now recruiting; Primary Completion Date pushed later by 1096 days; Start Date pushed later by 135 days</strong></td>
    <td>Solid tumors</td>
    <td>CNAO National Center of Oncological Hadrontherapy</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_58">Study Arms</button></td>
    <td><p>Carbon Ion Therapy; Immunotherapy (Pembrolizumab)</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_536">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05229614" target="_blank">NCT05229614</a></td><td><select class="form-select" id="select_form_71" name="NCT05229614"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Primary Completion Date pushed later by 182 days</strong></td>
    <td>Mesothelioma</td>
    <td>Arkadiusz Z. Dudek MD</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_59">Study Arms</button></td>
    <td><p>Nivolumab; Ramucirumab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_536">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03502746" target="_blank">NCT03502746</a></td><td><select class="form-select" id="select_form_72" name="NCT03502746"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 457 days; Primary Completion Date pushed later by 365 days</strong></td>
    <td>ALK-positive or ROS1-positive advanced NSCLC</td>
    <td>Shenzhen TargetRx Inc.</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_60">Study Arms</button></td>
    <td>TGRX-326</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05441956" target="_blank">NCT05441956</a></td><td><select class="form-select" id="select_form_73" name="NCT05441956"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 334 days; Enrollment increased by: 55; Now recruiting; Primary Completion Date pushed later by 213 days</strong></td>
    <td>EGFR Mutant Advanced Non-small Cell Lung Cancer</td>
    <td>J Ints Bio</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_61">Study Arms</button></td>
    <td>JIN-A02</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05394831" target="_blank">NCT05394831</a></td><td><select class="form-select" id="select_form_74" name="NCT05394831"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 426 days; Now recruiting; Primary Completion Date pushed later by 123 days; Start Date pushed later by 153 days</strong></td>
    <td>Pulmonary Nodules</td>
    <td>Shanghai Jiao Tong University School of Medicine</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_62">Study Arms</button></td>
    <td>Limonene capsule; Limonene capsules(Placebo)</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05525260" target="_blank">NCT05525260</a></td><td><select class="form-select" id="select_form_75" name="NCT05525260"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Primary Completion Date pushed later by 120 days</strong></td>
    <td>STS with lung metastases</td>
    <td>Moleculin Biotech Inc.</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_63">Study Arms</button></td>
    <td>Liposomal Annamycin (L-Annamycin)</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04887298" target="_blank">NCT04887298</a></td><td><select class="form-select" id="select_form_76" name="NCT04887298"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr data-toggle="collapse" data-target="#demo3" class="accordion-toggle">  <td colspan="7"><button type="button" class="btn btn-large btn-outline-primary">VIEW LARGE COMPANY TRIALS</button></td>
  </tr>
 <tr>  <td colspan="12" class="hiddenRow"> <div class="accordian-body collapse" id="demo3"><table class="table table-striped"><thead>
    <tr>
      <th><h3>Update</h3></th>
      <th><h3>Condition</h3></th>
      <th><h3>Sponsor</h3></th>
      <th><h3>Phase</h3></th>
      <th><h3>Intervention</h3></th>
      <th><h3>Trial ID</h3></th>
      <th><h3>Interest Level?</h3></th>
    </tr>
  </thead>
  <tbody>
  <tr>
    <td><strong>Completion Date moved earlier by 1326 days; Enrollment decreased by: 179; Trial terminated; Primary Completion Date moved earlier by 627 days</strong></td>
    <td>Stage IV non-small cell lung cancer</td>
    <td>Bristol-Myers Squibb</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_64">Study Arms</button></td>
    <td><p>Nivolumab; Ipilimumab; BMS-986207; Placebo</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_540">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05005273" target="_blank">NCT05005273</a></td><td><select class="form-select" id="select_form_77" name="NCT05005273"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date moved earlier by 126 days; Enrollment decreased by: 106; Changed status from recruiting to active</strong></td>
    <td>Non-Small Cell Lung Cancer; Small Cell Lung Cancer</td>
    <td>AstraZeneca</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_65">Study Arms</button></td>
    <td><p>Durvalumab; Cisplatin; Carboplatin; Etoposide</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_540">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04870112" target="_blank">NCT04870112</a></td><td><select class="form-select" id="select_form_78" name="NCT04870112"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Enrollment decreased by: 210</strong></td>
    <td>Non-Squamous Cell Non-small Cell Lung Cancer</td>
    <td>Bristol-Myers Squibb</td>
<td><p>Phase 3</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_66">Study Arms</button></td>
    <td><p>Nivolumab; Docetaxel</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_540">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT01673867" target="_blank">NCT01673867</a></td><td><select class="form-select" id="select_form_79" name="NCT01673867"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date moved earlier by 157 days; Trial completed</strong></td>
    <td>EGFRm+ non-small cell lung cancer (NSCLC)</td>
    <td>AstraZeneca</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_67">Study Arms</button></td>
    <td>AZD9291 tablets; Pharmacokinetic sampling - AZD9291; Dietary Fasted; Dietary High Fat; Pharmacokinetic sampling - AZ5140 and AZ7550</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT02163733" target="_blank">NCT02163733</a></td><td><select class="form-select" id="select_form_80" name="NCT02163733"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date moved earlier by 129 days; Primary Completion Date pushed later by 164 days</strong></td>
    <td>Advanced non-small cell lung cancer (NSCLC) harboring a KRAS G12C mutation</td>
    <td>Novartis Pharmaceuticals</td>
<td><p>Phase 3</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_68">Study Arms</button></td>
    <td><p>JDQ443; docetaxel</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_541">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05132075" target="_blank">NCT05132075</a></td><td><select class="form-select" id="select_form_81" name="NCT05132075"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Trial completed</strong></td>
    <td>Epidermal growth factor receptor single activating mutation positive (EGFRm+) locally advanced or metastatic Non Small Cell Lung Cancer</td>
    <td>Janssen Research & Development LLC</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_69">Study Arms</button></td>
    <td>Lazertinib</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04075396" target="_blank">NCT04075396</a></td><td><select class="form-select" id="select_form_82" name="NCT04075396"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Trial completed</strong></td>
    <td>Locally advanced or metastatic solid tumors</td>
    <td>Pfizer</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_70">Study Arms</button></td>
    <td><p>Avelumab 800 mg in combination with pemetrexed / carboplatin; Avelumab 800 mg in combination with gemcitabine / cisplatin.; Avelumab 1200 mg in combination with pemetrexed/carboplatin; Avelumab 1200 mg in combination with gemcitabine/cisplatin</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_542">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03317496" target="_blank">NCT03317496</a></td><td><select class="form-select" id="select_form_83" name="NCT03317496"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Trial completed</strong></td>
    <td>Relapsed/refractory SCLC</td>
    <td>Bristol-Myers Squibb</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_71">Study Arms</button></td>
    <td><p>BMS-986012 (anti-fucosyl-GM1); Nivolumab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_542">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT02247349" target="_blank">NCT02247349</a></td><td><select class="form-select" id="select_form_84" name="NCT02247349"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Trial terminated</strong></td>
    <td>Advanced or metastatic non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutation T790M negative mesenchymal-to-epithelial transition factor (MET) amplified</td>
    <td>Novartis Pharmaceuticals</td>
<td><p>Phase 3</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_72">Study Arms</button></td>
    <td><p>capmatinib; pemetrexed; cisplatin; carboplatin; osimertinib</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_542">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04816214" target="_blank">NCT04816214</a></td><td><select class="form-select" id="select_form_85" name="NCT04816214"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Enrollment decreased by: 166</strong></td>
    <td>Solid tumors that harbor an NTRK1/2/3 ROS1 or ALK gene fusion</td>
    <td>Hoffmann-La Roche</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_73">Study Arms</button></td>
    <td><p>Entrectinib</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_542">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT02568267" target="_blank">NCT02568267</a></td><td><select class="form-select" id="select_form_86" name="NCT02568267"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 656 days</strong></td>
    <td>NSCLC ovarian cancer or breast cancer</td>
    <td>Amgen</td>
<td><p>Phase 3</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_74">Study Arms</button></td>
    <td><p>Romiplostim; Placebo</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_542">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03937154" target="_blank">NCT03937154</a></td><td><select class="form-select" id="select_form_87" name="NCT03937154"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 364 days</strong></td>
    <td>Advanced Non Small Cell Lung Cancer</td>
    <td>AstraZeneca</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_75">Study Arms</button></td>
    <td>AZD9291</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT01802632" target="_blank">NCT01802632</a></td><td><select class="form-select" id="select_form_88" name="NCT01802632"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date moved earlier by 129 days; Primary Completion Date pushed later by 164 days</strong></td>
    <td>Advanced non-small cell lung cancer (NSCLC) harboring a KRAS G12C mutation</td>
    <td>Novartis Pharmaceuticals</td>
<td><p>Phase 3</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_76">Study Arms</button></td>
    <td><p>JDQ443; docetaxel</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_543">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05132075" target="_blank">NCT05132075</a></td><td><select class="form-select" id="select_form_89" name="NCT05132075"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Enrollment decreased by: 128; Primary Completion Date pushed later by 454 days</strong></td>
    <td>Non-small Cell Lung Cancer</td>
    <td>Amgen</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_77">Study Arms</button></td>
    <td><p>Sotorasib</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_543">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04933695" target="_blank">NCT04933695</a></td><td><select class="form-select" id="select_form_90" name="NCT04933695"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 412 days; Enrollment increased by: 46</strong></td>
    <td>Metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-null solid tumors</td>
    <td>Amgen</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_78">Study Arms</button></td>
    <td><p>AMG 193; Docetaxel; Comparator AMG 193 Test Tablet</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_543">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05094336" target="_blank">NCT05094336</a></td><td><select class="form-select" id="select_form_91" name="NCT05094336"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 388 days; Enrollment increased by: 480; Primary Completion Date pushed later by 378 days</strong></td>
    <td>Advanced solid tumors</td>
    <td>Bristol-Myers Squibb</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_79">Study Arms</button></td>
    <td><p>BMS-986340; BMS-936558-01; Docetaxel</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_543">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04895709" target="_blank">NCT04895709</a></td><td><select class="form-select" id="select_form_92" name="NCT04895709"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  </tbody>
</table>
</div></td></tr>  </tbody>
</table>
<!-- THE MODAL -->
<div class="modal fade" id="modal_18" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>The Phase 1 part of the study will determine the safety tolerability PK MTD and RP2D of TPX-0046.||The food-effect sub-study determines the effect of food on a dose of TPX-0046 at the RP2D dose level.||The Phase 2 part of the study will determine the safety tolerability PK and preliminary efficacy in specific cohorts.||Phase 2 Cohorts:||Cohort I (NSCLC + RET fusion RET TKI Therapy Naive)|Cohort II (NSCLC + RET fusion RET TKI Therapy Pre-treated)|Cohort III (MTC + RET mutation RET TKI Therapy Naive)|Cohort IV (MTC + RET mutation RET TKI Therapy Pre-treated)|Cohort V (advanced/metastatic tumor with RET fusion or mutation RET TKI Therapy Naive)|Cohort VI (advanced/metastatic tumor with RET fusion or mutation RET TKI Therapy Pre-Treated)</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: TPX-0046</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Incidence of first cycle dose-limiting toxicities (DLTs) of TPX-0046|Define the Recommended Phase 2 Dose</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Determine the maximum tolerated dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of TPX-0046; Evaluate the safety and tolerability of TPX-0046</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Approximately 24 months; Within 28 days of the first TPX-0046 dose for each patient</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_19" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Active Comparator; Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Lazertinib (240 mg or 160 mg orally once daily) plus Gefitinib-matching placebo (250 mg orally once daily) in accordance with the randomization schedule|Gefitinib (250 mg orally once daily) plus Lazertinib-matching placebo (240 mg or 160 mg orally once daily) in accordance with the randomization schedule</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Gefitinib-matching placebo 250 mg; Drug: Lazertinib-matching placebo 240 mg/160 mg; Drug: Gefitinib 250 mg; Drug: Lazertinib 240 mg/160 mg</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Progression-Free Survival (PFS) according to RECIST v1.1 by Investigator assessment</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>To assess the efficacy of lazertinib compared with gefitinib as measured by PFS</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>The primary analysis of PFS based on investigator assessment will occur when PFS maturity is observed at approximately 27 months after the first patient is randomized</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_20" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Nivolumab administration:||Three doses of nivolumab will be administered to enrolled patients on Day -42 Day -28 and Day-14 (+/- two days) prior to planned surgery on Day 0 or up to +10 days.|Nivolumab 360 mg IV Carboplatin AUC 5 or 6 IV and Paclitaxel 175 or 200 mg/m2 IV every 21 days for 3 cycles prior to planned surgery on Day 0.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Nivolumab; Drug: Carboplatin; Drug: Paclitaxel</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Safety as measured by number of participants with Grade 3 and 4 lab abnormalities as defined by CTCAE v4.03|Safety as assessed by number of Grade 3 and 4 adverse events</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Safety will be measured by drawing safety labs. (CBC and a Chemistry Panel will be drawn at 2 week intervals during Nivolumab administration). Grade 3 and 4 lab abnormalities will be recorded from both participating sites.; Number of Grade 3 and 4 adverse events as defined by CTCAE v4.03 that occur while a subject is participating in the study.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>8 weeks</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_21" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Active Comparator; Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Irinotecan liposome injection|Topotecan</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Topotecan; Drug: Irinotecan liposome injection</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Overall survival (OS)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Overall survival is defined as the time from day 1 (part 1) or from randomization (part 2) to date of death.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>40 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_22" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Participants receive SI-B001 as intravenous infusion for the first cycle (4 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: SI-B001</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Phase Ia: Dose limiting toxicity (DLT)|Phase Ia: Maximum tolerated dose (MTD)|Phase Ib: Recommended Phase II Dose (RP2D)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>The RP2D is defined as the dose level chosen by the sponsor (in consultation with the investigators) for phase II study based on safety tolerability efficacy PK and PD data collected during the dose escalation study of SI-B001.; MTD is defined as the highest dose level at which no more than 1 in 6 participants experienced a DLT during the first cycle (within 28 days of the first administration).; DLTs are assessed according to NCI-CTCAE v5.0 during the first cycle (28 days) and defined as occurrence of any of the toxicities in DLT definition if judged by the investigator to be possibly probably or definitely related to study drug administration.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 28 days after the first dose of SI-B001</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_23" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Participants receive DS-1205c (at planned doses given orally twice daily: 200 mg 400 mg 800 mg 1000 mg 1200 mg) in combination with daily 250 mg oral dose of gefitinib</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: DS-1205c; Drug: Gefitinib</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Number of Participants With Dose-limiting Toxicities (DLTs) Following Administration With DS-1205c in Combination With Gefitinib|Number of Participants With Treatment-emergent Adverse Events Occurring in Participants Following Administration With DS-1205c in Combination With Gefitinib</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>A dose-limiting toxicity (DLT) was defined as any treatment-emergent adverse event (TEAE) not attributable to disease or disease-related processes that occurs during the DLT-evaluation period (Cycle 0 Day 1 to Cycle 1 Day 21 of Dose Escalation) and is Grade 3 or above according to NCI-CTCAE version 5.0.; An adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding for example) symptom or disease temporally associated with the use of a medicinal product whether or not considered related to the medicinal product. A treatment-emergent adverse event (TEAE) was defined as an AE that occurs having been absent before the first dose of study drug or has worsened in severity after the initiating the study drug until 37 days after last dose of the study drug.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Screening Cycle 0 (7-day cycle) Days -1 1 2 4 6 and 7; Cycle 1 (21-day cycle) Days 1 4 8 and 15; Cycle 2 (21-day cycle) Days 1 2 and 8; Cycle 3 and beyond (21-day cycles) Day 1; and end-of-treatment 30 days after last dose up to 1 year; Cycle 0 Day 1 (7-day cycle) to Cycle 1 Day 21 (each cycle is 21 days)</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_24" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients receive platinum based doublet chemotherapy consisting of low dose carboplatin and paclitaxel standard etoposide cisplatin or carboplatin or standard pemetrexed with cisplatin or carboplatin weekly for up to 6 weeks at the discretion of the treating medical oncologist. Patients also undergo lower dose proton beam radiation therapy daily for a total of 60 Gy for up to 30 weekdays in the absence of disease progression or unacceptable toxicity.|Patients receive platinum based doublet chemotherapy consisting of low dose carboplatin and paclitaxel standard etoposide cisplatin or carboplatin or standard pemetrexed with cisplatin or carboplatin weekly for up to 6 weeks at the discretion of the treating medical oncologist. Patients also undergo higher dose proton beam radiation therapy daily for a total of 72 Gy for up to 36 weekdays in the absence of disease progression or unacceptable toxicity.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Radiation: Proton Beam Radiation Therapy; Drug: Etoposide; Drug: Cisplatin; Drug: Pemetrexed; Other: Questionnaire Administration; Drug: Carboplatin; Drug: Paclitaxel; Other: Quality-of-Life Assessment</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Progression free survival (PFS)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>A Cox proportional hazards model stratified by stratification factors will be used to model PFS as a function of dose to test for an overall dose effect (a one-sided p-value  0.10 will be considered as significant evidence of a dose effect). Subsequently separate Cox models stratified by stratification factors will compare PFS between 72 Gy and 60 Gy (for each a one-sided p-value  0.10 will be considered as significant evidence of superiority). Kaplan Meier estimates and curves by dose level will also be generated</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>From randomization to the earliest date of documentation of disease progression or death due to any cause assessed up to 5 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_25" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients receive atezolizumab and recombinant human hyaluronidase SC over 3-8 minutes on day 1. Cycles repeat every 3 weeks for 1 year (early-stage lung cancer) or up to 2 years (late-stage lung cancer) in the absence of disease progression or unacceptable toxicity.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Other: Survey Administration; Biological: Atezolizumab and Recombinant Human Hyaluronidase</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Incidence of adverse events (AEs) of home administration by a healthcare provider (HCP) of subcutaneous atezolizumab|Successful completion of home drug administration visits within the specified window</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>The number of successfully completed home visits per patient and the number of patients who successfully completed all home administrations will be calculated and reported.; Determined by rates of grade 3 or greater non-hematologic AE assessment by clinical assessment. Grading will be based on the NCI CTCAE v5.0 .</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 30 days after last dose; Up to 2 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_26" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Atezolizumab 1200 mg will be administrated every 3 week cycle</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Atezolizumab Injection [Tecentriq]</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Objective response rate (ORR)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>ORR between blood TMB-High vs. Low group</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>At the end of cycle 3 (each cycle is 21 days)</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_27" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>3 cycles of nivolumab+Paclitaxel (albumin-bound type)+ Carboplatin AUC5 (21 days/cycle); as well as BiFico (oral taking 4 capsules/time 2 times per day)</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: nivolumab 4.5mg/kg+Paclitaxel (albumin-bound type) 260mg / m2+ Carboplatin AUC5</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>adverse effects|Surgical complications (intra-operative and peri-operative)|non-R0 surgical events</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>effectiveness; safety</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>90 days after the first medication or 30 days after the operation whichever is later; 28 days after the completion of three cycles of neoadjuvant therapy</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_28" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Active Comparator; Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients receive 200mg pembrolizumab IV over 30 minutes every 3 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity.|Patients receive 200mg pembrolizumab IV over 30 minutes every 12 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: Pembrolizumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>1-year progression-free survival (PFS)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Measured using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Baseline to 12 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_29" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Dose finding at 8 mg 12 mg or 16 mg of poziotinib once daily in 28-day treatment cycles.|Dose finding at 4 mg 6 mg or 8 mg of poziotinib twice daily in 28-day treatment cycles.|Once Daily or Twice Daily Dosing as determined in Phase 1 in 28-day treatment cycles.||Cohort 1: EGFR exon 20 insertion mutations||Cohort 2: HER2 exon 20 insertion mutations</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Poziotinib Twice Daily Dosing; Drug: Poziotinib Once Daily Dosing or Twice Daily Dosing as determined in Phase 1; Drug: Poziotinib Once Daily Dosing</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Phase 1: Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD)|Phase 2: Objective Response Rate (ORR)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>The proportion of patients who achieve Complete Response (CR) or Partial response (PR) by the best response from the first dose of poziotinib to the end of the study.; MTD/MAD will be assessed based on the occurrence of defined dose-limiting toxicities (DLT) and all available safety information during first cycle of treatment.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>28 Days; 24 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_30" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Atezolizumab (Tecentriq) intravenous (IV) 1200mg flat dose day 1 then every 3 weeks.||Pirfenidone (Esbriet) orally (PO) with food according to this schedule:||Days 1-14: 267 milligrams (mg) orally three times per day (PO TID) Days 15-29: 534 mg PO TID Days 30 onward until progression: 801 mg PO TID</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Atezolizumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Occurrence of Grade 3 toxicity|Occurrence of Grade 4 toxicity</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>CTCAE v5.0</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Cycle 1 day 1 to Cycle 3 day 1 (Each cycle is 21 days)</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_31" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Number of Participants With Dose Limiting Toxicities (DLTs)|Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)|Number of Participants With Abnormal Laboratory Values</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An serious adverse event (SAE) is defined as an AE that meets one of the following criteria: fatal or life-threatening; results in persistent or significant disability/incapacity; constitutes a congenital anomaly/birth defect; medically significant (an event that jeopardizes the participant or may require medical or surgical intervention to prevent one of the outcomes listed above [medical and scientific judgment must be exercised in deciding whether an AE is 'medically significant']); required inpatient hospitalization or prolongation of existing hospitalization. A TEAE is defined as an AE occurring or worsening between the first dose of GEN1044 and 30 days after the last dose received.; Number of participants with laboratory values of Grade = 3 by NCI-CTCAE v5.0 are reported. The NCI-CTCAE is a descriptive terminology that is used for gradings (Grade 1-5) of Adverse Events (AEs) and of laboratory values; the latter being summarized here.; The DLT was defined as Grade (G) = 3 cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome; any G3 or 4 hematologic and non-hematologic toxicity (with exceptions defined by the protocol); laboratory abnormality that required clinically significant medical intervention led to hospitalization persisted for 1 week or resulted in a drug-induced liver injury; G3 or 4 febrile neutropenia; liver toxicity defined by Hy's law; any treatment-related toxicity that caused treatment discontinuation during Cycle 1; or any G5 toxicity.; In case a participant reported multiple severity grades for a laboratory value only the maximum grade was used.; This table reports laboratory values graded only on the numerical value of the reported parameter and is therefore not graded by symptoms or signs. The abnormal laboratory values assessed by the investigator as being AEs are reported also in the AE table.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>From Day 1 to Day 21 of first cycle; Day 1 through Day 263 (corresponding to maximum observed duration)</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_32" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>GFH018 80mg 7-Day on/ 7-Day off and 4 doses of Toripalimab 240mg Q3W concurrently with standard chemo-radiotherapy followed by GFH018 80mg 14-Day on/ 14-Day off and Toripalimab 3mg/kg Q2W for up to 48 weeks</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Cisplatin; Drug: Pemetrexed; Drug: Toripalimab; Drug: GFH018; Drug: Carboplatin; Drug: Paclitaxel; Radiation: Thoracic Radiation Therapy (TRT)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Objective Response Rate (ORR)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>OR was determined using the Response Evaluation Criteria in Solid Tumors (RECIST v1.1). OR is defined as the best overall response (Complete Response (disappearance of all target and non-target lesions; no new lesions) or Partial Response (â‰¥decrease in the sum of the largest diameters of target lesions; no new lesions)) across all assessment points from enrollment to termination of trial treatment. Radiological tumour assessment was performed using CT scans.; Objective response rate (ORR) is defined as the percentage of patients with objective response (OR).</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>From the date of enrolment of the first patient up to 28 months  which is also16 months after the enrolment of the last patient</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_33" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Active Comparator; Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Participants will receive poziotinib 8 mg orally BID in 21 day cycles or until disease progression death intolerable adverse events (AEs) initiation of non-protocol anti-cancer treatment or other protocol-specified reasons for participant withdrawal from the study.|Participants will receive docetaxel 75 mg/m^2 intravenously (IV) on Day 1 of each 21-day treatment cycle or until disease progression death intolerable AEs initiation of non-protocol anti-cancer treatment or other protocol-specified reasons for participant withdrawal from the study.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Poziotinib; Drug: Docetaxel</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Progression Free Survival (PFS)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>PFS is defined as the time (in months) from the start of the study treatment to the date of first documented disease progression by central radiographic evaluation per the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v.1.1) or death due to any cause whichever occurs first.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to approximately 5 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_34" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Treating patients of locally advanced or metastatic NSCLC with EGFR exon 20 insertions who have progressed during or after platinum-based chemotherapy.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Furmonertinib</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>ORR Objective Response Rate</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Percentage of patients with a confirmed CR or PR relative to the total number of patients.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Approximately 7.5 months following the last patient enrolled</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_35" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: AMT-151</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Recommended Phase 2 Dose (RP2D)|Maximum Tolerated Dose (MTD)|Incidence of Adverse Events</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>The RP2D will be determined using dose limiting toxicities (DLTs) and all other available study data; Safety and tolerability profile assessed by the Common Terminology Criteria for Adverse Events v5.0; The MTD will be determined using DLTs</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 24 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_36" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>XMT-2056 alone (monotherapy)</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: XMT-2056</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Frequency of dose-limiting toxicities (DLTs) associated with XMT-2056 during the first cycle of treatment (Dose Escalation)|Incidence of adverse events (Dose Escalation and Dose Expansion)|Objective Response Rate (ORR) (Dose Expansion)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Determine the maximum tolerated dose (MTD) of XMT-2056; Assess the safety and tolerability of XMT-2056 by determining the number of patients with adverse events from date of first dose to 30 days post last dose.; The percentage of patients with a best overall response of confirmed complete or partial response as assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>15 months; 3 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_37" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>PRT3789 will be administered by intravenous infusion</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: PRT3789</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Dose limiting toxicity (DLT) of PRT3789|Safety and tolerability of PRT3789: AEs CTCAE Assessments|Maximum tolerated dose (MTD)/ Recommended phase 2 dose (RP2D) of PRT3789</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>The MTD/RP2D will be established for further investigation in participants with advanced solid tumors; Safety and tolerability will be evaluated by incidence of DLTs laboratory measurements dose interruption modification and discontinuation due to adverse events (AEs) according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE); Dose limiting toxicities will be evaluated over the 21-day observation period</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Baseline through approximately 3 years; Baseline through Day 21</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_38" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Part 1 patients will receive MYTX-011.|Part 2 Cohort A patients will be randomized to two different dose levels of MYTX-011. Doses to be determined after completion of Part 1.|Part 2 Cohort B patients will receive MYTX-011 at the recommended phase 2 dose.|Part 2 Cohort C patients will receive MYTX-011 at the recommended phase 2 dose.|Part 2 Cohort D patients will receive MYTX-011 at the recommended phase 2 dose.|Part 2 Cohort E patients will receive MYTX-011 at the recommended phase 2 dose.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: MYTX-011</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Part 1: Number of patients with dose limiting toxicity (DLT)|Part 2: Number of patients with tumor response</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>The dose limiting toxicities will be based on number and severity of treatment-related adverse events.; The overall response rate will be based on number of complete responses and partial responses.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to Day 21; 2 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_39" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>No Intervention; Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Non-small cell lung cancer specimens are obtained from lung tumor surgery or biopsy and are used to grow organoids. Then organoids are used for drug sensitivity tests to obtain the sensitivity to drugs. Patients will receive a relatively sensitive antitumor regimen based on the test results.|According to the National Comprehensive Cancer Network's (NCCN) Guidelines for non-small cell lung Cancer physicians will determine antitumor protocols. They're also not sure what the drug susceptibility test says.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Antitumor therapy guided by organoid drug sensitivity test</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Progression-free survival</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Time from randomization to any disease progression and/or death defined according to strict RECIST (Response Evaluation Criteria in Solid Tumors) v1.1. Lesion will be assessed in comparison to baseline measurements.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>1 year</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_40" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Treatment includes administration of pembrolizumab and chemotherapy which are administered every 21 days||Pembrolizumab 200 mg and Pemetrexed 500 mg/m2 day 1 of 21 day cycle (for non-squamous only)|Treatment includes administration of pembrolizumab and chemotherapy which are administered every 21 days||Pembrolizumab 200 mg and Nab-paclitaxel 100 mg/m2 days 18 of 21 day cycle x 4 cycles followed by pembrolizumab alone</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Pembrolizumab; Other: Pemetrexed (Chemotherapy); Other: Nab-paclitaxel (Chemotherapy)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Number of participants with Adverse Events as a Measure of Safety and Tolerability</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Determine the rate of treatment-limiting toxicities in patients with advanced non-small cell lung cancer with ECOG PS 2 who are treated with pembrolizumab and single-agent chemotherapy</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>18 Months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_41" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Active Comparator; Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Eligible patients with ALK+ NSCLC will receive oral X-396 (ensartinib) at 225mg QD with or without food until progression or unacceptable toxicity develops|Eligible patients with ALK+ NSCLC will receive oral crizotinib at 250mg BID with or without food until progression or unacceptable toxicity develops</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: X-396 (ensartinib); Drug: crizotinib</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Progression-free survival (PFS) as assessed by independent radiology review based on RECIST v. 1.1 criteria</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>36 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_42" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Subjects will receive Abemaciclib (200 mg) orally every 12 hours on days 1 to 28 of a 28-day cycle for a total of 56 doses per cycle.|Subjects will be evaluated after 4 weeks (1st cycle) and then every 8 weeks (2 cycles) with radiographic imaging to assess response to treatment.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Abemaciclib</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Overall Response Rate (ORR)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to  10 mm.; PR: At least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum of diameters.; Overall Response Rate (ORR) defined as the proportion of subjects in the analysis population who have complete response (CR) or partial response (PR) using RECIST 1.1 criteria at any time during the study. Response for the primary analyses will be determined by independent radiology review.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 2 years from start of study</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_43" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Active Comparator; Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients receive temozolomide PO QD on days 1-5 and niraparib PO QD on days 1-28. Cycles repeats every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive standard of care atezolizumab IV every 3 weeks in the absence of disease progression or unacceptable toxicity.|Patients receive standard of care atezolizumab IV every 3 weeks in the absence of disease progression or unacceptable toxicity.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Temozolomide; Drug: Niraparib; Biological: Atezolizumab; Other: Questionnaire Administration; Other: Quality-of-Life Assessment</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Recommended phase II dose of niraparib and temozolomide combination (Phase Ib)|Progression-free survival (Phase II)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Assessed per Response Evaluation Criteria in Solid Tumors 1.1. A Cox proportional hazards model will be used to estimate the hazard ratio and its 95% confidence interval. A one-sided stratified log-rank tests will be used to compare Arm A versus Arm B.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>From randomization to cancer progression assessed up to 36 months; At 28 days</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_44" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental; Placebo Comparator</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: TORIPALIMAB INJECTION (JS001 ) combine with chemotherapy</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>PFS</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Progression free survival (PFS) evaluated by investigators according to the response evaluation criteria in solid tumors (RECIST 1.1)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 2 approximately years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_45" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Bintrafusp alfa</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Occurrence of Adverse Events and Treatment-Related Adverse Events</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Time from first treatment in parent study to planned final assessment at approximately up to 5 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_46" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>This is an open-label dose-escalating non-randomized single-center Phase I therapeutic study of GL-ONC1 originally administered intrapleurally as a single dose and now escalating to three consecutive daily doses in patients with a diagnosis (histologically or cytologically documented) of malignant pleural effusions.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: GL-ONC1</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Maximum Tolerated Dose (MTD)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>MTD is to provide a dosing recommendation for subsequent Phase II studies. Three patients will be enrolled in each cohort at the dose levels shown in the table below in order to determine the Maximum Tolerated Dose (MTD). At the beginning of a new dose level only one patient will be treated. The first patient in each cohort must be treated and complete 14 days of post-treatment evaluation prior to the treatment of the remaining two patients in that cohort.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>2 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_47" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients receive 18F-alphavbeta6-BP IV and then undergo 4 PET scans over 30 minutes each at 30 60 120 and 180 minutes post-injection.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: 18F-Î±vÎ²6-BP</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Assessment of safe administration of 18F-Î±vÎ²6-BP</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Assessed by measures and/or changes in a given vital sign</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 6 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_48" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>BRCA1/BAP1 negative mesothelioma; 600mg twice daily (BID) every 28 days.|p16INK4A negative mesothelioma; 200mg orally twice daily every 28 days.|No specific biomarker requirement: Pembrolizumab 200mg IV infusion on Day 1 only:||Bemcentinib loading dose of 400mg on days 1-3 on day 4 on-wards 200mg daily every 21-days.|PDL1 expression positive mesothelioma: Atezolizumab 1200 milligrams via intravenous nfusion; Bevacizumab 15 milligrams per kilogram via IV infusion both on Days 1 every 21-days.|Platinum sensitive mesothelioma: Niraparib 200-300mg daily every 21 days; Dostarlimab 500mg on day 1 of each 21 day cycle for 4 cycles then 1000mg on day 1 of each 42 day cycle.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Atezolizumab & Bevacizumab; Drug: pembrolizumab & bemcentinib; Drug: Rucaparib; Drug: Abemaciclib; Drug: Dostarlimab and Niraparib</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Disease control rate (DCR) at 12 weeks assessed by modified RECIST 1.1 in patients with relapsed mesothelioma.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>This will be assessed using CT scan evidence according to modified RECIST 1.1 criteria reporting. Scans will be undertaken every 6 weeks. Analysis will be timed from study entry using the baseline CT scan results until completion of treatment cycles confirmed disease progression or death - whichever comes first.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>12 weeks</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_49" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Nivolumab administration:||Three doses of nivolumab will be administered to enrolled patients on Day -42 Day -28 and Day-14 (+/- two days) prior to planned surgery on Day 0 or up to +10 days.|Nivolumab 360 mg IV Carboplatin AUC 5 or 6 IV and Paclitaxel 175 or 200 mg/m2 IV every 21 days for 3 cycles prior to planned surgery on Day 0.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Nivolumab; Drug: Carboplatin; Drug: Paclitaxel</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Safety as measured by number of participants with Grade 3 and 4 lab abnormalities as defined by CTCAE v4.03|Safety as assessed by number of Grade 3 and 4 adverse events</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Safety will be measured by drawing safety labs. (CBC and a Chemistry Panel will be drawn at 2 week intervals during Nivolumab administration). Grade 3 and 4 lab abnormalities will be recorded from both participating sites.; Number of Grade 3 and 4 adverse events as defined by CTCAE v4.03 that occur while a subject is participating in the study.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>8 weeks</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_50" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients receive osimertinib PO QD for 6-12 weeks. Patients then undergo surgery and/or radiation therapy daily for 5 consecutive days every week for up to 8 weeks. Patients continue osimertinib during and after radiation therapy. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.|Patients receive osimertinib PO QD. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Procedure: Therapeutic Conventional Surgery; Radiation: Radiation Therapy; Drug: Osimertinib</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Progression free survival (PFS)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Will be estimated using Kaplan-Meier method. The stratified log-rank test will be performed to test the difference in time-to-event distributions between treatment groups. Stratified Cox proportional hazards model will be utilized to include multiple covariates in the time-to-event analysis and to estimate hazard ratios.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>From the start date of osimertinib assessed up to 4 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_51" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>PROJECT 1: Patients receive standard of care and undergo collection of stool and blood samples.||PROJECT 2: Patients receive prednisone infliximab or vedolizumab per standard of care and undergo standard of care endoscopy 2 months after treatment. Patients also undergo collection of stool blood and tissue samples.||PROJECT 3: Patients undergo FMT.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: Infliximab; Other: Biospecimen Collection; Other: Best Practice; Procedure: Endoscopic Procedure; Other: Laboratory Biomarker Analysis; Procedure: Fecal Microbiota Transplantation; Biological: Vedolizumab; Drug: Prednisone</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Difference in stool microbiome pattern|Incidence of adverse events (AE) of fecal microbiota transplantation (FMT) (Project 3)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Adverse events will be recorded by Common Terminology Criteria for Adverse Events version 5 as well as FMT-specific events. All events will be recorded with grade and attribution to FMT. Adverse events that are related to fecal microbiota transplantation will be summarized using frequency and percentage by AE grade type and attributions.; The primary endpoint is alpha diversity of bacteria species (measured using inverse Simpson index). It is a measure of diversity which takes into account the number of species present as well as the relative abundance of each species. As species richness and evenness increase so diversity increases.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 1 year</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_52" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Active Comparator; Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Arm A: Carboplatin + Pemetrexed + Bevacizumab + Atezolizumab Maintenance: Pemetrexed + Bevacizumab + Atezolizumab|Arm B: Carboplatin + Pemetrexed + Bevacizumab Maintenance: Pemetrexed + Bevacizumab</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Arm B; Drug: Arm A</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Progression free survival</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Time a patient shows progression of disease from the time of intervention</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>12.5 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_53" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Active Comparator; Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Selpercatinib administered orally.|Pemetrexed administered intravenously (IV) plus the investigator's discretion of carboplatin IV or cisplatin IV with or without pembrolizumab IV.|Pemetrexed administered IV plus the investigator's discretion of carboplatin IV or cisplatin IV with pembrolizumab IV.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Pembrolizumab; Drug: Cisplatin; Drug: Pemetrexed; Drug: Carboplatin; Drug: Selpercatinib</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) (with Pembrolizumab)|PFS by BICR (with or without Pembrolizumab)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>PFS by BICR (with Pembrolizumab); PFS by BICR (with or without Pembrolizumab)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Baseline to Progressive Disease or Death from Any Cause (Estimated at up to 24 Months)</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_54" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>LOADING PHASE: Patients receive recombinant human EGF-rP64K/montanide ISA 51 vaccine IM at 0 2 4 and 6 weeks in the absence of disease progression or unacceptable toxicity.||MAINTENANCE PHASE: Patients receive recombinant human EGF-rP64K/montanide ISA 51 vaccine IM Q4W in the absence of disease progression or unacceptable toxicity.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Other: Questionnaire Administration; Other: Quality-of-Life Assessment; Biological: Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Percentage of participants with antibody titers = 1:4000 in response to vaccination|Molecular biomarker analysis|Number of patients with grade 3 4 or 5 toxicities that are attributable to recombinant human EGF-rP64K/montanide ISA 51 vaccine (CIMAvax)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Measured according to Cancer Therapy Evaluation Program (CTEP) National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5. The plausible range for the true (unobserved) event rate will be estimated by the upper one-sided 95% Jeffrey's interval.; The response to the vaccine will be measured using circulating EGF and anti-EGF antibodies replicating the results from the Cuban and Roswell trials. Human EGF will be determined by the Roswell Park Flow and Image Cytometry CCSG supported Resource using a commercial enzyme-linked immunosorbent assay (ELISA) assay (R&D Systems Minneapolis MN). EGF antibodies will also be determined by the Roswell Park Flow and Image Cytometry Resource using an in-house assay developed in cooperation with the Centro de Immunologia Molecular in La Habana Cuba.; Will access the molecular profile of blood bronchial brushes and bronchial biopsies to identify molecular markers associated with treatment and response. Biomarker scores will be analyzed for the molecular profile endpoint to test if they are significantly different post-treatment compared to pre-treatment (via paired t-test) or if a change in biomarker score (post-versus pre-) is significantly different among responders versus nonresponders (via t-test) as defined by histology and circulating levels of EGF ligand and anti-EGF antibodies. In addition to these biomarkers gene expression signatures will be analyzed. These include gene expression signatures associated with EGFR activity the high-grade lesion molecular subtype and the immune-associated signature predictive of progressive/stable lesions compared with regressive lesions.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 60 days post treatment</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_55" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>GRT-C903|GRT-R904|nivolumab|ipilimumab|GRT-C903|GRT-R904|nivolumab|ipilimumab||Phase 2 for some patients includes a monthly or every two month treatment schedule</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: nivolumab; Biological: GRT-R904; Biological: GRT-C903; Biological: ipilimumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Incidence of adverse events (AEs) serious adverse events (SAEs) and dose limiting toxicities (DLTs)|Objective Response Rate (ORR) in Phase 2 using RECIST v1.1|Identify the recommended Phase 2 dose (RP2D) of GRT-C903 and GRT-R904</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to approximately 6 months; Initiation of study treatment until disease progression (up to approximately 27 months); Initiation of study treatment through 100 days post-last dose (up to approximately 27 months)</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_56" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Tislelizumab on a 3-week cycle for 2 cycles followed by surgical resection (each cycle is 21 days)|Tislelizumab + ociperlimab on a 3-week cycle for 2 cycles followed by surgical resection (each cycle is 21 days)|Tislelizumab + LBL-007 on a 3-week cycle for 2 cycles followed by surgical resection (each cycle is 21 days)</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Tislelizumab; Drug: Ociperlimab; Drug: LBL-007</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Major Pathological Response (MPR)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>MPR is defined as the proportion of participants with â‰¤ 10% residual viable tumor in the resected primary tumor and all resected lymph nodes as assessed by blinded independent pathology review (BIPR)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to approximately 12 weeks after first dose</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_57" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Radiation: SBRT; Drug: Durvalumab; Drug: Tremelimumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Dose Limiting Toxicity (DLT)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Event possibly related to study drugs and fulfills any one of the following criteria using CTCAE Version 4.03</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Approximately 8 weeks</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_58" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Only cancer patients under treatment with pembrolizumab monotherapy administered within clinical practice and according to the Italian Drug Regulatory Agency (Agenzia Italiana del Farmaco AIFA) will be enrolled.||Patients diagnosed with NSCLC HNSCC melanoma and urothelial carcinoma will be eligible for the study.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Radiation: Carbon Ion Therapy; Drug: Immunotherapy (Pembrolizumab)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Objective response rate assessed by RECIST V1.1</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>To estimate the effect in terms of clinical response of immunotherapy associating carbon ion treatment (CIRT) in the palliative setting across different malignancies for which immunotherapy is currently the standard of care. Objective response rate (ORR) will be evaluated after CIRT administrated during immunotherapy maintenance in patients with stable disease. ORR will be assessed in the whole population according to RECIST v1.1. The proportion of ORR will be estimated within each disease.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>At least 8 weeks</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_59" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Nivolumab 240mg IV + Ramucirumab 8mg/kg IV</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Nivolumab; Drug: Ramucirumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Response Rate</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>â€¢ Evaluate response rate [complete response (CR) + partial response (PR)] of nivolumab in combination with ramucirumab in subjects with previously-treated mesothelioma. Response assessment will be performed using modified RECIST 1.1 criteria.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>24 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_60" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Subjects to be treated with the investigational drug TGRX-326</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: TGRX-326</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Maximal tolerated dose (MTD)|Recommended phase II dose (RP2D)|Safety profile (DLT)|Safety profile (AEs/SAEs)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>To record and analyse subjects with dose-limiting toxicities (DLTs); To record and analyse subjects with adverse events (AEs) and serious adverse events (SAEs); To determine the RP2D of TGRX-326 in NSCLC patients for Phase II; To determine the MTD of TGRX-326 in NSCLC patients</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Through completion of the study an average of 1.5 years; At end of Cycle 1 (each cycle is 21 days) when the probability of DLT of a dose level is higher than 33%; At completion of the dose expansion study an average of 1 year; Collect during Cycle 1 (each cycle is 21 days)</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_61" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Single arm</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: JIN-A02</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Maximum Tolerable Dose (MTD)|Adverse Events (AE) rate|Serious Adverse Events (SAE) rate|Dose Limiting Toxicity (DLT)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>DLT is evaluated for all subjects enrolled to cycle 1 (DLT evaluation period: 21 days) of the Part A dose escalation study. When a subject receives at least 75% of his or her assigned daily dose during the DLT period or shows DLT the subject is considered evaluable for DLT. All AEs that occur during the DLT period are possibly related to JIN-A02 in the least and satisfy all of the following criteria are designated as DLT. Also the occurrence of any of the toxicities outlined in this section will be considered a DLT unless clearly related to underlying disease or extraneous causes.; The dose level at which the estimated DLT rate is closest to the target toxicity rate 0.3 is selected as MTD. If two or more dose levels are selected at a rate lower than 0.3 a higher one is selected as MTD. If two or more dose levels are selected at a rate higher than 0.3 a lower one is selected as MTD.; In the Part A dose escalation study MTD is evaluated in DLT Set. When the study ends according to the BOIN design the DLT rate per dose level is estimated as posterior probability based on the beta-binomial model and 95% CI is presented.; Safety evaluation is analyzed based on the Safety Set. Safety is clinically evaluated by assessing all relevant endpoints including AE SAE laboratory tests vital signs ECG results and concomitant drugs. Reported AE terminologies are standardized using MedDRA and the AE grade and intensity are evaluated according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0. The AE summary focuses on AE that first occurred after initial administration of IP or that occurred after administration as an aggravation of pre-existing symptoms. AEs are summarized by the number and percentage of subjects experiencing AE per cohort based on the System Organ Class (SOC) and Preferred Term (PT).</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>21 days; 28 days</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_62" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Active Comparator; Placebo Comparator</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Limonene capsules(marketed product in China) donate by pharmaceutical company.|Same smell color and shape as limonene capsules(marketed product in China) without limonene in capsules.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Limonene capsule; Drug: Limonene capsules(Placebo)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Changes in the sum of longest diameters of target nodules (multiple nodules) between the drug group and the placebo group.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Difference in the sum of longest diameters of target nodules</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>at baseline three months and six months after administration</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_63" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Liposomal Annamycin (L-Annamycin)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Dose Limiting Toxicity</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Number of patients with a dose limiting toxicity (DLT) at each dose evaluated</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>21 days</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_64" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Other: Placebo; Drug: Ipilimumab; Drug: BMS-986207; Drug: Nivolumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Progression-free survival (PFS) based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by Blinded Independent Central Review (BICR)</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 25 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_65" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients with Non-Small Cell Lung Cancer|Patients with Small Cell Lung Cancer</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Etoposide; Drug: Carboplatin; Drug: Cisplatin; Drug: Durvalumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Observed serum concentration (Ctrough)|Number of patients with injection site reactions and immune-mediated reactions|Maximum observed serum concentration (Cmax)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Approximately 16 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_66" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Active Comparator; Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Nivolumab 3 mg/kg solution intravenously (IV) every 2 weeks until documented disease progression discontinuation due to toxicity withdrawal of consent or the study ends. Eligible patients may receive nivolumab at 480mg every 4 weeks until documented disease progression discontinuation withdrawal of consent or the study ends.|Docetaxel 75 mg/m^2 concentrate for solution for intravenous infusion every 3 weeks until documented disease progression discontinuation due to toxicity withdrawal of consent or the study ends. Eligible patients may receive nivolumab at 480mg every 4 weeks until documented disease progression discontinuation withdrawal of consent or the study ends.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: Nivolumab; Drug: Docetaxel</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Overall survival was defined as the time from randomization to the date of death. A participant who has not died will be censored at last known date alive. OS will be followed continuously while participants are on the study drug and every 3 months via in-person or phone contact after participants discontinue the study drug. Median and hazard ratio computed using Kaplan-Meier method.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Randomization until 413 deaths up to March 2015 (approximately 29 months)</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_67" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Other</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>AZD9291 tablets following a period of fasting|AZD9291 tablets following a high-fat meal.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Other: Dietary High Fat; Other: Dietary Fasted; Procedure: Pharmacokinetic sampling - AZD9291; Drug: AZD9291 tablets; Procedure: Pharmacokinetic sampling - AZ5140 and AZ7550</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>AUC(0-72) of AZD9291|Cmax of AZD9291</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Pharmacokinetics of AZD9291 by assessment of area under the plasma concentration time curve from zero to 72 hours.; Pharmacokinetics of AZD9291 by assessment of maximum plasma AZD9291 concentration.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Blood samples collected on Day 1 and Day 10 at pre-dose 0.5 1 1.5 2 3 4 6 8 10 12 24 48 and 72 hours post AZD9291 dose in Part A.; Blood samples collected on Day 1 and Day 10 at pre-dose 0.5 1 1.5 2 3 4 6 8 10 12 24 48 72 120 168 and 216 hours post AZD9291 dose in Part A.</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_68" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Active Comparator; Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Participants will be treated with JDQ443|Participant will be treated with docetaxel following local guidelines as per standard of care and product labels</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: JDQ443; Drug: docetaxel</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Progression free survival (PFS)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>PFS is the time from date of randomization/start of treatment to the date of event defined as the first documented progression or death due to any cause. PFS is based on central assessment and using RECIST 1.1 criteria.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Approximately up to 24 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_69" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Participants from outside of Korea with progressive disease and on prior epidermal growth factor receptor (EGFR) Tyrosine kinase inhibitor (TKI) therapy will receive recommended phase 2 doses based on safety tolerability efficacy and pharmacokinetics (PK) of Lazertinib.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Lazertinib</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Part D: Number of Participants with Adverse Event as a Measure of Safety and Tolerability|Part D: Plasma Concentration of Lazertinib After Administration of Single Dose (SD)|Part D: Plasma Concentration of Lazertinib After Administration of Multiple Dose (MD)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Plasma Concentration of Lazertinib after administration of multiple dose will be evaluated.; Plasma Concentration of Lazertinib after administration of single dose will be evaluated.; An adverse event is any untoward medical event that occurs in a participants administered an investigational product and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 2 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_70" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Non-squamous non-small cell lung cancer (NSCLC) patients treated with 800 mg avelumab plus pemetrexed/carboplatin|Cisplatin-eligible urothelial cancer (UC)patients treated with 800 mg avelumab plus gemcitabine/cisplatin|Non-squamous non-small cell lung cancer (NSCLC) patients treated with 1200 mg avelumab plus pemetrexed/carboplatin|Cisplatin-eligible urothelial cancer (UC) patients treated with 1200 mg avelumab plus gemcitabine/cisplatin</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Avelumab 1200 mg in combination with pemetrexed/carboplatin; Drug: Avelumab 1200 mg in combination with gemcitabine/cisplatin; Drug: Avelumab 800 mg in combination with gemcitabine / cisplatin.; Drug: Avelumab 800 mg in combination with pemetrexed / carboplatin</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Phase 1b Lead-in: Number of Participants With Dose-Limiting Toxicities (DLT)|Percentage of Participants With Confirmed Objective Response (OR) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1 by Investigator Assessment</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>DLTs=occurrence of any of the following AEs attributable to any study treatment in first 2 treatment cycles:Hematologic: grade(G)4 neutropenia lasting 7days;febrile neutropenia with body temperature =38 degree Celsius for 1hour; G=3 neutropenic infection(absolute neutrophil count 1.0*10^9/L)G=3 thrombocytopenia (platelet count[PC] 50.0-25.0*10^9/L)with bleeding;G4 thrombocytopenia(PC25.0*10^9/L)G4 anemia(life-threatening).Non-hematologic: any G4 toxicities;G3 toxicities persisting for 3days despite medical treatment(e.g.-nauseavomitingdiarrhea)except endocrinopathies controlled with hormonal therapy;ALT/AST 3*upper limit of normal(ULN)if normal at baseline or 2*Baseline(ULN at baseline)with total bilirubin 2*ULN and alkaline phosphatase 2*ULN;G3 QTcF prolongation after correction of any reversible cause(electrolyte abnormalities/hypoxia).Delay of =3weeks in scheduled administration/failure to deliver 75% of doses due to toxicities attributable to any study treatment.; OR defined as complete response(CR) or partial response(PR) as determined by investigator according to RECIST v1.1 from date of first dose of study treatment until date of first documentation of progressive disease(PD) and confirmed by repeat assessments performed no less than 4 weeks after first response. CR: disappearance of target and non-target lesions with exception of nodal disease and normalization of tumor markers. All nodes target and non-target must have short axis measures less than ()10 millimeter(mm). PR: =30% decrease in sum of measures (longest diameter for tumor lesions and short axis measure for nodes) of target lesions taking as reference baseline sum of diameters. Non-target lesions must be non-PD. PD: =20% increase in sum of diameters of target lesions taking as reference the smallest sum on study. In addition to relative increase of 20% sum must also demonstrate an absolute increase of at least 5mm appearance of one or more new lesions was considered PD.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Day 1 up to Week 6 (first 2 treatment cycles; 1 cycle = 21 days); From start of the treatment until disease progression or death due to any cause whichever occurred first (maximum up to 3.5 years approximately)</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_71" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity in combination with Nivolumab specified dose on specified days|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity in combination with Nivolumab specified dose on specified days|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity in combination with Nivolumab specified dose on specified days</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: Nivolumab; Biological: BMS-986012 (anti-fucosyl-GM1)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Safety as measured by frequency of worst grade of adverse events (AEs) worst grade of serious adverse events (SAEs) incidence of adverse events leading to discontinuations and deaths</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Safety as measured by frequency of worst grade of adverse events (AEs) worst grade of serious adverse events (SAEs) incidence of adverse events leading to discontinuations and deaths graded by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) as appropriate</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Weekly for 1st and 2nd 21-day cycles then once every 3 weeks during study treatment at end of treatment and every 30 days during clinical follow-up until resolution of adverse events or 100 days after the last dose of study medication (Approx 3 years)</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_72" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Active Comparator; Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>For run-in part: Up to 2 dose levels of capmatinib in combination with osimertinib may be investigated. The starting dose of combination is capmatinib 400 mg orally twice daily (b.i.d) and osimertinib 80 mg orally once per day (q.d). If a dose de-escalation is required a lower dose level is defined as capmatinib 400 mg orally twice a day (b.i.d) and osimertinib 40 mg orally once per day (q.d.)|For randomized part: capmatinib in combination with osimertinib administered at the recommended Phase III regimen (defined in the safety run-in part).|For randomized part: following local guidelines as per standard of care and products labels Participants randomized to platinum-pemetrexed based doublet chemotherapy arm will be allowed to crossover to receive capmatinib in combination with osimertinib</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: pemetrexed; Drug: cisplatin; Drug: capmatinib; Drug: carboplatin; Drug: osimertinib</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Run-in part: Incidence of dose limiting toxicities (DLTs)|Randomized part: Progression free survival (PFS)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Progression free survival (PFS) per Blinded Independent Review Committee (BIRC) according to Response Evaluation Criteria In Solid Tumors 1.1 (RECIST 1.1); Incidence of Dose Limiting Toxicities (DLT) during the first 21 days (3 weeks) of treatment for each dose level associated with administration of capmatinib in combination with osimertinib</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>3 weeks; 37 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_73" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Oral entrectinib (RXDX-101)|Oral entrectinib (RXDX-101)|with CNS-only progression previously treated with crizotinib (NOTE: The ALK-rearranged portion of this arm is now closed to enrollment.)||Oral entrectinib (RXDX-101)|Oral entrectinib (RXDX-101)|Oral entrectinib (RXDX-101)|Oral entrectinib (RXDX-101)|Oral entrectinib (RXDX-101)|Oral entrectinib (RXDX-101)|Oral entrectinib (RXDX-101)</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Entrectinib</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Objective Response Rate</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Assessed by blinded independent central review (BICR) using RECIST v1.1</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Approximately 24 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_74" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental; Placebo Comparator</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>The study in a 2:1 randomization ratio(108 subjects to romiplostim). Amgen investigational product (romiplostim or placebo) will be administered in the clinic by a qualified healthcare provider as a subcutaneous injection.|The study in a 2:1 randomization ratio (54 subjects to placebo) Amgen investigational product (romiplostim or placebo) will be administered in the clinic by a qualified healthcare provider as a subcutaneous injection.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Romiplostim; Drug: Placebo</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Incidence of either a chemotherapy dose delay or reduction</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>No thrombocytopenia-induced modification of any myelosuppressive agent in the second and third cycles of the planned on-study chemotherapy regimen. Thrombocytopenia-induced modifications include chemotherapy dose reduction delay omission or chemotherapy treatment discontinuation due to platelet counts below 100 x 109/L</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>48 days</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_75" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Daily oral dose of AZD9291</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: AZD9291</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Objective Response Rate (ORR) for Dose Expansion Population|Best Objective Response (BOR) for Dose Escalation Population|Objective Response Rate (ORR) for Extension Population</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Per Response Evaluation Criteria in Solid Tumours (RECIST v1.1) assessed by MRI or CT: Complete Response (CR): Disappearance of all target and non-target lesions and no new lesions; Partial Response (PR): = 30% decrease in the sum of diameters of Target Lesions (compared to baseline) and no new lesions. ORR is the percentage of patients with at least 1 visit response of CR or PR (by independent central review) that was confirmed at least 4 weeks later prior to progression or further anti-cancer therapy.; Per Response Evaluation Criteria in Solid Tumours (RECIST v1.1) assessed by MRI or CT: Complete Response (CR): Disappearance of all target and non-target lesions and no new lesions; Partial Response (PR): = 30% decrease in the sum of diameters of Target Lesions (compared to baseline) and no new lesions. ORR is the percentage of patients with at least 1 visit response of CR or PR (by investigator assessment) that was confirmed at least 4 weeks later prior to progression or further anti-cancer therapy.; Per Response Evaluation Criteria in Solid Tumours (RECIST v1.1) assessed by MRI or CT: Complete Response (CR): Disappearance of all target and non-target lesions and no new lesions; Partial Response (PR): = 30% decrease in the sum of diameters of Target Lesions (compared to baseline) and no new lesions; Stable disease (SD): Neither sufficient shrinkage to qualify as a response nor sufficient growth to qualify as progression; Progressive Disease (PD): = 20% increase in the sum of diameters of TLs and an absolute increase in sum of diameters of =5mm (compared to the previous minimum sum) or progression of NTLs or a new lesion. Not evaluable (NE): TL response is missing and there is no evidence of progression of NTLs and no new lesions. BOR is the best response (by investigator assessment) a patient has achieved where the order of best to worst is CR PR SD PD NE prior to or at progression and prior to further anti-cancer therapy.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>RECIST tumour assessments every 6 weeks from randomisation until objective disease progression up to approximately 21 months (at time of analysis); RECIST tumour assessments every 6 weeks from randomisation until objective disease progression up to approximately 12 months (at the time of analysis); RECIST tumour assessments every 6 weeks from randomisation until objective disease progression up to approximately 25 months (at time of analysis)</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_76" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Active Comparator; Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Participants will be treated with JDQ443|Participant will be treated with docetaxel following local guidelines as per standard of care and product labels</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: JDQ443; Drug: docetaxel</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Progression free survival (PFS)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>PFS is the time from date of randomization/start of treatment to the date of event defined as the first documented progression or death due to any cause. PFS is based on central assessment and using RECIST 1.1 criteria.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Approximately up to 24 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_77" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Participants with metastatic non-small cell lung cancer (NSCLC) with Kirsten rat sarcoma (KRAS) p.G12C mutation whose tumors express  1% programmed death-ligand 1 (PD-L1) and/or serine/threonine kinase 11 (STK11) mutation in need of first line treatment will be administered sotorasib 960 mg daily. Participants will be stratified by known presence of STK11 mutation.|Participants with metastatic non-small cell lung cancer (NSCLC) with Kirsten rat sarcoma (KRAS) p.G12C mutation whose tumors express  1% programmed death-ligand 1 (PD-L1) and/or serine/threonine kinase 11 (STK11) mutation in need of first line treatment will be administered sotorasib 240 mg daily. Participants will be stratified by known presence of STK11 mutation.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Sotorasib</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Objective Response Rate (OR)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>OR is defined as the total of Complete Response (CR) and Partial Response (PR).</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 6 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_78" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Participants with MTAP-null solid tumors will receive escalating doses of AMG 193 to estimate the MTD and/or the RP2D.||A group of these participants in the United States will have the option to take part in a Drug Substance Particle Size (DSPS) assessment. These participants will receive escalating doses of AMG 193 and a dose of a comparator AMG 193 test tablet.|Participants will receive the identified MTD/RP2D of AMG 193 in the following cohort:||MTAP-null squamous NSCLC.|Participants with MTAP-null NSCLC will receive escalating doses of AMG 193 + a fixed dose of docetaxel to estimate the MTD/RP2D of the combination.|Participants with MTAP-null NSCLC will receive the identified MTD/RP2D of AMG 193 + docetaxel.|Participants with MTAP-null NSCLC will receive AMG 193.|Participants will receive the identified MTD/RP2D of AMG 193 in the following cohort:||MTAP-null adenocarcinoma NSCLC|Participants will receive the identified MTD/RP2D of AMG 193 in the following cohort:||MTAP-null BTC|Participants will receive the identified MTD/RP2D of AMG 193 in the following cohort:||MTAP-null head and neck squamous cell carcinoma (HNSCC)|Participants will receive the identified MTD/RP2D of AMG 193 in the following cohort:||MTAP-null pancreatic adenocarcinoma|Participants will receive the identified MTD/RP2D of AMG 193 in the following cohort:||MTAP-null solid tumor other than squamous or adenocarcinoma NSCLC BTC HNSCC pancreatic adenocarcinoma primary brain tumor and lymphoma.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: AMG 193; Drug: Comparator AMG 193 Test Tablet; Drug: Docetaxel</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Parts 1 and 2: Number of Participants Who Experience a Dose-Limiting Toxicity (DLT)|Parts 1 and 2: Number of Participants Who Experience a Treatment-emergent Adverse Event (TEAE)|Part 3: Objective Response Rate (ORR)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Other medically important serious event; Serious AEs (SAEs) are defined as any event that meets at least 1 of the following serious criteria:; Adverse events (AEs) are defined as any untoward medical occurrence in clinical study participant irrespective of a causal relationship with the study treatment. TEAEs are any event that occurs after the participant has received study treatment. Any clinically significant changes in vital signs electrocardiograms (ECGs) and clinical laboratory tests will be recorded as TEAEs.; Results in persistent or significant disability/incapacity; Is a congenital anomaly/birth defect; Results in death (fatal); Requires in-patient hospitalization or prolongation of existing hospitalization</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>28 days; Up to approximately 2 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_79" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: BMS-986340; Drug: Docetaxel; Drug: BMS-936558-01</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Incidence of adverse events (AEs)|Incidence of serious adverse events (SAEs)|Incidence of AEs meeting protocol defined dose-limiting toxicity (DLT) criteria|Incidence of AEs leading to discontinuation|Incidence of AEs leading to death</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 120 weeks</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>


<!-- ############################### -->
<!-- ############################### -->
<!-- ########### NEW IT ############ -->
<!-- ############################### -->
<!-- ############################### -->

<br><h2 id="new_it">New Trials - Intratumoral</h2>
<h4><a href="#home">Home</a></h4>
<table border="1" summary="Long-term goals table" width="100%" cellspacing="0" cellpadding="0">
  <thead>
    <tr>
      <th><h3>Condition</h3></th>
      <th><h3>Sponsor</h3></th>
      <th><h3>Phase</h3></th>
      <th><h3>Intervention</h3></th>
      <th><h3>Trial ID</h3></th>
      <th><h3>Interest Level?</h3></th>
    </tr>
  </thead>
  <tbody>
  <tr>
    <td>Advanced hepatocellular carcinoma</td>
    <td>Binhui Biopharmaceutical Co. Ltd.</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_80">Study Arms</button></td>
    <td>OH2 injection</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05698459" target="_blank">NCT05698459</a></td><td><select class="form-select" id="select_form_93" name="NCT05698459"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td>Advanced hepatocellular carcinoma</td>
    <td>Wan-Guang Zhang</td>
<td><p>N/A</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_81">Study Arms</button></td>
    <td><p>HAIC; Bevacizumab plus Atezolizumab; Bevacizumab Biosimilar IBI305 plus sintilimab; Lenvatinib; Sorafenib; Donafenib; Regorafenib; apatinib plus camrelizumab; Anti-PD-1 monoclonal antibody</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_544">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05713994" target="_blank">NCT05713994</a></td><td><select class="form-select" id="select_form_94" name="NCT05713994"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td>Diffuse Glioma; Malignant Glioma</td>
    <td>Mayo Clinic</td>
<td><p>Early Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_82">Study Arms</button></td>
    <td>Biospecimen Collection; Computed Tomography; Eflornithine; Magnetic Resonance Imaging; Placebo Administration; Polyamine Transport Inhibitor AMXT-1501 Dicaprate; Resection</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05717153" target="_blank">NCT05717153</a></td><td><select class="form-select" id="select_form_95" name="NCT05717153"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td>Progressive DIPG</td>
    <td>Capital Medical University</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_83">Study Arms</button></td>
    <td>Ad-TD-nsIL12</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05717699" target="_blank">NCT05717699</a></td><td><select class="form-select" id="select_form_96" name="NCT05717699"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td>Primary DIPG</td>
    <td>Capital Medical University</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_84">Study Arms</button></td>
    <td>Ad-TD-nsIL12</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05717712" target="_blank">NCT05717712</a></td><td><select class="form-select" id="select_form_97" name="NCT05717712"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td>Advanced hepatocellular carcinoma</td>
    <td>Tongji Hospital</td>
<td><p>N/A</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_85">Study Arms</button></td>
    <td><p>TACE; Lenvatinib; Anti-PD-1 monoclonal antibody; Bevacizumab Biosimilar IBI305 plus sintilimab; Bevacizumab plus Atezolizumab; apatinib plus camrelizumab; Sorafenib; Donafenib; Regorafenib</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_548">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05717738" target="_blank">NCT05717738</a></td><td><select class="form-select" id="select_form_98" name="NCT05717738"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr data-toggle="collapse" data-target="#demo4" class="accordion-toggle">  <td colspan="6">NO LARGE COMPANY TRIALS</td>
  </tr>
  </tbody>
</table>
<!-- THE MODAL -->
<div class="modal fade" id="modal_80" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Administrationï¼šintratumoral injection Frequencyï¼šonce every 3 weeks</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: OH2 injection</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>DLTs (Dose Limiting Toxicity)|MTD (Maximum Tolerance dose)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Toxic reactions according to the NCI-CTCAE 5.0 grading standard that occur within 3 weeks from the first administration are judged to be drug-related by the investigator and meet the non-hematological toxicity and hematological toxicity conditions specified in the clinical protocol; If â‰¥2/6 subjects developed DLT the previous dose group was MTD</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>2 years; 3 weeks from the first administration</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_81" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients with advanced hepatocellular carcinoma who was initially evaluated unsuitable for the radical therapy and received combined HAIC plus bevacizumab (A) and atezolizumab (T) as conversion therapy for downstaging.|Patients with advanced hepatocellular carcinoma who was initially evaluated unsuitable for the radical therapy and received combined HAIC plus lenvatinib (Len) and anti-PD-1 antibody as conversion therapy for downstaging.|Patients with advanced hepatocellular carcinoma who was initially evaluated unsuitable for the radical therapy and received combined HAIC plus bevacizumab biosimilar (Byvasda B) and Sintilimab (Tyvyt S) antibody as conversion therapy for downstaging.|Patients with advanced hepatocellular carcinoma who was initially evaluated unsuitable for the radical therapy and received combined HAIC plus Apatinib (Apa) and Camrelizumab (C) antibody as conversion therapy for downstaging.|Patients with advanced hepatocellular carcinoma who was initially evaluated unsuitable for the radical therapy and received combined HAIC plus sorafenib (Sor) and anti-PD-1 antibody as conversion therapy for downstaging.|Patients with advanced hepatocellular carcinoma who was initially evaluated unsuitable for the radical therapy and received combined HAIC plus donafenib (Don) and anti-PD-1 antibody as conversion therapy for downstaging.|Patients with advanced hepatocellular carcinoma who was initially evaluated unsuitable for the radical therapy and received combined HAIC plus regorafenib (Reg) and anti-PD-1 antibody as conversion therapy for downstaging.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Procedure: HAIC; Drug: Anti-PD-1 monoclonal antibody; Drug: apatinib plus camrelizumab; Drug: Sorafenib; Drug: Donafenib; Drug: Bevacizumab Biosimilar IBI305 plus sintilimab; Drug: Regorafenib; Drug: Bevacizumab plus Atezolizumab; Drug: Lenvatinib</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Number of Patients Amendable to Curative Surgical Interventions</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Number of patients amendable to curative surgical interventions defined as number of patients receiving curative surgical resection transplantation or ablation after successful down-sizing of tumor(s) by intervention.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>from the date of first treatment to the date of last treatment an average of 3 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_82" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Active Comparator; Experimental; Placebo Comparator</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients undergo magnetic resonance imaging (MRI) and surgical resection at baseline. Patients receive eflornithine PO in combination with AMXT 1501 PO on days 1-5 post-surgery. Patients also undergo CT after surgery and collection of blood on study.|Patients undergo magnetic MRI and surgical resection at baseline. Patients receive placebo PO on days 1 and 2 post-surgery and then receive eflornithine PO and AMXT 1501 PO on days 3-5 post-surgery. Patients also undergo CT after surgery and collection of blood on study.|Patients undergo magnetic MRI and surgical resection at baseline. Patients receive eflornithine PO alone on days 1 and 2 post-surgery then receive eflornithine PO in combination with AMXT 1501 PO on days 3-5 post-surgery. Patients also undergo CT after surgery and collection of blood on study.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Polyamine Transport Inhibitor AMXT-1501 Dicaprate; Procedure: Biospecimen Collection; Procedure: Resection; Procedure: Magnetic Resonance Imaging; Drug: Placebo Administration; Drug: Eflornithine; Procedure: Computed Tomography</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Change in the tumor/brain extracellular guanidinoacetate ratio</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Targeted metabolomics will be performed using the microdialysate aliquot collected at each time point to quantify guanidinoacetate content. Fold change values will be calculated between each time point within a patient. Fold changes values between time points will be compared across the three arms for statistically significant differences using a Wilcoxon signed rank test; p  0.05 will be considered statistically significant.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 2 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_83" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Single intratumoral injection of Ad-TD-nsIL12. Total dose will be 3x10^9vp 1x10^10vp or 3x10^10 vp suspended in 1 ml according to cohort design.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: Ad-TD-nsIL12</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Safety of Ad-TD-nsIL12 intratumoral injection in progressive pediatric DIPG patients.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>The trial will look for possible hematologic and neurologic toxicity of Ad-TD-nsIL12 by NCI-CTCAE v5.0 to determine maximum tolerated dose of this oncolytic adenovirus.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>3 months after virus injection</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_84" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Single intratumoral injection of Ad-TD-nsIL12. Total dose will be 3x10^9vp 1x10^10vp or 3x10^10 vp suspended in 1 ml according to cohort design.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: Ad-TD-nsIL12</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Safety of Ad-TD-nsIL12 intratumoral injection in primary pediatric DIPG patients.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>The trial will look for possible hematologic and neurologic toxicity of Ad-TD-nsIL12 by NCI-CTCAE v5.0 to determine maximum tolerated dose of this oncolytic adenovirus.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>3 months after virus injection</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_85" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients with advanced hepatocellular carcinoma who was initially evaluated unsuitable for the radical therapy and received combined TACE plus lenvatinib (Len) and anti-PD-1 antibody as conversion therapy for downstaging.|Patients with advanced hepatocellular carcinoma who was initially evaluated unsuitable for the radical therapy and received combined TACE plus bevacizumab (A) and atezolizumab (T) as conversion therapy for downstaging.|Patients with advanced hepatocellular carcinoma who was initially evaluated unsuitable for the radical therapy and received combined TACE plus bevacizumab biosimilar (Byvasda B) and Sintilimab (Tyvyt S) antibody as conversion therapy for downstaging.|Patients with advanced hepatocellular carcinoma who was initially evaluated unsuitable for the radical therapy and received combined TACE plus Apatinib (Apa) and Camrelizumab (C) antibody as conversion therapy for downstaging.|Patients with advanced hepatocellular carcinoma who was initially evaluated unsuitable for the radical therapy and received combined TACE plus sorafenib (Sor) and anti-PD-1 antibody as conversion therapy for downstaging.|Patients with advanced hepatocellular carcinoma who was initially evaluated unsuitable for the radical therapy and received combined TACE plus donafenib (Don) and anti-PD-1 antibody as conversion therapy for downstaging.|Patients with advanced hepatocellular carcinoma who was initially evaluated unsuitable for the radical therapy and received combined TACE plus regorafenib (Reg) and anti-PD-1 antibody as conversion therapy for downstaging.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Anti-PD-1 monoclonal antibody; Drug: apatinib plus camrelizumab; Drug: Sorafenib; Drug: Donafenib; Procedure: TACE; Drug: Bevacizumab Biosimilar IBI305 plus sintilimab; Drug: Regorafenib; Drug: Bevacizumab plus Atezolizumab; Drug: Lenvatinib</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Number of Patients Amendable to Curative Surgical Interventions</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Number of patients amendable to curative surgical interventions defined as number of patients receiving curative surgical resection transplantation or ablation after successful down-sizing of tumor(s) by intervention.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>from the date of first treatment to the date of last treatment an average of 3 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>


<!-- ############################### -->
<!-- ############################### -->
<!-- ######### EXISTING IT ######### -->
<!-- ############################### -->
<!-- ############################### -->

<br><h2 id="existing_it">Existing Trials - Intratumoral</h2>
<h4><a href="#home">Home</a></h4>
<table border="1" summary="Long-term goals table" width="100%" cellspacing="0" cellpadding="0">
  <thead>
    <tr>
      <th><h3>Update</h3></th>
      <th><h3>Condition</h3></th>
      <th><h3>Sponsor</h3></th>
      <th><h3>Phase</h3></th>
      <th><h3>Intervention</h3></th>
      <th><h3>Trial ID</h3></th>
      <th><h3>Interest Level?</h3></th>
    </tr>
  </thead>
  <tbody>
  <tr>
    <td><strong>Completion Date moved earlier by 214 days; Primary Completion Date pushed later by 105 days</strong></td>
    <td>Newly diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) and recurrent/refractory H3 K27M gliomas</td>
    <td>Chimerix</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_86">Study Arms</button></td>
    <td>ONC201</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03416530" target="_blank">NCT03416530</a></td><td><select class="form-select" id="select_form_99" name="NCT03416530"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Now recruiting</strong></td>
    <td>Relapsed or Refractory B-cell Lymphoma</td>
    <td>Second Affiliated Hospital School of Medicine Zhejiang University</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_87">Study Arms</button></td>
    <td>RGV004</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04887025" target="_blank">NCT04887025</a></td><td><select class="form-select" id="select_form_100" name="NCT04887025"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Now recruiting</strong></td>
    <td>Breast Cancer</td>
    <td>University of Pennsylvania</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_88">Study Arms</button></td>
    <td>huCART-meso cells; Mesothelin Expression Testing</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05623488" target="_blank">NCT05623488</a></td><td><select class="form-select" id="select_form_101" name="NCT05623488"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 731 days</strong></td>
    <td>Advanced Tumors</td>
    <td>Coordination Pharmaceuticals Inc.</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_89">Study Arms</button></td>
    <td>RiMO-301</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03444714" target="_blank">NCT03444714</a></td><td><select class="form-select" id="select_form_102" name="NCT03444714"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 335 days; Start Date pushed later by 365 days</strong></td>
    <td>Relapsed/refractory B-cell non-Hodgkin lymphoma</td>
    <td>City of Hope Medical Center</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_90">Study Arms</button></td>
    <td>CpG-STAT3 siRNA CAS3/SS3; Radiation Therapy</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04995536" target="_blank">NCT04995536</a></td><td><select class="form-select" id="select_form_103" name="NCT04995536"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Start Date pushed later by 90 days</strong></td>
    <td>Advanced colorectal cancer</td>
    <td>Binhui Biopharmaceutical Co. Ltd.</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_91">Study Arms</button></td>
    <td><p>OH2; Capecitabine; Bevacizumab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_554">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05648006" target="_blank">NCT05648006</a></td><td><select class="form-select" id="select_form_104" name="NCT05648006"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 200 days; Enrollment decreased by: 30; Now recruiting; Primary Completion Date pushed later by 139 days; Start Date pushed later by 495 days</strong></td>
    <td>AFP positive solid tumors</td>
    <td>Beijing Syngentech Co. Ltd.</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_92">Study Arms</button></td>
    <td>SynOV1.1</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04612504" target="_blank">NCT04612504</a></td><td><select class="form-select" id="select_form_105" name="NCT04612504"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date moved earlier by 214 days; Primary Completion Date pushed later by 105 days</strong></td>
    <td>Newly diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) and recurrent/refractory H3 K27M gliomas</td>
    <td>Chimerix</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_93">Study Arms</button></td>
    <td>ONC201</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03416530" target="_blank">NCT03416530</a></td><td><select class="form-select" id="select_form_106" name="NCT03416530"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 184 days; Enrollment increased by: 51; Changed status from recruiting to active; Primary Completion Date pushed later by 1005 days</strong></td>
    <td>Locally advanced or metastatic CSCC</td>
    <td>Replimune Inc.</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_94">Study Arms</button></td>
    <td>Cemiplimab; RP1</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04050436" target="_blank">NCT04050436</a></td><td><select class="form-select" id="select_form_107" name="NCT04050436"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 487 days; Primary Completion Date pushed later by 427 days</strong></td>
    <td>Advanced cutaneous malignancies</td>
    <td>Replimune Inc.</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_95">Study Arms</button></td>
    <td>RP1 intra-tumoral injection oncolytic virus</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04349436" target="_blank">NCT04349436</a></td><td><select class="form-select" id="select_form_108" name="NCT04349436"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr data-toggle="collapse" data-target="#demo5" class="accordion-toggle">  <td colspan="7"><button type="button" class="btn btn-large btn-outline-primary">VIEW LARGE COMPANY TRIALS</button></td>
  </tr>
 <tr>  <td colspan="12" class="hiddenRow"> <div class="accordian-body collapse" id="demo5"><table class="table table-striped"><thead>
    <tr>
      <th><h3>Update</h3></th>
      <th><h3>Condition</h3></th>
      <th><h3>Sponsor</h3></th>
      <th><h3>Phase</h3></th>
      <th><h3>Intervention</h3></th>
      <th><h3>Trial ID</h3></th>
      <th><h3>Interest Level?</h3></th>
    </tr>
  </thead>
  <tbody>
  <tr>
    <td><strong>Completion Date moved earlier by 333 days</strong></td>
    <td>Advanced/metastatic or recurrent malignancies</td>
    <td>Merck Sharp & Dohme LLC</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_96">Study Arms</button></td>
    <td><p>Gebasaxturev; Pembrolizumab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_558">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04521621" target="_blank">NCT04521621</a></td><td><select class="form-select" id="select_form_109" name="NCT04521621"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Enrollment decreased by: 81</strong></td>
    <td>Solid tumors</td>
    <td>Boehringer Ingelheim</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_97">Study Arms</button></td>
    <td>BI 1387446; BI 754091</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04147234" target="_blank">NCT04147234</a></td><td><select class="form-select" id="select_form_110" name="NCT04147234"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Changed status from recruiting to active</strong></td>
    <td>Incurable non-metastatic hepatocellular carcinoma (HCC)</td>
    <td>Merck Sharp & Dohme LLC</td>
<td><p>Phase 3</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_98">Study Arms</button></td>
    <td><p>Lenvatinib; Pembrolizumab; Oral Placebo; IV Placebo; TACE</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_559">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04246177" target="_blank">NCT04246177</a></td><td><select class="form-select" id="select_form_111" name="NCT04246177"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  </tbody>
</table>
</div></td></tr>  </tbody>
</table>
<!-- THE MODAL -->
<div class="modal fade" id="modal_86" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Pediatric patients with glioma who are positive for the H3 K27M mutation (positive testing in CLIA laboratory) and have completed at least one line of prior therapy. Evidence of progression is not required so that ONC201 may be administered to patients in the maintenance setting or to patients with recurrent/refractory disease.|Pediatric patients with newly diagnosed diffuse intrinsic pontine glioma (DIPG) defined as tumors with a pontine epicenter and diffuse involvement of the pons are eligible with or without histologic confirmation. If H3 K27M status of tumor is unknown or archival tumor tissue is not available then patients must agree to submit a post-mortem biopsy specimen.|Pediatric patients midline gliomas are eligible with or without histologic confirmation and must be eligible for tumor biopsy as deemed by the site Investigator.|Pediatric patients with recurrent glioma who are positive for the H3 K27M mutation (positive testing in CLIA laboratory) have completed at least one line of prior therapy must be willing to undergo serial lumbar puncture to obtain cerebrospinal fluid (CSF) and must be scheduled to undergo sedated MRIs.|Patients with glioma who are positive for the H3 K27M mutation (positive testing in CLIA laboratory) or have diagnosed diffuse intrinsic pontine glioma (DIPG) defined as tumors with a pontine epicenter and diffuse involvement of the pons are eligible with or without histologic confirmation. Patients must be 2-12 weeks from completion of first-line radiation.|Pediatric patients with previously-treated histologically confirmed high-grade glioma with a known H3 K27M mutation evidence of progressive disease contrast-enhanced brain MRI as defined by RANO-HGG criteria. Prior therapy with at least radiotherapy is required.|Pediatric patients with glioma who are positive for the H3 K27M mutation (positive testing in CLIA laboratory) and have completed at least one line of prior therapy will be enrolled to define the RP2D for single agent ONC201 given on two consecutive days of each week.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: ONC201</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>RP2D</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Determination of recommended Phase 2 dose (RP2D) as a single agent or in combination with radiation</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>28 days</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_87" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Subjects will be treated with RGV004 as a single injection one time.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: RGV004</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>To define the Max tolerated dose (MTD) of RGV004|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>To evaluate the number of Grade III and above side effects assessed by CTCAE v5.0 for patients who received intratumoral administration of RGV004 injection in patients with R/R B-cell lymphoma.; According to the principle of '3+3' dose escalation if one patient experiences a Dose limiting Toxicity (DLT) up to three additional patients will be treated at the same dose level. If DLT is observed in only one of six patients treated at a given dose level the next cohort of three patients will be treated at the next higher dose level. If two or more patients experience DLT at a particular dose level then the dose escalation will cease and any subsequent patients will be treated at a lower dose level. Thus finding the Max tolerated dose (MTD)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 28 days; Up to 2 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_88" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>3.00 x 10^7 CAR T cells administered intratumoral|3.00 x 10^6 CAR T cells administered intratumoral</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Device: Mesothelin Expression Testing; Drug: huCART-meso cells</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Occurrence of treatment-limiting toxicities (TLTs)|Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE v5.0.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>15 years; 90 days</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_89" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>3 dose levels (5% 10% and 15% of the total baseline tumor volume respectively) will be tested in a 3 + 3 dose escalation study</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: RiMO-301</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Maximum Tolerated Dose (MTD)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>â€¢ To determine the maximum tolerated dose (MTD) which is defined as the dose level at which fewer than 33% of patients experience a dose limiting toxicity (DLT) using a 3+3 strategy</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>45 days</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_90" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients undergo radiation therapy on days 1 and 2 tumor-bearing lymph node and receive CAS3/SS3 intratumorally on days 2 4 16 and 18. Patients assigned to dose level 3 also receive CAS3/SS3 intratumorally on days 9 11 23 and 25.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: CpG-STAT3 siRNA CAS3/SS3; Radiation: Radiation Therapy</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Incidence of adverse events|Dose Limiting Toxicity</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Toxicity will be graded according to the National Cancer Institute-Common Terminology Criteria for Adverse Events version 5. Observed toxicities will be summarized in terms of type (organ affected or laboratory determination) severity attribution time of onset duration and reversibility or outcome.; Grade 3 or higher toxicities at least possibly related to study treatment as assessed by CTCAE with noted exceptions.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 6 months; Up to 56 days</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_91" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Active Comparator; Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>OH2: 10^7 CCID50/mL intratumoral injection once every 2 weeks; Capecitabine: 1000 mg/m2 orally administered twice a day D1 to D14 repeated every 3 weeks|Capecitabine: 1000 mg/m2 orally administered twice a day D1 to D14 repeated every 3 weeks Bevacizumab: 7.5 mg/kg intravenously once every 3 weeks.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Bevacizumab; Biological: OH2; Drug: Capecitabine</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Progression-free survival</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Time after treatment to clinical and radiographic disease progression will be evaluated.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>2 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_92" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: SynOV1.1</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>The dose-limiting toxicities (DLTs) of SynOV1.1 in patients with HCC|The maximum-tolerated dose (MTD) of SynOV1.1 in patients with HCC|The response rate of patients with HCC receiving SynOV1.1</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>response rate based on RECIST ver. 1.1; MTD for patients with HCC received SynOV1.1 treatment.; Incidence and nature of DLT of SynOV1.1 in in patients with HCC graded according to NCI CTCAE v5</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>30 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_93" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Pediatric patients with glioma who are positive for the H3 K27M mutation (positive testing in CLIA laboratory) and have completed at least one line of prior therapy. Evidence of progression is not required so that ONC201 may be administered to patients in the maintenance setting or to patients with recurrent/refractory disease.|Pediatric patients with newly diagnosed diffuse intrinsic pontine glioma (DIPG) defined as tumors with a pontine epicenter and diffuse involvement of the pons are eligible with or without histologic confirmation. If H3 K27M status of tumor is unknown or archival tumor tissue is not available then patients must agree to submit a post-mortem biopsy specimen.|Pediatric patients midline gliomas are eligible with or without histologic confirmation and must be eligible for tumor biopsy as deemed by the site Investigator.|Pediatric patients with recurrent glioma who are positive for the H3 K27M mutation (positive testing in CLIA laboratory) have completed at least one line of prior therapy must be willing to undergo serial lumbar puncture to obtain cerebrospinal fluid (CSF) and must be scheduled to undergo sedated MRIs.|Patients with glioma who are positive for the H3 K27M mutation (positive testing in CLIA laboratory) or have diagnosed diffuse intrinsic pontine glioma (DIPG) defined as tumors with a pontine epicenter and diffuse involvement of the pons are eligible with or without histologic confirmation. Patients must be 2-12 weeks from completion of first-line radiation.|Pediatric patients with previously-treated histologically confirmed high-grade glioma with a known H3 K27M mutation evidence of progressive disease contrast-enhanced brain MRI as defined by RANO-HGG criteria. Prior therapy with at least radiotherapy is required.|Pediatric patients with glioma who are positive for the H3 K27M mutation (positive testing in CLIA laboratory) and have completed at least one line of prior therapy will be enrolled to define the RP2D for single agent ONC201 given on two consecutive days of each week.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: ONC201</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>RP2D</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Determination of recommended Phase 2 dose (RP2D) as a single agent or in combination with radiation</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>28 days</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_94" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Active Comparator; Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Cemiplimab administered intravenously every 3 weeks in combination with RP1 administered as an intratumoral injection every 3 weeks|Cemiplimab administered intravenously as a single therapy every 3 weeks</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: RP1; Drug: Cemiplimab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Objective Response Rate (ORR) according to blinded independent review|Complete Response Rate (CRR) according to blinded independent review</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>up to 5 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_95" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>RP1 administered as an intra-tumoral injection every 2 weeks.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: RP1 intra-tumoral injection oncolytic virus</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Primary Safety Outcome Measure|Primary Efficacy Outcome Measure|Incidence of subjects with treatment-emergent adverse events greater than or equal to Grade 3|Incidence of subjects with Serious adverse events (SAEs)|Incidence of subjects with fatal adverse events|Treatment-emergent adverse events requiring withdrawal from IP and incidence of organ allograft rejection</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Assess the safety and tolerability of single-agent RP1 in solid organ transplant patients with cutaneous malignancies by incidence of subjects with treatment-emergent adverse events; The objective response rate (ORR) according to investigator assessment using modified RECIST version 1.1.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>36 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_96" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>This arm will enroll participants with triple-negative breast cancer (TNBC) solid tumors. Participants receive gebasaxturev intratumorally for 8 cycles and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 is 28 days and cycles 2-35 are 21 days.|This arm will enroll participants with head and neck squamous cell carcinoma (HNSCC) solid tumors. Participants receive gebasaxturev intratumorally for 8 cycles and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 is 28 days and cycles 2-35 are 21 days.|This arm will enroll participants with cutaneous squamous cell carcinoma (cSCC) solid tumors. Participants receive gebasaxturev intratumorally for 8 cycles and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 is 28 days and cycles 2-35 are 21 days.|This arm will enroll participants with solid tumors with liver metastases. Participants receive dose level 1 of gebasaxturev intratumorally for 8 cycles and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 is 28 days and cycles 2-35 are 21 days.|This arm will enroll participants with solid tumors with liver metastases. Participants receive dose level 2 of gebasaxturev intratumorally for 8 cycles and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 is 28 days and cycles 2-35 are 21 days.|This arm will enroll participants with solid tumors with liver metastases. Participants receive dose level 3 of gebasaxturev intratumorally for 8 cycles and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 is 28 days and cycles 2-35 are 21 days.|This arm will enroll participants with hepatocellular carcinoma (HCC) solid tumors. Participants receive the gebasaxturev recommended phase 2 dose (RP2D) intratumorally for 8 cycles and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 is 28 days and cycles 2-35 are 21 days.|This arm will enroll participants with gastric carcinoma solid tumors. Participants receive the gebasaxturev recommended phase 2 dose (RP2D) intratumorally for 8 cycles and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 is 28 days and cycles 2-35 are 21 days.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Pembrolizumab; Biological: Gebasaxturev</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Part 1: Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Investigator|Number of Participants who Experience a Dose-Limiting Toxicity (DLT)|Part 2: Number of Participants Who Experienced One or More Adverse Events (AEs)|Part 2: Number of Participants Who Discontinued Study Intervention Due to an Adverse Event (AE)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>ORR is defined as the percentage of participants in the analysis population who had a Complete Response (CR: Disappearance of all target lesions and no new lesions) or a Partial Response (PR: â‰¥30% decrease in the sum of diameters of target lesions) per RECIST 1.1 as assessed by investigator. For this study RECIST 1.1 has been modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ and to specify that intratumoral injection does not render a lesion non-evaluable. Only the Part 1 arms will be analyzed in this outcome measure.; DLTs are defined as toxicities that: are possibly probably or definitely related to study intervention administration; and meet pre-defined study criteria.; An AE is defined as any unfavorable and unintended sign symptom disease or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. Only the Part 2 arms will be analyzed in this outcome measure.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to approximately 107 weeks; Up to approximately 103 weeks; Up to approximately 44 months; Up to approximately 4 weeks</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_97" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>superficial lesions|superficial lesions</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: BI 1387446; Drug: BI 754091</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Maximum tolerated dose (MTD) based on number of Dose-limiting toxicities (DLTs)|Number of patients with Dose limiting Toxicity (DLT) in the Maximum tolerated dose (MTD) evaluation period</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>3 weeks; up to 3 weeks</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_98" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Active Comparator; Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Participants will receive a combination of lenvatinib pembrolizumab and TACE. Lenvatinib will be administered at a dose of 12 mg (for participants with screening body weight â‰¥60 kg) or 8 mg (for participants with screening body weight 60 kg) orally once a day during each 21-day cycle until progressive disease or unacceptable toxicity (up to 2 years [~35 cycles] or longer with Sponsor approval). Pembrolizumab will be administered via IV infusion at a dose of 400 mg once every 6 weeks (Q6W) for up to 2 years (~17 doses). Participants will undergo TACE as a background procedure of chemotherapeutic and embolic agent(s).|Participants will receive a combination of lenvatinib-matching oral placebo pembrolizumab-matching IV placebo and TACE. Lenvatinib-matching oral placebo will be administered once a day during each 21-day cycle for up to 2 years (~35 cycles) or longer with Sponsor approval and pembrolizumab-matching IV placebo will be administered once every 6 weeks (Q6W) for up to 2 years (~17 doses). Participants will undergo TACE as a background procedure of chemotherapeutic and embolic agent(s).</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: Pembrolizumab; Drug: IV Placebo; Procedure: TACE; Drug: Oral Placebo; Drug: Lenvatinib</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)|Overall Survival (OS)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>PFS is defined as the time from randomization to the first documented progressive disease or death due to any cause whichever occurs first. Responses are according to RECIST 1.1 as assessed by blinded independent central review (BICR).; OS is defined as the time from randomization to death due to any cause.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to ~43 months; Up to ~95 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>


<!-- ############################### -->
<!-- ############################### -->
<!-- ########### NEW  CT ########### -->
<!-- ############################### -->
<!-- ############################### -->

<br><h2 id="new_ct">New Trials - Cytotoxic</h2>
<h4><a href="#home">Home</a></h4>
<table border="1" summary="Long-term goals table" width="100%" cellspacing="0" cellpadding="0">
  <thead>
    <tr>
      <th><h3>Condition</h3></th>
      <th><h3>Sponsor</h3></th>
      <th><h3>Phase</h3></th>
      <th><h3>Intervention</h3></th>
      <th><h3>Trial ID</h3></th>
      <th><h3>Interest Level?</h3></th>
    </tr>
  </thead>
  <tbody>
  <tr>
    <td>Early stage HER2-positive breast cancer</td>
    <td>Cancer Trials Ireland</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_99">Study Arms</button></td>
    <td><p>trastuzumab deruxtecan (T-DXd) (IV)</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_559">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05710666" target="_blank">NCT05710666</a></td><td><select class="form-select" id="select_form_112" name="NCT05710666"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td>Metastatic Tumor</td>
    <td>David Palma</td>
<td><p>Phase 3</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_100">Study Arms</button></td>
    <td>Palliative Radiotherapy; Chemotherapy; Hormone therapy; Immunotherapy; Targeted Systemic Therapy; Observation; Stereotactic Ablative Radiotherapy; Surgery; Radiofrequency Therapy (RFA); Fractionated Radiation</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05717166" target="_blank">NCT05717166</a></td><td><select class="form-select" id="select_form_113" name="NCT05717166"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr data-toggle="collapse" data-target="#demo6" class="accordion-toggle">  <td colspan="6">NO LARGE COMPANY TRIALS</td>
  </tr>
  </tbody>
</table>
<!-- THE MODAL -->
<div class="modal fade" id="modal_99" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: trastuzumab deruxtecan (T-DXd) (IV)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>The percentage of patients who achieve pCR after T-DXd treatment</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>The percentage of patients who achieve pCR after T-DXd treatment and thus avoid standard cytotoxic chemotherapy</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>From registration until surgery approximately 18 weeks</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_100" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Active Comparator; Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Radiotherapy for patients in the standard arm should follow the principles of palliative radiotherapy as per the individual institution with the goal of alleviating symptoms or preventing imminent complications.|Consists of treatment to the primary tumor and metastases with SABR preferred but other options all allowable (e.g. surgery RFA fractionated radiation chemoradiation) if those are deemed to be preferable by the treating oncologists.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Other: Observation; Drug: Immunotherapy; Radiation: Palliative Radiotherapy; Radiation: Fractionated Radiation; Radiation: Stereotactic Ablative Radiotherapy; Drug: Chemotherapy; Drug: Hormone therapy; Drug: Targeted Systemic Therapy; Other: Radiofrequency Therapy (RFA); Procedure: Surgery</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Overall Survival</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Time from randomization to death from any cause or date of last follow-up whichever occurs first.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Approximately end of year 6 (Study Completion)</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>


<!-- ############################### -->
<!-- ############################### -->
<!-- ######### EXISTING CT ######### -->
<!-- ############################### -->
<!-- ############################### -->

<br><h2 id="existing_ct">Existing Trials - Cytotoxic</h2>
<h4><a href="#home">Home</a></h4>
<table border="1" summary="Long-term goals table" width="100%" cellspacing="0" cellpadding="0">
  <thead>
    <tr>
      <th><h3>Update</h3></th>
      <th><h3>Condition</h3></th>
      <th><h3>Sponsor</h3></th>
      <th><h3>Phase</h3></th>
      <th><h3>Intervention</h3></th>
      <th><h3>Trial ID</h3></th>
      <th><h3>Interest Level?</h3></th>
    </tr>
  </thead>
  <tbody>
  <tr>
    <td><strong>Completion Date moved earlier by 1341 days; Trial terminated; Primary Completion Date moved earlier by 976 days</strong></td>
    <td>Graft Vs Host Disease</td>
    <td>UNC Lineberger Comprehensive Cancer Center</td>
<td><p>Early Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_101">Study Arms</button></td>
    <td>Fluorothymidine (FLT)</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03546556" target="_blank">NCT03546556</a></td><td><select class="form-select" id="select_form_114" name="NCT03546556"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date moved earlier by 117 days; Changed status from recruiting to active; Primary Completion Date pushed later by 546 days</strong></td>
    <td>Prostate Cancer</td>
    <td>Washington University School of Medicine</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_102">Study Arms</button></td>
    <td><p>Ibrutinib; Blood samples for PSA and immune assays; Radical prostatectomy</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_562">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT02643667" target="_blank">NCT02643667</a></td><td><select class="form-select" id="select_form_115" name="NCT02643667"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Trial completed</strong></td>
    <td>Covid19</td>
    <td>Thomas Jefferson University</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_103">Study Arms</button></td>
    <td>Cytotoxic T Lymphocytes</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04765449" target="_blank">NCT04765449</a></td><td><select class="form-select" id="select_form_116" name="NCT04765449"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Changed status from recruiting to active</strong></td>
    <td>Hepatocellular Carcinoma</td>
    <td>Fundacion Clinic per a la Recerca Biomdica</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_104">Study Arms</button></td>
    <td><p>Regorafenib; Nivolumab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_563">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04170556" target="_blank">NCT04170556</a></td><td><select class="form-select" id="select_form_117" name="NCT04170556"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Now recruiting</strong></td>
    <td>Solid Tumor</td>
    <td>Bliss Biopharmaceutical (Hangzhou) Co. Ltd</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_105">Study Arms</button></td>
    <td>BB-1705</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05217693" target="_blank">NCT05217693</a></td><td><select class="form-select" id="select_form_118" name="NCT05217693"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Enrollment decreased by: 70</strong></td>
    <td>Recurrent platinum resistant epithelial ovarian cancer (EOC) fallopian tube or primary peritoneal cancer</td>
    <td>Cordgenics LLC</td>
<td><p>Phase 3</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_106">Study Arms</button></td>
    <td>ChemoID Assay; Standard Chemotherapy</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03949283" target="_blank">NCT03949283</a></td><td><select class="form-select" id="select_form_119" name="NCT03949283"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Now recruiting</strong></td>
    <td>Advanced castration-resistant prostate cancer</td>
    <td>Rana McKay MD</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_107">Study Arms</button></td>
    <td><p>Cabozantinib; Nivolumab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_565">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05502315" target="_blank">NCT05502315</a></td><td><select class="form-select" id="select_form_120" name="NCT05502315"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 863 days; Trial completed</strong></td>
    <td>Colorectal Cancer Metastatic</td>
    <td>Centre Georges Francois Leclerc</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_108">Study Arms</button></td>
    <td><p>Durvalumab Tremelimumab and FOLFOX</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_565">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03202758" target="_blank">NCT03202758</a></td><td><select class="form-select" id="select_form_121" name="NCT03202758"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 365 days</strong></td>
    <td>Advanced Solid Tumors</td>
    <td>Changchun Intellicrown Pharmaceutical Co. LTD</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_109">Study Arms</button></td>
    <td>KN044</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04126590" target="_blank">NCT04126590</a></td><td><select class="form-select" id="select_form_122" name="NCT04126590"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 365 days</strong></td>
    <td>Undifferentiated pleomorphic sarcoma or dedifferentiated liposarcoma</td>
    <td>M.D. Anderson Cancer Center</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_110">Study Arms</button></td>
    <td><p>Ipilimumab; Nivolumab; Radiation Therapy</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_566">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03307616" target="_blank">NCT03307616</a></td><td><select class="form-select" id="select_form_123" name="NCT03307616"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 90 days</strong></td>
    <td>Clear-Cell Renal Cell Carcinoma</td>
    <td>Mirati Therapeutics Inc.</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_111">Study Arms</button></td>
    <td><p>Sitravatinib; Nivolumab; Ipilimumab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_566">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04518046" target="_blank">NCT04518046</a></td><td><select class="form-select" id="select_form_124" name="NCT04518046"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 365 days</strong></td>
    <td>Recurrent Glioblastoma</td>
    <td>Cordgenics LLC</td>
<td><p>Phase 3</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_112">Study Arms</button></td>
    <td>ChemoID assay; Chemotherapy</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03632135" target="_blank">NCT03632135</a></td><td><select class="form-select" id="select_form_125" name="NCT03632135"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date moved earlier by 117 days; Changed status from recruiting to active; Primary Completion Date pushed later by 546 days</strong></td>
    <td>Prostate Cancer</td>
    <td>Washington University School of Medicine</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_113">Study Arms</button></td>
    <td><p>Ibrutinib; Blood samples for PSA and immune assays; Radical prostatectomy</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_567">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT02643667" target="_blank">NCT02643667</a></td><td><select class="form-select" id="select_form_126" name="NCT02643667"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 274 days; Primary Completion Date pushed later by 365 days</strong></td>
    <td>Colorectal Cancer; Pancreatic Cancer; Gastric Cancers; Cholangiocarcinoma</td>
    <td>Bold Therapeutics Inc.</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_114">Study Arms</button></td>
    <td>BOLD-100 in combination with FOLFOX Chemotherapy (Dose Expansion); BOLD-100 in combination with FOLFOX Chemotherapy (Dose Escalation)</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04421820" target="_blank">NCT04421820</a></td><td><select class="form-select" id="select_form_127" name="NCT04421820"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 365 days; Primary Completion Date pushed later by 366 days</strong></td>
    <td>Diffuse Intrinsic Pontine Glioma; Diffuse Midline Glioma H3 K27M-Mutant</td>
    <td>Ann & Robert H Lurie Children's Hospital of Chicago</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_115">Study Arms</button></td>
    <td>rHSC-DIPGVax; Balstilimab; Zalifrelimab</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04943848" target="_blank">NCT04943848</a></td><td><select class="form-select" id="select_form_128" name="NCT04943848"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Changed status from recruiting to active; Primary Completion Date pushed later by 537 days</strong></td>
    <td>Operable gastro-oesophageal adenocarcinoma</td>
    <td>Royal Marsden NHS Foundation Trust</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_116">Study Arms</button></td>
    <td>FLOT-A</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03399071" target="_blank">NCT03399071</a></td><td><select class="form-select" id="select_form_129" name="NCT03399071"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 396 days; Primary Completion Date pushed later by 397 days</strong></td>
    <td>Glioblastoma multiform</td>
    <td>Centre Francois Baclesse</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_117">Study Arms</button></td>
    <td><p>Olaparib; Temozolomide (TMZ); IMRT (Intensity Modulated Radiation Therapy)</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_570">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03212742" target="_blank">NCT03212742</a></td><td><select class="form-select" id="select_form_130" name="NCT03212742"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Start Date pushed later by 153 days</strong></td>
    <td>Advanced Cholangiocarcinoma</td>
    <td>Second Affiliated Hospital School of Medicine Zhejiang University</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_118">Study Arms</button></td>
    <td><p>Lenvatinib tislelizumab gemcitabine and cisplatin; gemcitabine and cisplatin</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_570">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05532059" target="_blank">NCT05532059</a></td><td><select class="form-select" id="select_form_131" name="NCT05532059"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 378 days; Now recruiting; Primary Completion Date pushed later by 197 days</strong></td>
    <td>Advanced colorectal cancer</td>
    <td>Tianjin Medical University Cancer Institute and Hospital</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_119">Study Arms</button></td>
    <td><p>Sintilimabregofinibcetuximab; KRAS BRAF mutant Sintilimab + regafinil</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_570">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04745130" target="_blank">NCT04745130</a></td><td><select class="form-select" id="select_form_132" name="NCT04745130"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 335 days; Changed status from recruiting to active; Primary Completion Date pushed later by 201 days</strong></td>
    <td>COVID-19</td>
    <td>R-Pharm</td>
<td><p>Phase 3</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_120">Study Arms</button></td>
    <td>Olokizumab; Standard therapy</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05187793" target="_blank">NCT05187793</a></td><td><select class="form-select" id="select_form_133" name="NCT05187793"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 669 days; Changed status from active to suspended; Primary Completion Date pushed later by 731 days</strong></td>
    <td>Recurrent epithelial ovarian cancer (EOC) fallopian tube or primary peritoneal cancer</td>
    <td>Cordgenics LLC</td>
<td><p>Phase 3</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_121">Study Arms</button></td>
    <td>ChemoID assay; Chemotherapy</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03632798" target="_blank">NCT03632798</a></td><td><select class="form-select" id="select_form_134" name="NCT03632798"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr data-toggle="collapse" data-target="#demo7" class="accordion-toggle" style = "background-color: #E1EBEE;">  <td colspan="7"><button type="button" class="btn btn-large btn-outline-primary">VIEW LARGE COMPANY TRIALS</button></td>
  </tr>
 <tr>  <td colspan="12" class="hiddenRow"> <div class="accordian-body collapse" id="demo7"><table class="table table-striped"><thead>
    <tr>
      <th><h3>Update</h3></th>
      <th><h3>Condition</h3></th>
      <th><h3>Sponsor</h3></th>
      <th><h3>Phase</h3></th>
      <th><h3>Intervention</h3></th>
      <th><h3>Trial ID</h3></th>
      <th><h3>Interest Level?</h3></th>
    </tr>
  </thead>
  <tbody>
  <tr>
    <td><strong>Completion Date pushed later by 180 days</strong></td>
    <td>Non-metastatic Castration-resistant Prostate Cancer</td>
    <td>Bayer</td>
<td><p>Phase 4</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_122">Study Arms</button></td>
    <td><p>Darolutamide (Nubeqa BAY1841788)</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_572">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05348876" target="_blank">NCT05348876</a></td><td><select class="form-select" id="select_form_135" name="NCT05348876"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  </tbody>
</table>
</div></td></tr>  </tbody>
</table>
<!-- THE MODAL -->
<div class="modal fade" id="modal_101" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>A total of 12 patients who have undergone allogenic bone marrow transplantation will undergo Fluorothymidine FLT-PET-MRI imaging on two separate occasions.|3 patients undergoing autologous stem cell transplant will also undergo Fluorothymidine FLT-PET-MRI imaging the same two time points in order to determine how much of the FLT signal observed after allogeneic transplant is unique to that population and the result of allo-antigen driven T cell expansion.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Fluorothymidine (FLT)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Overall FLT-PET Bone Marrow Signal|Overall FLT-PET Signal Intensity within Host Secondary Lymphoid Sites</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Compare the overall FLT-PET bone marrow signal on transplant day +25 between allogeneic stem cell transplant recipients who do and do not go on to achieve complete donor bone marrow reconstitution by transplant day +35.; Compare the overall FLT-PET signal intensity within host secondary lymphoid sites on transplant day +60 between allogeneic stem cell transplant recipients who do and do not develop acute GVHD by transplant day +100.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>100 Days (Approximate); 35 Days (Approximate)</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_102" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Ibrutinib: will be given by mouth daily|Blood samples for PSA and for immune assays will be collected at baseline before RP and after RP|Radical prostatectomy will be performed at least 7 days but not more than 12 days following the last scheduled dose of ibrutinib|Ibrutinib: will be given by mouth daily|Blood samples for PSA and for immune assays will be collected at baseline before RP and after RP|Radical prostatectomy will be performed at least 7 days but not more than 12 days following the last scheduled dose of ibrutinib</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Procedure: Blood samples for PSA and immune assays; Drug: Ibrutinib; Procedure: Radical prostatectomy</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Dose Limiting Toxicities (Safety Run-In)|B cell infiltration (Phase 2)|T cell infiltration (Phase 2)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>DLTs will be defined as any of the following that are attributable to ibrutinib.; Any grade 3 toxicity.; Any grade 4 toxicity including hematologic toxicities with the exception of lymphocytosis. Lymphocytosis in the absence of clinical symptoms is excluded from DLT as this may be considered an on-target pharmacodynamics effect of BTK inhibition.; Any delay of RP due to study-drug related toxicity.; Any complications of RP (e.g. bleeding delayed wound healing) deemed to be related to study drug.; Immunohistochemistry (ICH); CTCAE v.4.0; Any recurrence of the same grade 3 toxicity.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Completion of follow-up (approximately 10 weeks after start of treatment); Completion of enrollment of Phase I portion of patients</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_103" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>No Intervention; Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients who have an HLA antigen in common with COVID-19 fighting T cells will receive the COVID-19 T cells. They will be premedicated with diphenhydramine and acetaminophen before the cells are infused intravenously. Close monitoring will continue in the patients' homes for 14 days. Three to six patients will receive a specific dose of T cells and then if there are no serious side effects the dose will be increased for the next group of patients. There are 4 doses of T cells to be tested and each patient will complete a 14 day monitoring period before the next patient can be treated.|Patients in the observation arm will not have inherited an HLA antigen in common with the COVID-19 T cells and so cannot receive the T cells. They will be monitored by the study staff for the 14 day monitoring period in their homes. They will be taught to record their own blood pressure temperature and oxygen level (pulse oximetry) at home and report this information as well as their progress in getting over the COVID-19 infection to the study staff every day by phone. The outcomes of patients on arm B will be compared to the outcomes of patients treated on Arm A to see if the T cells made a difference in how patients recovered from COVID-19. Patients in Arm B are not prevented from being treated with any available COVID-19 therapy.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Cytotoxic T Lymphocytes</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Safety of COVID-19-specific CTLs: Infusion Reactions|Safety of COVID-19-specific CTLs: Grade 4 AEs|Safety of COVID-19-specific CTLs: GVHD|Safety of COVID-19-specific CTLs: Marrow Aplasia|Safety of COVID-19-specific CTLs: Neurotoxicty|Safety of COVID-19-specific CTLs: CRS</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Safety will be measured by the absence of: Grade â‰¥ 2+ Neurotoxicity as measured by the ASTCT/ICANS consensus grading system; Safety will be measured by the absence of: Any manifestation of acute GVHD (for acute grades 2-4 GVHD-Glucksberg criteria) 53 resistant to 2 mg/kg of solumedrol or equivalent; Safety will be measured by the absence of: Any grade 4 or higher adverse event thought to be related to the CTL therapy and outside the spectrum of identified COVID related events.; Safety will be measured by the absence of: Marrow aplasia due to 3rd party engraftment; Safety will be measured by the absence of: Grade â‰¥ 2+ CRS as measured by the ASTCT Consensus Grading Criteria for CRS; Safety will be measured by the absence of: Grade â‰¥ 3 acute infusion reactions</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Within 48 Hours of CTL Infusion; Within 14 days of CTL infusion</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_104" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Regorafenib will be initiated at full dose (160 mg/day; 3 weeks on and 1 week off) in monotherapy for the first 8 weeks. After week 8 regorafenib will be continued in combination with nivolumab until symptomatic tumor progression unacceptable adverse events patient decision or death</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Regorafenib; Drug: Nivolumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Incidence of Treatment-Emergent Adverse Events|Incidence of related Treatment-Emergent Adverse Events|Incidence of Treatment-Emergent Adverse Events</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Rate of adverse events (AE); Rate of related-AEs; Rate of death</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 24 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_105" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Drug: BB-1705 BB-1705 will be administered as an intravenous infusion by Q3W for 8cycles|BB-1705 will be administered as an intravenous infusion by Q3W for 8cycles</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: BB-1705</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Number of subjects with adverse events and serious adverse events|Number of subjects with dose limiting toxicity (DLT)|MTD</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>MTD is defined as the highest dose level at which no more than 1 out of 6 subjects experiences a DLT during the first cycle.; Subjects are evaluated for all study drug related and treatment emergent toxicities based on the National Cancer Institute Common Toxicity Criteria for adverse events (NCI-CTCAE); To evaluate the safety and tolerability of BB-1705</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Cycle 1. Duration of each cycle is 21 days.; up to 2 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_106" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Active Comparator; Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Participants will be treated with control chemotherapy treatment (standard-of-care chemotherapy chosen by the physician from the provided list).||Control chemotherapy treatment will be chosen from any of the following standard-of-care chemotherapy drugs or combinations:||Liposomal Doxorubicin;|Docetaxel;|Paclitaxel;|Carboplatin;|Cisplatin;|Gemcitabine;|Topotecan;|Carboplatin Gemcitabine;|Cisplatin Gemcitabine;|Carboplatin Liposomal Doxorubicin;|Carboplatin Paclitaxel;|Carboplatin Docetaxel. The treating physician will NOT receive the ChemoID assay results from the ChemoID lab.|Participants will be treated with ChemoID-guided standard-of-care chemotherapy drugs from the provided list.||ChemoID-guided treatment will be chosen from the following standard-of-care chemotherapy drugs or combinations:||Liposomal Doxorubicin;|Docetaxel;|Paclitaxel;|Carboplatin;|Cisplatin;|Gemcitabine;|Topotecan;|Carboplatin Gemcitabine;|Cisplatin Gemcitabine;|Carboplatin Liposomal Doxorubicin;|Carboplatin Paclitaxel;|Carboplatin Docetaxel.||The treating physician will receive the ChemoID assay results from the ChemoID lab.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Standard Chemotherapy; Diagnostic Test: ChemoID Assay</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Objective response rate</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Objective response rate (ORR) as measured by RECIST version 1.1 criteria in recurrent EOC patients who have had ChemoID-guided treatment versus physician choice control treatment (chemotherapy chosen by the physician from the provided list).</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>24 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_107" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>40 mg of cabozantinib taken orally every day (days 1-28) of a 28 day cycle||480 mg of nivolumab given intravenously on the first day (day 1) of each 28 day cycle</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Cabozantinib; Drug: Nivolumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Radiographic Progression Free Survival (rPFS)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>The primary endpoint is the efficacy of treatment via assessment of 6 month rPFS defined by RECIST version 1.1 for soft tissue and Prostate Cancer Working Group 3 (PCWG3) criteria for bone metastases. rPFS is defined as the duration of time from the first day of the start of study treatment to time of radiographic progression or death due to any cause whichever occurs first.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>6 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_108" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Other</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Durvalumab for 12 months|Tremelimumab for up to 4 doses/cycles|FOLFOX</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Durvalumab Tremelimumab and FOLFOX</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Evaluation of the safety of Durvalumab plus Tremelimumab in combination with FOLFOX chemotherapy</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Criteria RECIST 1.1</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>1 month</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_109" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>KN044 0.03 mg/kg dose grouponce every 3 weeksï¼Œa total of four cycles|KN044 0.1 mg/kg dose grouponce every 3 weeksï¼Œa total of four cycles|KN044 0.3mg/kg dose grouponce every 3 weeksï¼Œa total of four cycles|KN044 1 mg/kg dose grouponce every 3 weeksï¼Œa total of four cycles|KN044 3 mg/kg dose grouponce every 3 weeksï¼Œa total of four cycles|KN044 6mg/kg dose grouponce every 3 weeksï¼Œa total of four cycles|KN044 10mg/kg dose grouponce every 3 weeksï¼Œa total of four cycles</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: KN044</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Dose-limiting toxicity for The maximum tolerated dose|KN044 of adverse event|KN044 of abnormalities of physical findings and laboratory tests</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Dose-limiting toxicity observation period 6 weeks after the first dose; the adverse events are recorded according to the actual occurrence; The data of the clinical research center is collected and analyzed according to the time point of the test flow chart</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>up to 6 weeks; through study completion an average of 210 days</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_110" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients receive nivolumab IV over 1 hour on days 1 15 and 29 in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgery within 2 weeks after day 43.|Patients receive nivolumab as in Arm A. Patients also receive ipilimumab IV over 90 minutes on day 1 in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgery within 2 weeks after day 43.|Patients receive nivolumab IV over 1 hour on days 1 15 29 and 43. Patients also undergo RT QD for 5 days during days 15-47 in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgery within 2 weeks after day 71.|Patients receive nivolumab as in Arm C ipilimumab as in Arm B and RT as in Arm C in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgery within 2 weeks after day 71.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: Nivolumab; Radiation: Radiation Therapy; Biological: Ipilimumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Pathologic response</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Pathologic response will be assessed at time of surgical resection by percentage hyalinization. The study will estimate the difference of the pathologic response between the treatment arms (A versus [vs] B C vs D) along with the estimate of variation of the difference. Given the longitudinal nature of the data linear mixed effect models for longitudinal measures will be employed to assess the change in the magnitude of the measures over time adjusting for multiple covariates including patient's characteristics and tumor characteristics. Appropriate transformation of the outcome assessment values will be used to satisfy the normality assumption of linear mixed effect model.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>At day 43 (Arm A/B) or 71 (Arm C/D)</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_111" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients with poor- or intermediate-risk RCC with clear cell component for first-line treatment.|Patients with poor- or intermediate-risk RCC with clear cell component for first-line treatment|Patients with favorable-risk RCC with clear cell component for first-line treatment.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Sitravatinib; Drug: Ipilimumab; Drug: Nivolumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Frequency of patients experiencing treatment-emergent AEs</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Characterization of AEs by incidence severity timing seriousness & relationship to study treatment</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Through study completion an average of 12 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_112" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Active Comparator; Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Participants will be treated with control chemotherapy treatment (standard-of-care chemotherapy chosen by the Physician from the provided list).||Control chemotherapy treatment will be chosen from any of the following standard-of-care chemotherapy drugs or combinations:||Carboplatin;|Irinotecan;|Etoposide;|BCNU;|CCNU;|Temozolomide;|Procarbazine;|Vincristine;|Imatinib;|Procarbazine CCNU Vincristine;|Carboplatin Irinotecan;|Carboplatin Etoposide;|Temozolomide Etoposide;|Temozolomide Imatinib. The treating physician will NOT receive the ChemoID assay results from the ChemoID lab.|Participants will be treated with ChemoID-guided standard-of-care chemotherapy drugs from the provided list.||ChemoID-guided treatment will be chosen from the following standard-of-care chemotherapy drugs or combinations:||Carboplatin;|Irinotecan;|Etoposide;|BCNU;|CCNU;|Temozolomide;|Procarbazine;|Vincristine;|Imatinib;|Procarbazine CCNU Vincristine;|Carboplatin Irinotecan;|Carboplatin Etoposide;|Temozolomide Etoposide;|Temozolomide Imatinib.||The treating physician will receive the ChemoID assay results from the ChemoID lab.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Chemotherapy; Diagnostic Test: ChemoID assay</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Median Overall Survival (OS)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Overall survival (OS) in recurrent GBM patients who have had a ChemoID assay-guided treatment compared to standard therapy chosen by the physician.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>36 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_113" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Ibrutinib: will be given by mouth daily|Blood samples for PSA and for immune assays will be collected at baseline before RP and after RP|Radical prostatectomy will be performed at least 7 days but not more than 12 days following the last scheduled dose of ibrutinib|Ibrutinib: will be given by mouth daily|Blood samples for PSA and for immune assays will be collected at baseline before RP and after RP|Radical prostatectomy will be performed at least 7 days but not more than 12 days following the last scheduled dose of ibrutinib</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Procedure: Blood samples for PSA and immune assays; Drug: Ibrutinib; Procedure: Radical prostatectomy</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Dose Limiting Toxicities (Safety Run-In)|B cell infiltration (Phase 2)|T cell infiltration (Phase 2)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>DLTs will be defined as any of the following that are attributable to ibrutinib.; Any grade 3 toxicity.; Any grade 4 toxicity including hematologic toxicities with the exception of lymphocytosis. Lymphocytosis in the absence of clinical symptoms is excluded from DLT as this may be considered an on-target pharmacodynamics effect of BTK inhibition.; Any delay of RP due to study-drug related toxicity.; Any complications of RP (e.g. bleeding delayed wound healing) deemed to be related to study drug.; Immunohistochemistry (ICH); CTCAE v.4.0; Any recurrence of the same grade 3 toxicity.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Completion of follow-up (approximately 10 weeks after start of treatment); Completion of enrollment of Phase I portion of patients</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_114" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Arm closed to enrollment.|Arm closed to enrollment.|Arm closed to enrollment.|Arm closed to enrollment.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: BOLD-100 in combination with FOLFOX Chemotherapy (Dose Escalation); Drug: BOLD-100 in combination with FOLFOX Chemotherapy (Dose Expansion)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Incidence and severity of adverse events (AEs) according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0|Incidence of serious adverse events (SAE) and suspected unexpected serious adverse reactions;|Incidence of dose-limiting toxicities (DLT)|Incidence of clinically significant changes or abnormalities from Physical Examinations ECGs Vital Signs Laboratory Results (chemistry hematology coagulation urinalysis) Eastern Cooperative Oncology Group (ECOG) performance status</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Screening to Study Discontinuation (an average of 2 months)</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_115" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>rHSC-DIPGVax for 8 total doses|rHSC-DIPGVax (8 total doses) + BALSTILIMAB (1 year of therapy or 27 cycles whichever comes first)||Patients will enroll 6-10 weeks post standard of care (SOC) radiation completion. Steroid dose must be at or below 0.5mg/kg/day for a minimum of 7 days. The first 3 patients must be 5 years or older to 18. Subsequently subjects ages 12 months to 18 years can be enrolled. Up to six patients will be enrolled on Part A. Once safety is established for rHSC-DIPGVax plus anti-PD1 (BALSTILIMAB) the study will proceed to Part B.|rHSC-DIPGVax (8 total doses) + BALSTILIMAB + ZALIFRELIMAB (1 year of therapy or 9 cycles whichever comes first)||Patients will enroll 6-10 weeks post standard of care (SOC) radiation therapy. Steroid dose must be at or below 0.5mg/kg/day for a minimum of 7 days. The first 3 patients must be 5 years or older to 18. Subsequently subjects ages 12 months to 18 years can be enrolled. Up to 12 patients will be enrolled on Part B. Once safety is established for rHSC-DIPGVax plus anti-PD1 (BALSTILIMAB) plus anti-CTLA4 (ZALIFRELIMAB) the study will proceed to Part C.|rHSC-DIPGVax (8 total doses) + BALSTILIMAB + ZALIFRELIMAB (at RP2D from Part B) (1 year of therapy or 9 cycles whichever comes first)||Patients will enroll 6-10 weeks post standard of care (SOC) radiation therapy. Steroid dose must be at or below 0.5mg/kg/day for a minimum of 7 days. Up to 12 patients will be enrolled on Part C. All subjects in Part C will be monitored for DLT's for the duration of their participation in the study to monitor for excess toxicity.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: rHSC-DIPGVax; Drug: Balstilimab; Drug: Zalifrelimab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Safety and Tolerability: Dose limiting toxicities of rHSC-DIPGVax|Safety and Tolerability: Dose limiting toxicities of rHSC-DIPGVax plus BALSTILIMAB|Safety and Tolerability: Dose limiting toxicities of rHSC-DIPGVax plus BALSTILIMAB and ZALIFRELIMAB</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Number of DLT's per CTCAE version 5.0 and iRANO guidelines.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>DLT period of 28 days for Part A; DLT period of 28 days for rHSC-DIPGVax monotherapy; DLT period of 42 days for Part B</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_116" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Avelumab 10mg/kg (or Maximum Administered Dose established in safety run-in) iv infusion over 1 hour.||Followed by FLOT: Oxaliplatin 85mg/m2 iv infusion day 1 over 2 hours Folinic acid 200mg/m2 iv infusion day 1 over 2 hours Docetaxel 50mg/m2 iv day 1 over 1 hour Fluorouracil 2600mg/m2 over 24 hours iv</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: FLOT-A</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Pathological complete response rate of combination FLOT-A</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>The primary objective is to assess the efficacy of FLOT-A in the peri-operative setting in patients with operable GOAs. We aim to increase the pCR rate after peri-operative treatment from 10% (minimum expected path CR rate for peri-operative FLOT chemotherapy) to a superior pCR rate of 25% by adding Avelumab to FLOT.; Complete histopathologic response is defined by no vital tumour cells neither in the oesophagus the stomach nor in the regional lymph nodes. In cases of residual tumour the response assessment will follow criteria described by Mandard et al.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Within 2 years of study opening</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_117" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>The therapeutic regimen will be divided into 2 different periods:||Radiotherapy period The patient will start IMRT (60Gy/30fr/6 weeks) TMZ(Temozolomide) chemotherapy (75mg/mÂ²/day) and olaparib on the same day on a Monday (day 1) within 6 weeks after surgery. The daily dose of TMZ (75 mg/mÂ²) will be continued until the end of radiotherapy (6 weeks) and olaparib will be continued with the same dose until 4 weeks after the end of IMRT as a single agent.|Maintenance period TMZ will then be re-introduced 4 weeks after the end of IMRT at the dose of 150 mg/m2/day on days 1 to 5 every 28 days for a total of 6 cycles. Concomitantly olaparib will be daily given at the maintenance dose level up to confirmed disease progression or unacceptable toxicities.||We propose 7 dose levels to reach the target dose of 400 mg per day (200 mg twice daily) of olaparib continuously</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Olaparib; Drug: Temozolomide (TMZ); Radiation: IMRT (Intensity Modulated Radiation Therapy)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>The Recommended Phase II Dose (RP2D) - Phase I|Overall survival - Phase II</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>The primary objective for the phase II is to assess the 12-month overall survival of the combination; The primary objective for the phase I is to determine the Recommended Phase II Dose (RP2D) of olaparib combined with the Stupp protocol (TMZ and concomitant fractionated radiotherapy: 60Gy/30 fractions/6 weeks) in first line treatment of patients with unresectable high-grade gliomas</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>The RP2D will be evaluated 4 weeks after the end of radiotherapy; 12 months after the first administration of treatment</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_118" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Active Comparator; Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>intravenous gemcitabine 1000 mg/m2 and cisplatin 25 mg/m2 on days 1 and 8; oral lenvatinib 8 mg/day (60kg) or 12 mg/ dï¼ˆâ‰¥60kgï¼‰from days 1 to 21; intravenous tislelizumab 200 mg on day 15|intravenous gemcitabine 1000 mg/m2 and cisplatin 25 mg/m2 on days 1 and 8</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Lenvatinib tislelizumab gemcitabine and cisplatin; Drug: gemcitabine and cisplatin</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>objective remission rate (ORR)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>According to RECIST v1.1 the proportion of patients with at least one complete response (CR) or partial response (PR) (%)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>4 cycle treatment (each cycle is 21 days)</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_119" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>KRAS BRAF mutant Sintilimab 200mg D1 Q3W + regafinil 80mg D1-21 Q4W|KRAS BRAF wild type Sintilimab 200mg d1q3w+ regofinib 80mg d1-21 q4w with cetuximab 500mg/m2 q2w</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: KRAS BRAF mutant Sintilimab + regafinil; Drug: Sintilimabï¼Œregofinibï¼Œcetuximab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Progression-free Survival (PFS)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Progression-free Survival (PFS) (median) was determined using the number of months measured from the initial date of treatment to the date of documented progression or the date of death (in the absence of progression) of participants. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) as a 20% increase in the sum of the longest diameter of target lesions or a measurable increase in a non-target lesion or the appearance of new lesions.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>up to 6 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_120" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Active Comparator; Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>"Subject randomized to receive intravenous infusion of 08 ml solution of Olokizumab one (128 mg) or two (256 mg) doses in addition to standard therapy in line with the current temporary guidelines ""Prevention diagnosis and treatment of new coronavirus infection (COVID-19)"" of the Ministry of Health of Russian Federation.||Standard therapy includes:||Baricitinib p.o. 4 mg once daily for 7 days||Favipiravir p.o.||for patients weighing 75 kg: 1600 mg twice daily on Day 1 then 600 mg twice daily from the 2nd to the 10th day;|for patients weighing â‰¥ 75 kg: 1800 mg twice daily on Day 1 then 800 mg twice daily from the 2nd to the 10th day; (Patients who have started etiotropic therapy with favipiravir or remdesivir prior to randomization will continue the initiated treatment.)|dexamethasone at doses of 4 - 20 mg / day or methylprednisolone at a dose of 1 mg / kg / intravenous injection every 12 hours.|Standard therapy in line with the current temporary guidelines ""Prevention diagnosis and treatment of new coronavirus infection (COVID-19)"" of the Ministry of Health of Russian Federation including:||Baricitinib p.o. 4 mg once daily for 7 days||Favipiravir p.o.||for patients weighing 75 kg: 1600 mg twice daily on Day 1 then 600 mg twice daily from the 2nd to the 10th day;|for patients weighing â‰¥ 75 kg: 1800 mg twice daily on Day 1 then 800 mg twice daily from the 2nd to the 10th day; (Patients who have started etiotropic therapy with favipiravir or remdesivir prior to randomization will continue the initiated treatment.)|dexamethasone at doses of 4 - 20 mg / day or methylprednisolone at a dose of 1 mg / kg / intravenous injection every 12 hours."</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Olokizumab; Drug: Standard therapy</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Clinical recovery rate at day 7</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>"(In the case of the ""rescue"" therapy use or the development of clinical deterioration (an increase in the score by 1 point or more) during the follow-up period in a previously recovered patient the patient is not considered as a ""responder"" i.e. who has reached the primary endpoint.); Clinical recovery defined as score of 3 or less on a 10-point ordinal scale of clinical improvement.; Criteria for transition from category ""4"" to category ""3"" (criteria for potential discharge): body temperature  37 Â°C; respiratory rate â‰¤ 20 per minute; SpO2 â‰¥ 95% without oxygen support CRP  10 mg/l. If any emergency procedures should be prescribed and/or signs of progression on CT are detected the patient cannot be discharged/transferred to category ""3"".; (From 0 ""Healthy - no clinical manifestations no viral RNA detected"" to 10 ""Death"".) 7 days are counted from the day of the first administration / intake of study therapy / comparison therapy depending on study group."</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to day 7</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_121" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Active Comparator; Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Participants will be treated with control chemotherapy treatment (Bevacizumab plus standard-of-care chemotherapy chosen by the Physician from the provided list).||Control chemotherapy treatment will be chosen from any of the following standard-of-care chemotherapy drugs or combinations:||Liposomal Doxorubicin;|Docetaxel;|Paclitaxel;|Carboplatin;|Cisplatin;|Gemcitabine;|Topotecan;|Carboplatin Gemcitabine;|Cisplatin Gemcitabine;|Carboplatin Liposomal Doxorubicin;|Carboplatin Paclitaxel;|Carboplatin Docetaxel.||The treating physician will NOT receive the ChemoID assay results from the ChemoID lab.|Participants will be treated with Bevacizumab plus ChemoID-guided standard-of-care chemotherapy drugs from the provided list.||ChemoID-guided treatment will be chosen from the following standard-of-care chemotherapy drugs or combinations:||Liposomal Doxorubicin;|Docetaxel;|Paclitaxel;|Carboplatin;|Cisplatin;|Gemcitabine;|Topotecan;|Carboplatin Gemcitabine;|Cisplatin Gemcitabine;|Carboplatin Liposomal Doxorubicin;|Carboplatin Paclitaxel;|Carboplatin Docetaxel.||The treating physician will receive the ChemoID assay results from the ChemoID lab.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Chemotherapy; Diagnostic Test: ChemoID assay</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Progression free survival (PFS)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Progression free survival (PFS) in patients with recurrent epithelial ovarian cancer (EOC) who receive standard of care treatment (Bevacizumab plus chemotherapy chosen by the Physician from the provided list) versus Bevacizumab plus ChemoID drug response assay-directed chemotherapy.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>36 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_122" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Participants with high-risk nmCRPC will receive darolutamide.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Darolutamide (Nubeqa BAY1841788)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Number of participants with adverse events (AEs) and serious adverse events (SAEs) and their severity|Number of participants with discontinuations of study treatment due to AEs|Number of participants with dose modifications of study treatment due to AEs|Number of participants with clinically significant abnormalities in laboratory parameters|Number of participants with clinically significant electrocardiograms abnormalities|Number of participants with clinically significant physical examination abnormalities|Number of participants with clinically significant changes in vital signs|Number of participants with changes in eastern cooperative oncology group (ECOG) performance status</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>From baseline to approximately 15 months; Approximately 15 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>


<!-- ############################### -->
<!-- ############################### -->
<!-- ########### NEW IA ############ -->
<!-- ############################### -->
<!-- ############################### -->

<br><h2 id="new_ia">New Trials - Immune Activation</h2>
<h4><a href="#home">Home</a></h4>
<table border="1" summary="Long-term goals table" width="100%" cellspacing="0" cellpadding="0">
  <thead>
    <tr>
      <th><h3>Condition</h3></th>
      <th><h3>Sponsor</h3></th>
      <th><h3>Phase</h3></th>
      <th><h3>Intervention</h3></th>
      <th><h3>Trial ID</h3></th>
      <th><h3>Interest Level?</h3></th>
    </tr>
  </thead>
  <tbody>
  <tr>
    <td>CMV</td>
    <td>University Hospital Rouen</td>
<td><p>N/A</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_123">Study Arms</button></td>
    <td><p>Belatacept</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_572">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05708534" target="_blank">NCT05708534</a></td><td><select class="form-select" id="select_form_136" name="NCT05708534"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr data-toggle="collapse" data-target="#demo8" class="accordion-toggle" style = "background-color: #E1EBEE;">  <td colspan="6">NO LARGE COMPANY TRIALS</td>
  </tr>
  </tbody>
</table>
<!-- THE MODAL -->
<div class="modal fade" id="modal_123" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>To study the quantitative changes in anti-CMV T-lymphocyte immunity to the IE-1 antigen within 6 months of a switch from anticalcineurin treatment to belatacept in a cohort of kidney transplant recipients seropositive for CMV</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Number of interferon gamma-producing T lymphocytes in response to the IE-1 antigen determined by ELISPOT at M0 M3 and M6.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>6 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>


<!-- ############################### -->
<!-- ############################### -->
<!-- ######### EXISTING IA ######### -->
<!-- ############################### -->
<!-- ############################### -->

<br><h2 id="existing_ia">Existing Trials - Immune Activation</h2>
<h4><a href="#home">Home</a></h4>
<table border="1" summary="Long-term goals table" width="100%" cellspacing="0" cellpadding="0">
  <thead>
    <tr>
      <th><h3>Update</h3></th>
      <th><h3>Condition</h3></th>
      <th><h3>Sponsor</h3></th>
      <th><h3>Phase</h3></th>
      <th><h3>Intervention</h3></th>
      <th><h3>Trial ID</h3></th>
      <th><h3>Interest Level?</h3></th>
    </tr>
  </thead>
  <tbody>
  <tr>
    <td><strong>Completion Date moved earlier by 373 days; Trial completed</strong></td>
    <td>Solid tumor</td>
    <td>Nova Scotia Health Authority</td>
<td><p>Phase 4</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_124">Study Arms</button></td>
    <td>Ranitidine</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03145012" target="_blank">NCT03145012</a></td><td><select class="form-select" id="select_form_137" name="NCT03145012"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Trial completed</strong></td>
    <td>Refractory Malignant Ascites</td>
    <td>Fudan University</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_125">Study Arms</button></td>
    <td>Oncorine (H101)</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04771676" target="_blank">NCT04771676</a></td><td><select class="form-select" id="select_form_138" name="NCT04771676"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Now recruiting</strong></td>
    <td>Breast cancer or melanoma that cannot be removed by surgery (unresectable) and has spread to other places in the body (metastatic)</td>
    <td>University of Southern California</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_126">Study Arms</button></td>
    <td>Anti-CD40 Agonist Monoclonal Antibody CDX-1140; Poly ICLC; Radiation Therapy; Recombinant Flt3 Ligand</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04616248" target="_blank">NCT04616248</a></td><td><select class="form-select" id="select_form_139" name="NCT04616248"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Changed status from recruiting to active</strong></td>
    <td>High-risk non-muscle invasive bladder cancer</td>
    <td>Fundacion Oncosur</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_127">Study Arms</button></td>
    <td><p>Atezolizumab; BCG</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_576">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04134000" target="_blank">NCT04134000</a></td><td><select class="form-select" id="select_form_140" name="NCT04134000"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Changed status from recruiting to active</strong></td>
    <td>Diffuse Cutaneous Systemic Sclerosis (dcSSc)</td>
    <td>National Institute of Allergy and Infectious Diseases (NIAID)</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_128">Study Arms</button></td>
    <td><p>Brentuximab Vedotin; Placebo</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_576">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03222492" target="_blank">NCT03222492</a></td><td><select class="form-select" id="select_form_141" name="NCT03222492"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 731 days; Primary Completion Date pushed later by 365 days</strong></td>
    <td>GVHD in leukemic and myelodysplastic patients who have had a partially mismatched bone marrow transplant (haploidentical)</td>
    <td>University of Kansas Medical Center</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_129">Study Arms</button></td>
    <td>EAGD T-cell infusion (Phase I); EAGD T-cell infusion (Expansion)</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03533816" target="_blank">NCT03533816</a></td><td><select class="form-select" id="select_form_142" name="NCT03533816"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 232 days; Primary Completion Date pushed later by 152 days</strong></td>
    <td>Macrophage Activation Syndrome</td>
    <td>University of Alabama at Birmingham</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_130">Study Arms</button></td>
    <td>kineret; placebo</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT02780583" target="_blank">NCT02780583</a></td><td><select class="form-select" id="select_form_143" name="NCT02780583"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 92 days; Primary Completion Date pushed later by 109 days; Start Date pushed later by 108 days</strong></td>
    <td>HER2-positive metastatic breast cancer</td>
    <td>Breast Cancer Trials Australia and New Zealand</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_131">Study Arms</button></td>
    <td><p>Tucatinib; Pembrolizumab; Trastuzumab; Capecitabine</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_578">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04789096" target="_blank">NCT04789096</a></td><td><select class="form-select" id="select_form_144" name="NCT04789096"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 851 days; Changed status from unknown status to active; Primary Completion Date pushed later by 182 days</strong></td>
    <td>Oesophageal Cancer</td>
    <td>Simon C Pacey MD</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_132">Study Arms</button></td>
    <td><p>Durvalumab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_578">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03653052" target="_blank">NCT03653052</a></td><td><select class="form-select" id="select_form_145" name="NCT03653052"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Primary Completion Date pushed later by 365 days</strong></td>
    <td>Oligorecurrent and Oligoprogressive Prostate Cancer Patients</td>
    <td>Istituto Clinico Humanitas</td>
<td><p>Not Applicable</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_133">Study Arms</button></td>
    <td>Radiotherapy; androgen deprivation therapy (ADT); immune evaluation</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04624828" target="_blank">NCT04624828</a></td><td><select class="form-select" id="select_form_146" name="NCT04624828"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr data-toggle="collapse" data-target="#demo9" class="accordion-toggle">  <td colspan="7">NO LARGE COMPANY TRIALS</td>
  </tr>
  </tbody>
</table>
<!-- THE MODAL -->
<div class="modal fade" id="modal_124" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>This is a one arm study in which all individuals receive the treatment; therefore there is no allocation or randomization.||Thirty subjects will receive ranitidine to a maximum of 900 mg/day in 2 daily doses for 6 weeks. The dosage target is 8 mg/kg/day but the range of ranitidine intake will be between 7.5- 9 mg/kg/day. This is due to the formulation of the tablets sold as 75 150 and 300mg tablets. The ranitidine will be taken orally.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Ranitidine</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Intra-individual frequency and function of immune cell subsets</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>To determine the effect of histamine 2 receptor antagonists on immune cell function in healthy humans. Frequency and function of B cell T cell monocyte NK cell and MDSC cells will be assessed by flow cytometry and ELISPOT.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Frequency and function were calculated as the values at 6 wks after treatment compared to the values at baseline.</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_125" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>H101 diluted in 5ml 0.9% sodium chloride solution will be intraperitoneally injected through the drainage catheter. Each patient will receive a dose of 1.5Ã—10^12 vp by i.p. administration on day 1 and 3.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Oncorine (H101)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Time to repeat paracentesis (TTRP)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Defined as the number of days between the first paracentesis (baseline) and the subsequent repeat paracentesis.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>max 6 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_126" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients receive recombinant Flt3 ligand IT on days 1-5 and undergo radiation therapy on day 8 or 9. Patients also receive agonistic anti-CD40 monoclonal antibody CDX-1140 IT and Poly-ICLC IT on day 9 or 10. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.|Patients receive recombinant Flt3 ligand IT on days 1-5 and undergo radiation therapy on day 8 or 9. Patients also receive agonistic anti-CD40 monoclonal antibody IT and IV over 90 minutes and Poly-ICLC IT on day 9 or 10. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: Recombinant Flt3 Ligand; Radiation: Radiation Therapy; Drug: Poly ICLC; Biological: Anti-CD40 Agonist Monoclonal Antibody CDX-1140</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Incidence of adverse events|Maximum tolerated dose or maximum administered dose</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>The dose limiting toxicity rate will be estimated by cohort and dose-level (if appropriate) using 90% confidence intervals obtained by Jeffrey's prior method.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 30 days</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_127" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Ten patient will be enrolled in first cohort starting on level 0 (DL 0) receiving BCG 1 instillation per week and Atezolizumab 1200 mg IV every three weeks (q3w).||The next level of dose in case is necessary is BCG 1/2 instillation per week and Atezolizumab 1200 mg IV every three weeks (q3w)</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Atezolizumab; Drug: BCG</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Dose limiting toxicity (DLT)|Recurrence free survival.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Incidence and nature of DLT of BCG plus atezolizumab combination in NMIBC graded according to NCI CTCAE v5.; Time from the date of start of treatment until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from therapy or receives another anticancer therapy prior to progression according to RECIST 1.1 as assessed by the Investigator</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 24 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_128" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental; Placebo Comparator</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>This is the first of three ascending dose cohorts. Participants in this cohort will receive 0.6 mg/kg brentuximab vedotin (to a maximum dose 60 mg) every 3 weeks from week 0 (initial dose) to week 21 a total of 8 treatments. Brentuximab vedotin will be administered as an intravenous infusion over 30 minutes.||Cohort 1 Randomization schedule: N=6 assigned to brentuximab vedotin: N=2 assigned to placebo.|0.6 mg/kg placebo (to a maximum dose 60 mg). Participants in this cohort will receive 0.6 mg/kg placebo every 3 weeks from week 0 (initial dose) to week 21 a total of 8 treatments. Placebo will be administered as an intravenous infusion over 30 minutes.||Cohort 1 Randomization schedule: N=6 assigned to brentuximab vedotin: N=2 assigned to placebo.|This is the second of three ascending dose cohorts. Participants in this cohort will receive 1.2 mg/kg brentuximab vedotin (to a maximum dose 60 mg) every 3 weeks from week 0 (initial dose) to week 21 a total of 8 treatments. Brentuximab vedotin will be administered as an intravenous infusion over 30 minutes.||Cohort 2 Randomization schedule: N=6 assigned to brentuximab vedotin: N=2 assigned to placebo.|1.2 mg/kg placebo (to a maximum dose 60 mg). Participants in this cohort will receive 1.2 mg/kg placebo every 3 weeks from week 0 (initial dose) to week 21 a total of 8 treatments. Placebo will be administered as an intravenous infusion over 30 minutes.||Cohort 2 Randomization schedule: N=6 assigned to brentuximab vedotin: N=2 assigned to placebo.|This is the third/last of three ascending dose cohorts. Participants in this cohort will receive 1.8 mg/kg brentuximab vedotin (to a maximum dose 60 mg) every 3 weeks from week 0 (initial dose) to week 21 a total of 8 treatments. Brentuximab vedotin will be administered as an intravenous infusion over 30 minutes.||Cohort 3 Randomization schedule: N=6 assigned to brentuximab vedotin: N=2 assigned to placebo.|1.8 mg/kg placebo (to a maximum dose 60 mg). Participants in this cohort will receive 1.8 mg/kg placebo every 3 weeks from week 0 (initial dose) to week 21 a total of 8 treatments. Placebo will be administered as an intravenous infusion over 30 minutes.||Cohort 3 Randomization schedule: N=6 assigned to brentuximab vedotin: N=2 assigned to placebo.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: Brentuximab Vedotin; Biological: Placebo</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Proportion of participants who experience at least one Grade 3 or higher adverse event</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Severity will be reported using NCI-CTCAE grading criteria. Reference: the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 (November 272017): http://ctep.cancer.gov/reporting/ctc.html.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>From week 0 (â‰¥first dose of assigned treatment) to week 48 post-randomization</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_129" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Peripheral blood is collected by leukapheresis from the donor expanded and activated on CliniMACS-Prodigy further depleted of alpha beta T-cells using the CliniMACS Alpha Beta T-Cell Depletion System which leaves a gamma delta T-cell rich product. This product is then infused into the recipient at either 1 3 or 10 x 1000000 cells/kg concentrations depending upon the cohort.|Peripheral blood is collected by leukapheresis from the donor expanded and activated on CliniMACS-Prodigy further depleted of alpha beta T-cells using the CliniMACS Alpha Beta T-Cell Depletion System which leaves a gamma delta T-cell rich product. This product is then infused into the recipient at the maximum tolerated dose as determined from Phase I.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: EAGD T-cell infusion (Phase I); Drug: EAGD T-cell infusion (Expansion)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Phase I - Dose-limiting toxicity (DLT)|Phase I - Severe acute adverse events following infusion of EAGD T-cells|Expansion phase - Rate of acute GVHD</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Monitoring for GVHD is assessed with Grade II-IV adverse events as identified by the National Cancer Common Terminology Criteria for Adverse Events (CTCAE) version 4.; The dose escalation strategy will follow the Food and Drug Administration Guideline for design of early phase clinical trials of cellular therapy products.; Safety of the infusion will be based on the risk of treatment-related severe adverse events as identified in the National Cancer Common Terminology Criteria for Adverse Events (CTCAE) version 4.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Baseline to Day 30; Baseline to Day 100</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_130" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental; Placebo Comparator</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>methylprednisolone intravenously placebo shots every 6 hours|methylprednisolone intravenously anakinra shots every 6 hours</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: placebo; Drug: kineret</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Number of acquired infections deaths in treatment group vs placebo group</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>The primary outcome measure is to determine whether hospital acquired infections or deaths are increased when anakinra is added to corticosteroid use during the first 72 hours of MAS management</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>within 72 hours after baseline</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_131" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Participants will receive:||Tucatinib (oral) at a dose of 300 mg BD on day 1-21 of each 21-day cycle|Pembrolizumab will be administered at a dose of 200 mg IV on day 1 of each 21 day cycle|Trastuzumab will be given as a loading dose of 8 mg/kg IV (if loading required otherwise 6 mg/kg) on day 1 followed by 6 mg/kg on day 1 of each 21 day cycle.|Participants will receive:||Tucatinib (oral) at a dose of 300 mg BD on day 1-21|Capecitabine (oral) at a dose of 1000 mg/m^2 BD on day 1-14 of each 21-day cycle|Pembrolizumab will be administered at a dose of 200 mg IV on day 1 of each 21 day cycle|Trastuzumab will be given as a loading dose of 8 mg/kg IV (if loading required otherwise 6 mg/kg) on day 1 followed by 6 mg/kg on day 1 of each 21 day cycle.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Tucatinib; Drug: Pembrolizumab; Drug: Capecitabine; Drug: Trastuzumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Objective Response Rate (ORR) in the PD-L1 positive cohort</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Defined as complete response (CR) or partial response (PR) assessed as per RECIST 1.1</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Through to study completion an average of 24 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_132" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients with advanced oesophageal cancer will be administered with 1500mg of durvalumab once every 4 weeks for up to 6 months.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Durvalumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Clinical response to therapy (durvalumab)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Changes in ctDNA levels (from baseline to C1/C2) compared with objective RECIST radiological response at 26 weeks</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>26 weeks</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_133" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>RT treatment Schedule as for clinical practice: Stereotactic body radiation treatment (SBRT) will be delivered with image guidance (image-guided radiation therapy or IGRT) and in the form of volumetric modulated arc therapy (VMAT).||RT treatment Schedule: SBRT will be delivered in 1 to 6 fractions on bone or lymph node metastases. The dose and fractionation schedule will depend on the size and location of the lesion and the surrounding normal tissue constraints.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: androgen deprivation therapy (ADT); Biological: immune evaluation; Procedure: Radiotherapy</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>immune evaluation</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Analysis of the immunitary background performed before SBRT and evaluation of immune modulation after RT treatment. Our panels will include markers of T cell differentiation and activation including CD25 CD39 PD-1 CTL4 KLRG1 TIM3 TIGIT. In addition we will investigate the phenotype and functional state of myeloid subsets in enrolled patients comprising neutrophils monocytes and dendritic cells. To this end markers such as CD66b CD24 CD16 MHC-II LOX1 CD36 and CD62L will be included in our analysis.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>from the baseline (before SBRT) to 7 days after the end of radiotherapy treatment</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>


<!-- ############################### -->
<!-- ############################### -->
<!-- ######## FDA APPROVALS ######## -->
<!-- ############################### -->
<!-- ############################### -->

<br><h2 id="approvals">Drug Approvals/Applications</h2>
<h4><a href="#home">Home</a></h4>
<table border="1" summary="Long-term goals table" width="100%" cellspacing="0" cellpadding="0" class="fda">
  <thead>
    <tr>
      <th><h3>Company</h3></th>
      <th><h3>Update</h3></th>
      <th><h3>Trial ID</h3></th>
      <th><h3>Interest Level?</h3></th>
    </tr>
  </thead>
  <tbody>
  <tr>
    <td>Gracell Biotechnologies</td>
    <td>Gracell Biotechnologies Announces China NMPA Clearance for IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for Treatment of Relapsed/Refractory Multiple Myeloma</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04935580" target="_blank">NCT04935580</a></td><td><select class="form-select" id="select_form_147" name="NCT04935580"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr data-toggle="collapse" data-target="#demo10" class="accordion-toggle" style = "background-color: #E1EBEE;">    <td>FCS</td>
    <td>FCS Clinical Trials Lead to FDA Approval of New Targeted Drug for Patients with Mantle Cell Lymphoma</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03740529" target="_blank">NCT03740529</a></td><td><select class="form-select" id="select_form_148" name="NCT03740529"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  </tbody>
</table>
<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_500" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>nivolumab</td>
          <td>Opdivo</td>
          <td>Bristol-Myers Squibb Company</td>
          <td>['10/4/2017' '8/27/2021' '12/22/2014']</td>
          <td>Intravenous</td>
          <td>['240MG/24ML' '100MG/10ML' '120MG/12ML' '40MG/4ML']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_501" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>pembrolizumab</td>
          <td>Keytruda</td>
          <td>Merck Sharp & Dohme Corp.</td>
          <td>['9/4/2014' '1/15/2015']</td>
          <td>Intravenous</td>
          <td>['50MG' '100MG/4ML (25MG/ML)']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_502" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>pembrolizumab</td>
          <td>Keytruda</td>
          <td>Merck Sharp & Dohme Corp.</td>
          <td>['9/4/2014' '1/15/2015']</td>
          <td>Intravenous</td>
          <td>['50MG' '100MG/4ML (25MG/ML)']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_509" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>CARBOPLATIN</td>
          <td>PARAPLATIN</td>
          <td>CORDEN PHARMA</td>
          <td>Mar 3 1989</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['450MG/VIAL' '150MG/VIAL' '50MG/VIAL']</td>
            </tr>
            <tr>
          <td>CARBOPLATIN</td>
          <td>PARAPLATIN</td>
          <td>CORDENPHARMA</td>
          <td>['Jan 15 2004' 'Jul 14 2003']</td>
          <td>INJECTABLE;INTRAVENOUS</td>
          <td>['150MG/15ML (10MG/ML)' '600MG/60ML (10MG/ML)' '450MG/45ML (10MG/ML)' '50MG/5ML (10MG/ML)']</td>
            </tr>
            <tr>
          <td>PACLITAXEL</td>
          <td>ABRAXANE</td>
          <td>ABRAXIS BIOSCIENCE</td>
          <td>Jan 7 2005</td>
          <td>POWDER;INTRAVENOUS</td>
          <td>100MG/VIAL</td>
            </tr>
            <tr>
          <td>PACLITAXEL</td>
          <td>TAXOL</td>
          <td>HQ SPCLT PHARMA</td>
          <td>Dec 29 1992</td>
          <td>INJECTABLE;INJECTION</td>
          <td>6MG/ML</td>
            </tr>
            <tr>
          <td>PEMETREXED</td>
          <td>PEMETREXED</td>
          <td>ACTAVIS LLC</td>
          <td>Aug 21 2020</td>
          <td>SOLUTION;INTRAVENOUS</td>
          <td>['1GM/40ML (25MG/ML)' '500MG/20ML (25MG/ML)' '100MG/4ML (25MG/ML)']</td>
            </tr>
            <tr>
          <td>PEMETREXED</td>
          <td>PEMFEXY</td>
          <td>EAGLE PHARMS</td>
          <td>Feb 8 2020</td>
          <td>SOLUTION;INTRAVENOUS</td>
          <td>500MG/20ML (25MG/ML)</td>
            </tr>
            <tr>
          <td>ipilimumab</td>
          <td>Yervoy</td>
          <td>Bristol-Myers Squibb Company</td>
          <td>3/25/2011</td>
          <td>Intravenous</td>
          <td>['200MG/40ML (5MG/ML)' '50MG/10ML (5MG/ML)']</td>
            </tr>
            <tr>
          <td>nivolumab</td>
          <td>Opdivo</td>
          <td>Bristol-Myers Squibb Company</td>
          <td>['10/4/2017' '8/27/2021' '12/22/2014']</td>
          <td>Intravenous</td>
          <td>['240MG/24ML' '100MG/10ML' '120MG/12ML' '40MG/4ML']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_511" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>BRIGATINIB</td>
          <td>ALUNBRIG</td>
          <td>TAKEDA PHARMS USA</td>
          <td>['Apr 28 2017' 'Oct 2 2017']</td>
          <td>TABLET;ORAL</td>
          <td>['90MG' '30MG' '180MG']</td>
            </tr>
            <tr>
          <td>durvalumab</td>
          <td>Imfinzi</td>
          <td>AstraZeneca UK Ltd</td>
          <td>5/1/2017</td>
          <td>Intravenous</td>
          <td>['120MG/2.4ML (50MG/ML)' '500MG/10ML (50MG/ML)']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_513" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>canakinumab</td>
          <td>Ilaris</td>
          <td>Novartis Pharmaceuticals Corporation</td>
          <td>['6/17/2009' '12/22/2016']</td>
          <td>Subcutaneous</td>
          <td>['150MG/ML' '150MG']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_515" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>BRIGATINIB</td>
          <td>ALUNBRIG</td>
          <td>TAKEDA PHARMS USA</td>
          <td>['Apr 28 2017' 'Oct 2 2017']</td>
          <td>TABLET;ORAL</td>
          <td>['90MG' '30MG' '180MG']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_516" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>CARBOPLATIN</td>
          <td>PARAPLATIN</td>
          <td>CORDEN PHARMA</td>
          <td>Mar 3 1989</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['450MG/VIAL' '150MG/VIAL' '50MG/VIAL']</td>
            </tr>
            <tr>
          <td>CARBOPLATIN</td>
          <td>PARAPLATIN</td>
          <td>CORDENPHARMA</td>
          <td>['Jan 15 2004' 'Jul 14 2003']</td>
          <td>INJECTABLE;INTRAVENOUS</td>
          <td>['150MG/15ML (10MG/ML)' '600MG/60ML (10MG/ML)' '450MG/45ML (10MG/ML)' '50MG/5ML (10MG/ML)']</td>
            </tr>
            <tr>
          <td>CISPLATIN</td>
          <td>CISPLATIN</td>
          <td>HQ SPCLT PHARMA</td>
          <td>Nov 8 1988</td>
          <td>INJECTABLE;INJECTION</td>
          <td>1MG/ML</td>
            </tr>
            <tr>
          <td>CISPLATIN</td>
          <td>PLATINOL</td>
          <td>HQ SPCLT PHARMA</td>
          <td>Approved Prior to Jan 1 1982</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['10MG/VIAL' '50MG/VIAL']</td>
            </tr>
            <tr>
          <td>CISPLATIN</td>
          <td>PLATINOL-AQ</td>
          <td>HQ SPCLT PHARMA</td>
          <td>Jul 18 1984</td>
          <td>INJECTABLE;INJECTION</td>
          <td>0.5MG/ML</td>
            </tr>
            <tr>
          <td>PACLITAXEL</td>
          <td>ABRAXANE</td>
          <td>ABRAXIS BIOSCIENCE</td>
          <td>Jan 7 2005</td>
          <td>POWDER;INTRAVENOUS</td>
          <td>100MG/VIAL</td>
            </tr>
            <tr>
          <td>PACLITAXEL</td>
          <td>TAXOL</td>
          <td>HQ SPCLT PHARMA</td>
          <td>Dec 29 1992</td>
          <td>INJECTABLE;INJECTION</td>
          <td>6MG/ML</td>
            </tr>
            <tr>
          <td>PEMETREXED</td>
          <td>PEMETREXED</td>
          <td>ACTAVIS LLC</td>
          <td>Aug 21 2020</td>
          <td>SOLUTION;INTRAVENOUS</td>
          <td>['1GM/40ML (25MG/ML)' '500MG/20ML (25MG/ML)' '100MG/4ML (25MG/ML)']</td>
            </tr>
            <tr>
          <td>PEMETREXED</td>
          <td>PEMFEXY</td>
          <td>EAGLE PHARMS</td>
          <td>Feb 8 2020</td>
          <td>SOLUTION;INTRAVENOUS</td>
          <td>500MG/20ML (25MG/ML)</td>
            </tr>
            <tr>
          <td>hyaluronidase</td>
          <td>Amphadase</td>
          <td>Amphastar Pharmaceuticals Inc.</td>
          <td>10/26/2004</td>
          <td>Subcutaneous</td>
          <td>150UNITS/ML</td>
            </tr>
            <tr>
          <td>hyaluronidase</td>
          <td>Hydase</td>
          <td>Akorn Inc.</td>
          <td>10/25/2005</td>
          <td>Subcutaneous</td>
          <td>150UNITS/ML</td>
            </tr>
            <tr>
          <td>hyaluronidase</td>
          <td>Vitrase</td>
          <td>Bausch & Lomb Incorporated</td>
          <td>['12/2/2004' '5/5/2004']</td>
          <td>Subcutaneous</td>
          <td>['6200UNITS/ML' '200UNITS/ML']</td>
            </tr>
            <tr>
          <td>pembrolizumab</td>
          <td>Keytruda</td>
          <td>Merck Sharp & Dohme Corp.</td>
          <td>['9/4/2014' '1/15/2015']</td>
          <td>Intravenous</td>
          <td>['50MG' '100MG/4ML (25MG/ML)']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_518" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>CARBOPLATIN</td>
          <td>PARAPLATIN</td>
          <td>CORDEN PHARMA</td>
          <td>Mar 3 1989</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['450MG/VIAL' '150MG/VIAL' '50MG/VIAL']</td>
            </tr>
            <tr>
          <td>CARBOPLATIN</td>
          <td>PARAPLATIN</td>
          <td>CORDENPHARMA</td>
          <td>['Jan 15 2004' 'Jul 14 2003']</td>
          <td>INJECTABLE;INTRAVENOUS</td>
          <td>['150MG/15ML (10MG/ML)' '600MG/60ML (10MG/ML)' '450MG/45ML (10MG/ML)' '50MG/5ML (10MG/ML)']</td>
            </tr>
            <tr>
          <td>PACLITAXEL</td>
          <td>ABRAXANE</td>
          <td>ABRAXIS BIOSCIENCE</td>
          <td>Jan 7 2005</td>
          <td>POWDER;INTRAVENOUS</td>
          <td>100MG/VIAL</td>
            </tr>
            <tr>
          <td>PACLITAXEL</td>
          <td>TAXOL</td>
          <td>HQ SPCLT PHARMA</td>
          <td>Dec 29 1992</td>
          <td>INJECTABLE;INJECTION</td>
          <td>6MG/ML</td>
            </tr>
            <tr>
          <td>nivolumab</td>
          <td>Opdivo</td>
          <td>Bristol-Myers Squibb Company</td>
          <td>['10/4/2017' '8/27/2021' '12/22/2014']</td>
          <td>Intravenous</td>
          <td>['240MG/24ML' '100MG/10ML' '120MG/12ML' '40MG/4ML']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_520" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>pembrolizumab</td>
          <td>Keytruda</td>
          <td>Merck Sharp & Dohme Corp.</td>
          <td>['9/4/2014' '1/15/2015']</td>
          <td>Intravenous</td>
          <td>['50MG' '100MG/4ML (25MG/ML)']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_521" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>atezolizumab</td>
          <td>Tecentriq</td>
          <td>Genentech Inc.</td>
          <td>['5/18/2016' '3/8/2019']</td>
          <td>Intravenous</td>
          <td>['840MG/14ML (60MG/ML)' '1200MG/20ML (60MG/ML)']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_522" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>DOCETAXEL</td>
          <td>DOCEFREZ</td>
          <td>SUN PHARM</td>
          <td>May 3 2011</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['80MG/VIAL' '20MG/VIAL']</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>DOCETAXEL</td>
          <td>ACCORD HLTHCARE</td>
          <td>['Apr 20 2012' 'Jun 8 2011']</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['80MG/4ML (20MG/ML)' '80MG/2ML (40MG/ML)' '20MG/ML (20MG/ML)' '20MG/0.5ML (40MG/ML)' '160MG/8ML (20MG/ML)']</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>DOCETAXEL</td>
          <td>ACTAVIS LLC</td>
          <td>['Sep 21 2015' 'Apr 12 2013']</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['160MG/8ML (20MG/ML)' '80MG/4ML (20MG/ML)' '20MG/ML (20MG/ML)' '140MG/7ML (20MG/ML)']</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>DOCETAXEL</td>
          <td>APOTEX INC</td>
          <td>Jan 11 2012</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['20MG/0.5ML (40MG/ML)' '80MG/2ML (40MG/ML)']</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>DOCETAXEL</td>
          <td>HOSPIRA INC</td>
          <td>['Jan 24 2017' 'Jun 23 2016' 'Mar 8 2011']</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['160MG/16ML (10MG/ML)' '80MG/4ML (20MG/ML)' '20MG/ML (20MG/ML)' '80MG/8ML (10MG/ML)' '120MG/6ML (20MG/ML)' '160MG/8ML (20MG/ML)' '20MG/2ML (10MG/ML)']</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>DOCETAXEL</td>
          <td>PFIZER LABS</td>
          <td>Mar 13 2014</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['200MG/20ML (10MG/ML)' '130MG/13ML (10MG/ML)' '80MG/8ML (10MG/ML)' '20MG/2ML (10MG/ML)']</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>DOCETAXEL</td>
          <td>SANDOZ</td>
          <td>Jun 29 2011</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['160MG/16ML (10MG/ML)' '80MG/8ML (10MG/ML)' '20MG/2ML (10MG/ML)']</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>DOCETAXEL</td>
          <td>SHILPA</td>
          <td>Dec 22 2015</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['160MG/8ML (20MG/ML)' '80MG/4ML (20MG/ML)' '20MG/ML (20MG/ML)']</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>DOCETAXEL</td>
          <td>SUN PHARM</td>
          <td>Jan 8 2019</td>
          <td>SOLUTION;INTRAVENOUS</td>
          <td>['160MG/8ML (20MG/ML)' '80MG/4ML (20MG/ML)' '20MG/ML (20MG/ML)']</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>TAXOTERE</td>
          <td>SANOFI AVENTIS US</td>
          <td>['Aug 2 2010' 'Aug 3 2010' 'Apr 13 2012' 'May 14 1996']</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['160MG/8ML (20MG/ML)' '80MG/4ML (20MG/ML)' '40MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**' '20MG/ML (20MG/ML)']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_528" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>TEMOZOLOMIDE</td>
          <td>TEMODAR</td>
          <td>MERCK SHARP DOHME</td>
          <td>['Aug 11 1999' 'Feb 27 2009' 'Oct 19 2006']</td>
          <td>['CAPSULE;ORAL' 'POWDER;INTRAVENOUS']</td>
          <td>['140MG' '180MG' '250MG' '100MG' '5MG' '20MG' '100MG/VIAL']</td>
            </tr>
            <tr>
          <td>atezolizumab</td>
          <td>Tecentriq</td>
          <td>Genentech Inc.</td>
          <td>['5/18/2016' '3/8/2019']</td>
          <td>Intravenous</td>
          <td>['840MG/14ML (60MG/ML)' '1200MG/20ML (60MG/ML)']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_532" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>CARBOPLATIN</td>
          <td>PARAPLATIN</td>
          <td>CORDEN PHARMA</td>
          <td>Mar 3 1989</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['450MG/VIAL' '150MG/VIAL' '50MG/VIAL']</td>
            </tr>
            <tr>
          <td>CARBOPLATIN</td>
          <td>PARAPLATIN</td>
          <td>CORDENPHARMA</td>
          <td>['Jan 15 2004' 'Jul 14 2003']</td>
          <td>INJECTABLE;INTRAVENOUS</td>
          <td>['150MG/15ML (10MG/ML)' '600MG/60ML (10MG/ML)' '450MG/45ML (10MG/ML)' '50MG/5ML (10MG/ML)']</td>
            </tr>
            <tr>
          <td>PACLITAXEL</td>
          <td>ABRAXANE</td>
          <td>ABRAXIS BIOSCIENCE</td>
          <td>Jan 7 2005</td>
          <td>POWDER;INTRAVENOUS</td>
          <td>100MG/VIAL</td>
            </tr>
            <tr>
          <td>PACLITAXEL</td>
          <td>TAXOL</td>
          <td>HQ SPCLT PHARMA</td>
          <td>Dec 29 1992</td>
          <td>INJECTABLE;INJECTION</td>
          <td>6MG/ML</td>
            </tr>
            <tr>
          <td>nivolumab</td>
          <td>Opdivo</td>
          <td>Bristol-Myers Squibb Company</td>
          <td>['10/4/2017' '8/27/2021' '12/22/2014']</td>
          <td>Intravenous</td>
          <td>['240MG/24ML' '100MG/10ML' '120MG/12ML' '40MG/4ML']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_533" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>PREDNISONE</td>
          <td>DELTASONE</td>
          <td>PHARMACIA AND UPJOHN</td>
          <td>Approved Prior to Jan 1 1982</td>
          <td>TABLET;ORAL</td>
          <td>['2.5MG' '10MG' '50MG' '5MG' '20MG']</td>
            </tr>
            <tr>
          <td>PREDNISONE</td>
          <td>METICORTEN</td>
          <td>SCHERING</td>
          <td>Approved Prior to Jan 1 1982</td>
          <td>TABLET;ORAL</td>
          <td>['1MG' '5MG']</td>
            </tr>
            <tr>
          <td>PREDNISONE</td>
          <td>PARACORT</td>
          <td>PARKE DAVIS</td>
          <td>Approved Prior to Jan 1 1982</td>
          <td>TABLET;ORAL</td>
          <td>5MG</td>
            </tr>
            <tr>
          <td>PREDNISONE</td>
          <td>PREDNISONE</td>
          <td>ROXANE</td>
          <td>Approved Prior to Jan 1 1982</td>
          <td>TABLET;ORAL</td>
          <td>20MG</td>
            </tr>
            <tr>
          <td>PREDNISONE</td>
          <td>RAYOS</td>
          <td>HORIZON</td>
          <td>Jul 26 2012</td>
          <td>TABLET DELAYED RELEASE;ORAL</td>
          <td>['1MG' '2MG' '5MG']</td>
            </tr>
            <tr>
          <td>infliximab</td>
          <td>Remicade</td>
          <td>Janssen Biotech Inc.</td>
          <td>8/24/1998</td>
          <td>Intravenous</td>
          <td>100MG</td>
            </tr>
            <tr>
          <td>vedolizumab</td>
          <td>Entyvio</td>
          <td>Takeda Pharmaceuticals U.S.A. Inc.</td>
          <td>5/20/2014</td>
          <td>Intravenous</td>
          <td>300MG</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_534" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>CARBOPLATIN</td>
          <td>PARAPLATIN</td>
          <td>CORDEN PHARMA</td>
          <td>Mar 3 1989</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['450MG/VIAL' '150MG/VIAL' '50MG/VIAL']</td>
            </tr>
            <tr>
          <td>CARBOPLATIN</td>
          <td>PARAPLATIN</td>
          <td>CORDENPHARMA</td>
          <td>['Jan 15 2004' 'Jul 14 2003']</td>
          <td>INJECTABLE;INTRAVENOUS</td>
          <td>['150MG/15ML (10MG/ML)' '600MG/60ML (10MG/ML)' '450MG/45ML (10MG/ML)' '50MG/5ML (10MG/ML)']</td>
            </tr>
            <tr>
          <td>CISPLATIN</td>
          <td>CISPLATIN</td>
          <td>HQ SPCLT PHARMA</td>
          <td>Nov 8 1988</td>
          <td>INJECTABLE;INJECTION</td>
          <td>1MG/ML</td>
            </tr>
            <tr>
          <td>CISPLATIN</td>
          <td>PLATINOL</td>
          <td>HQ SPCLT PHARMA</td>
          <td>Approved Prior to Jan 1 1982</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['10MG/VIAL' '50MG/VIAL']</td>
            </tr>
            <tr>
          <td>CISPLATIN</td>
          <td>PLATINOL-AQ</td>
          <td>HQ SPCLT PHARMA</td>
          <td>Jul 18 1984</td>
          <td>INJECTABLE;INJECTION</td>
          <td>0.5MG/ML</td>
            </tr>
            <tr>
          <td>PEMETREXED</td>
          <td>PEMETREXED</td>
          <td>ACTAVIS LLC</td>
          <td>Aug 21 2020</td>
          <td>SOLUTION;INTRAVENOUS</td>
          <td>['1GM/40ML (25MG/ML)' '500MG/20ML (25MG/ML)' '100MG/4ML (25MG/ML)']</td>
            </tr>
            <tr>
          <td>PEMETREXED</td>
          <td>PEMFEXY</td>
          <td>EAGLE PHARMS</td>
          <td>Feb 8 2020</td>
          <td>SOLUTION;INTRAVENOUS</td>
          <td>500MG/20ML (25MG/ML)</td>
            </tr>
            <tr>
          <td>SELPERCATINIB</td>
          <td>RETEVMO</td>
          <td>LOXO ONCOLOGY INC</td>
          <td>May 8 2020</td>
          <td>CAPSULE;ORAL</td>
          <td>['80MG' '40MG']</td>
            </tr>
            <tr>
          <td>pembrolizumab</td>
          <td>Keytruda</td>
          <td>Merck Sharp & Dohme Corp.</td>
          <td>['9/4/2014' '1/15/2015']</td>
          <td>Intravenous</td>
          <td>['50MG' '100MG/4ML (25MG/ML)']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_535" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>ipilimumab</td>
          <td>Yervoy</td>
          <td>Bristol-Myers Squibb Company</td>
          <td>3/25/2011</td>
          <td>Intravenous</td>
          <td>['200MG/40ML (5MG/ML)' '50MG/10ML (5MG/ML)']</td>
            </tr>
            <tr>
          <td>nivolumab</td>
          <td>Opdivo</td>
          <td>Bristol-Myers Squibb Company</td>
          <td>['10/4/2017' '8/27/2021' '12/22/2014']</td>
          <td>Intravenous</td>
          <td>['240MG/24ML' '100MG/10ML' '120MG/12ML' '40MG/4ML']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_536" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>nivolumab</td>
          <td>Opdivo</td>
          <td>Bristol-Myers Squibb Company</td>
          <td>['10/4/2017' '8/27/2021' '12/22/2014']</td>
          <td>Intravenous</td>
          <td>['240MG/24ML' '100MG/10ML' '120MG/12ML' '40MG/4ML']</td>
            </tr>
            <tr>
          <td>ramucirumab</td>
          <td>Cyramza</td>
          <td>Eli Lilly and Company</td>
          <td>4/21/2014</td>
          <td>Intravenous</td>
          <td>['100MG/10ML (10MG/ML)' '500MG/50ML (10MG/ML)']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_540" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>DOCETAXEL</td>
          <td>DOCEFREZ</td>
          <td>SUN PHARM</td>
          <td>May 3 2011</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['80MG/VIAL' '20MG/VIAL']</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>DOCETAXEL</td>
          <td>ACCORD HLTHCARE</td>
          <td>['Apr 20 2012' 'Jun 8 2011']</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['80MG/4ML (20MG/ML)' '80MG/2ML (40MG/ML)' '20MG/ML (20MG/ML)' '20MG/0.5ML (40MG/ML)' '160MG/8ML (20MG/ML)']</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>DOCETAXEL</td>
          <td>ACTAVIS LLC</td>
          <td>['Sep 21 2015' 'Apr 12 2013']</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['160MG/8ML (20MG/ML)' '80MG/4ML (20MG/ML)' '20MG/ML (20MG/ML)' '140MG/7ML (20MG/ML)']</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>DOCETAXEL</td>
          <td>APOTEX INC</td>
          <td>Jan 11 2012</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['20MG/0.5ML (40MG/ML)' '80MG/2ML (40MG/ML)']</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>DOCETAXEL</td>
          <td>HOSPIRA INC</td>
          <td>['Jan 24 2017' 'Jun 23 2016' 'Mar 8 2011']</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['160MG/16ML (10MG/ML)' '80MG/4ML (20MG/ML)' '20MG/ML (20MG/ML)' '80MG/8ML (10MG/ML)' '120MG/6ML (20MG/ML)' '160MG/8ML (20MG/ML)' '20MG/2ML (10MG/ML)']</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>DOCETAXEL</td>
          <td>PFIZER LABS</td>
          <td>Mar 13 2014</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['200MG/20ML (10MG/ML)' '130MG/13ML (10MG/ML)' '80MG/8ML (10MG/ML)' '20MG/2ML (10MG/ML)']</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>DOCETAXEL</td>
          <td>SANDOZ</td>
          <td>Jun 29 2011</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['160MG/16ML (10MG/ML)' '80MG/8ML (10MG/ML)' '20MG/2ML (10MG/ML)']</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>DOCETAXEL</td>
          <td>SHILPA</td>
          <td>Dec 22 2015</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['160MG/8ML (20MG/ML)' '80MG/4ML (20MG/ML)' '20MG/ML (20MG/ML)']</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>DOCETAXEL</td>
          <td>SUN PHARM</td>
          <td>Jan 8 2019</td>
          <td>SOLUTION;INTRAVENOUS</td>
          <td>['160MG/8ML (20MG/ML)' '80MG/4ML (20MG/ML)' '20MG/ML (20MG/ML)']</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>TAXOTERE</td>
          <td>SANOFI AVENTIS US</td>
          <td>['Aug 2 2010' 'Aug 3 2010' 'Apr 13 2012' 'May 14 1996']</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['160MG/8ML (20MG/ML)' '80MG/4ML (20MG/ML)' '40MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**' '20MG/ML (20MG/ML)']</td>
            </tr>
            <tr>
          <td>nivolumab</td>
          <td>Opdivo</td>
          <td>Bristol-Myers Squibb Company</td>
          <td>['10/4/2017' '8/27/2021' '12/22/2014']</td>
          <td>Intravenous</td>
          <td>['240MG/24ML' '100MG/10ML' '120MG/12ML' '40MG/4ML']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_541" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>DOCETAXEL</td>
          <td>DOCEFREZ</td>
          <td>SUN PHARM</td>
          <td>May 3 2011</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['80MG/VIAL' '20MG/VIAL']</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>DOCETAXEL</td>
          <td>ACCORD HLTHCARE</td>
          <td>['Apr 20 2012' 'Jun 8 2011']</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['80MG/4ML (20MG/ML)' '80MG/2ML (40MG/ML)' '20MG/ML (20MG/ML)' '20MG/0.5ML (40MG/ML)' '160MG/8ML (20MG/ML)']</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>DOCETAXEL</td>
          <td>ACTAVIS LLC</td>
          <td>['Sep 21 2015' 'Apr 12 2013']</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['160MG/8ML (20MG/ML)' '80MG/4ML (20MG/ML)' '20MG/ML (20MG/ML)' '140MG/7ML (20MG/ML)']</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>DOCETAXEL</td>
          <td>APOTEX INC</td>
          <td>Jan 11 2012</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['20MG/0.5ML (40MG/ML)' '80MG/2ML (40MG/ML)']</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>DOCETAXEL</td>
          <td>HOSPIRA INC</td>
          <td>['Jan 24 2017' 'Jun 23 2016' 'Mar 8 2011']</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['160MG/16ML (10MG/ML)' '80MG/4ML (20MG/ML)' '20MG/ML (20MG/ML)' '80MG/8ML (10MG/ML)' '120MG/6ML (20MG/ML)' '160MG/8ML (20MG/ML)' '20MG/2ML (10MG/ML)']</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>DOCETAXEL</td>
          <td>PFIZER LABS</td>
          <td>Mar 13 2014</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['200MG/20ML (10MG/ML)' '130MG/13ML (10MG/ML)' '80MG/8ML (10MG/ML)' '20MG/2ML (10MG/ML)']</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>DOCETAXEL</td>
          <td>SANDOZ</td>
          <td>Jun 29 2011</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['160MG/16ML (10MG/ML)' '80MG/8ML (10MG/ML)' '20MG/2ML (10MG/ML)']</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>DOCETAXEL</td>
          <td>SHILPA</td>
          <td>Dec 22 2015</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['160MG/8ML (20MG/ML)' '80MG/4ML (20MG/ML)' '20MG/ML (20MG/ML)']</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>DOCETAXEL</td>
          <td>SUN PHARM</td>
          <td>Jan 8 2019</td>
          <td>SOLUTION;INTRAVENOUS</td>
          <td>['160MG/8ML (20MG/ML)' '80MG/4ML (20MG/ML)' '20MG/ML (20MG/ML)']</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>TAXOTERE</td>
          <td>SANOFI AVENTIS US</td>
          <td>['Aug 2 2010' 'Aug 3 2010' 'Apr 13 2012' 'May 14 1996']</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['160MG/8ML (20MG/ML)' '80MG/4ML (20MG/ML)' '40MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**' '20MG/ML (20MG/ML)']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_542" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>romiplostim</td>
          <td>Nplate</td>
          <td>Amgen Inc.</td>
          <td>['8/22/2008' '10/17/2019']</td>
          <td>Subcutaneous</td>
          <td>['125MCG' '250MCG' '500MCG']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_543" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>DOCETAXEL</td>
          <td>DOCEFREZ</td>
          <td>SUN PHARM</td>
          <td>May 3 2011</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['80MG/VIAL' '20MG/VIAL']</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>DOCETAXEL</td>
          <td>ACCORD HLTHCARE</td>
          <td>['Apr 20 2012' 'Jun 8 2011']</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['80MG/4ML (20MG/ML)' '80MG/2ML (40MG/ML)' '20MG/ML (20MG/ML)' '20MG/0.5ML (40MG/ML)' '160MG/8ML (20MG/ML)']</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>DOCETAXEL</td>
          <td>ACTAVIS LLC</td>
          <td>['Sep 21 2015' 'Apr 12 2013']</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['160MG/8ML (20MG/ML)' '80MG/4ML (20MG/ML)' '20MG/ML (20MG/ML)' '140MG/7ML (20MG/ML)']</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>DOCETAXEL</td>
          <td>APOTEX INC</td>
          <td>Jan 11 2012</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['20MG/0.5ML (40MG/ML)' '80MG/2ML (40MG/ML)']</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>DOCETAXEL</td>
          <td>HOSPIRA INC</td>
          <td>['Jan 24 2017' 'Jun 23 2016' 'Mar 8 2011']</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['160MG/16ML (10MG/ML)' '80MG/4ML (20MG/ML)' '20MG/ML (20MG/ML)' '80MG/8ML (10MG/ML)' '120MG/6ML (20MG/ML)' '160MG/8ML (20MG/ML)' '20MG/2ML (10MG/ML)']</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>DOCETAXEL</td>
          <td>PFIZER LABS</td>
          <td>Mar 13 2014</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['200MG/20ML (10MG/ML)' '130MG/13ML (10MG/ML)' '80MG/8ML (10MG/ML)' '20MG/2ML (10MG/ML)']</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>DOCETAXEL</td>
          <td>SANDOZ</td>
          <td>Jun 29 2011</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['160MG/16ML (10MG/ML)' '80MG/8ML (10MG/ML)' '20MG/2ML (10MG/ML)']</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>DOCETAXEL</td>
          <td>SHILPA</td>
          <td>Dec 22 2015</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['160MG/8ML (20MG/ML)' '80MG/4ML (20MG/ML)' '20MG/ML (20MG/ML)']</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>DOCETAXEL</td>
          <td>SUN PHARM</td>
          <td>Jan 8 2019</td>
          <td>SOLUTION;INTRAVENOUS</td>
          <td>['160MG/8ML (20MG/ML)' '80MG/4ML (20MG/ML)' '20MG/ML (20MG/ML)']</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>TAXOTERE</td>
          <td>SANOFI AVENTIS US</td>
          <td>['Aug 2 2010' 'Aug 3 2010' 'Apr 13 2012' 'May 14 1996']</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['160MG/8ML (20MG/ML)' '80MG/4ML (20MG/ML)' '40MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**' '20MG/ML (20MG/ML)']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_544" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>REGORAFENIB</td>
          <td>STIVARGA</td>
          <td>BAYER HLTHCARE</td>
          <td>Sep 27 2012</td>
          <td>TABLET;ORAL</td>
          <td>40MG</td>
            </tr>
            <tr>
          <td>atezolizumab</td>
          <td>Tecentriq</td>
          <td>Genentech Inc.</td>
          <td>['5/18/2016' '3/8/2019']</td>
          <td>Intravenous</td>
          <td>['840MG/14ML (60MG/ML)' '1200MG/20ML (60MG/ML)']</td>
            </tr>
            <tr>
          <td>bevacizumab</td>
          <td>Avastin</td>
          <td>Genentech Inc.</td>
          <td>2/26/2004</td>
          <td>Intravenous</td>
          <td>['400MG/16ML (25MG/ML)' '100MG/4ML (25MG/ML)']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_548" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>REGORAFENIB</td>
          <td>STIVARGA</td>
          <td>BAYER HLTHCARE</td>
          <td>Sep 27 2012</td>
          <td>TABLET;ORAL</td>
          <td>40MG</td>
            </tr>
            <tr>
          <td>atezolizumab</td>
          <td>Tecentriq</td>
          <td>Genentech Inc.</td>
          <td>['5/18/2016' '3/8/2019']</td>
          <td>Intravenous</td>
          <td>['840MG/14ML (60MG/ML)' '1200MG/20ML (60MG/ML)']</td>
            </tr>
            <tr>
          <td>bevacizumab</td>
          <td>Avastin</td>
          <td>Genentech Inc.</td>
          <td>2/26/2004</td>
          <td>Intravenous</td>
          <td>['400MG/16ML (25MG/ML)' '100MG/4ML (25MG/ML)']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_554" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>CAPECITABINE</td>
          <td>XELODA</td>
          <td>HOFFMANN LA ROCHE</td>
          <td>Apr 30 1998</td>
          <td>TABLET;ORAL</td>
          <td>['150MG' '500MG']</td>
            </tr>
            <tr>
          <td>bevacizumab</td>
          <td>Avastin</td>
          <td>Genentech Inc.</td>
          <td>2/26/2004</td>
          <td>Intravenous</td>
          <td>['400MG/16ML (25MG/ML)' '100MG/4ML (25MG/ML)']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_558" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>pembrolizumab</td>
          <td>Keytruda</td>
          <td>Merck Sharp & Dohme Corp.</td>
          <td>['9/4/2014' '1/15/2015']</td>
          <td>Intravenous</td>
          <td>['50MG' '100MG/4ML (25MG/ML)']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_559" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>trastuzumab</td>
          <td>Herceptin</td>
          <td>Genentech Inc.</td>
          <td>['2/10/2017' '9/25/1998']</td>
          <td>Intravenous</td>
          <td>['150MG' '420MG']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_562" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>IBRUTINIB</td>
          <td>IMBRUVICA</td>
          <td>PHARMACYCLICS INC</td>
          <td>['Feb 16 2018' 'Dec 20 2017' 'Nov 13 2013']</td>
          <td>['CAPSULE;ORAL' 'TABLET;ORAL']</td>
          <td>['140MG' '280MG' '420MG' '560MG' '70MG']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_563" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>REGORAFENIB</td>
          <td>STIVARGA</td>
          <td>BAYER HLTHCARE</td>
          <td>Sep 27 2012</td>
          <td>TABLET;ORAL</td>
          <td>40MG</td>
            </tr>
            <tr>
          <td>nivolumab</td>
          <td>Opdivo</td>
          <td>Bristol-Myers Squibb Company</td>
          <td>['10/4/2017' '8/27/2021' '12/22/2014']</td>
          <td>Intravenous</td>
          <td>['240MG/24ML' '100MG/10ML' '120MG/12ML' '40MG/4ML']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_565" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>durvalumab</td>
          <td>Imfinzi</td>
          <td>AstraZeneca UK Ltd</td>
          <td>5/1/2017</td>
          <td>Intravenous</td>
          <td>['120MG/2.4ML (50MG/ML)' '500MG/10ML (50MG/ML)']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_566" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>ipilimumab</td>
          <td>Yervoy</td>
          <td>Bristol-Myers Squibb Company</td>
          <td>3/25/2011</td>
          <td>Intravenous</td>
          <td>['200MG/40ML (5MG/ML)' '50MG/10ML (5MG/ML)']</td>
            </tr>
            <tr>
          <td>nivolumab</td>
          <td>Opdivo</td>
          <td>Bristol-Myers Squibb Company</td>
          <td>['10/4/2017' '8/27/2021' '12/22/2014']</td>
          <td>Intravenous</td>
          <td>['240MG/24ML' '100MG/10ML' '120MG/12ML' '40MG/4ML']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_567" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>IBRUTINIB</td>
          <td>IMBRUVICA</td>
          <td>PHARMACYCLICS INC</td>
          <td>['Feb 16 2018' 'Dec 20 2017' 'Nov 13 2013']</td>
          <td>['CAPSULE;ORAL' 'TABLET;ORAL']</td>
          <td>['140MG' '280MG' '420MG' '560MG' '70MG']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_570" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>cetuximab</td>
          <td>Erbitux</td>
          <td>Eli Lilly and Company</td>
          <td>['3/28/2007' '2/12/2004']</td>
          <td>Intravenous</td>
          <td>['100MG/50ML (2MG/ML)' '200MG/100ML (2MG/ML)']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_572" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>belatacept</td>
          <td>Nulojix</td>
          <td>Bristol-Myers Squibb Company</td>
          <td>6/15/2011</td>
          <td>Intravenous</td>
          <td>250MG</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_576" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>brentuximab vedotin</td>
          <td>Adcetris</td>
          <td>Seagen Inc.</td>
          <td>8/19/2011</td>
          <td>Intravenous</td>
          <td>50MG</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_578" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>durvalumab</td>
          <td>Imfinzi</td>
          <td>AstraZeneca UK Ltd</td>
          <td>5/1/2017</td>
          <td>Intravenous</td>
          <td>['120MG/2.4ML (50MG/ML)' '500MG/10ML (50MG/ML)']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<center><button type="submit" value="submit">Submit</button></center></div></form><br><p><strong> <em>Disclaimer: This weekly digest is a product created exclusively by Lexidyne LLC, in collaboration with Janssen. The intended purpose is to identify clinical phase assets with new data related to lung cancer, priority mechanisms of action, local/intratumoral delivery, and/or increased potency for acquisition & business development consideration. </em> </strong></p><p><em>Sources used include but are not limited to: PubMed, ClinicalTrials.gov, ASCO, AACR, NIH, EU Clinical Trials Register, European Pharmaceutical Review, FDA.gov, PRNewsWire, FiercePharma, and BioSpace. </em> </p><center><div class="subscription"><a href="https://docs.google.com/forms/d/e/1FAIpQLSffyxD4xZGkc99oZTy9lF0xPdIaqUMfCVpI2lWJzBkH3uDEag/viewform" target="_blank">Subscribe</a></div><div class="subscription"><p>|</p></div><div class="subscription"><a href="https://docs.google.com/forms/d/e/1FAIpQLSdaRqTScaPylLdbIIgAaWs3eYn3wMcF_qF408_-D9caWHAgLw/viewform" target="_blank">Unsubscribe</a></div><div class="subscription"><p>|</p></div><div class="subscription"><a href="https://docs.google.com/forms/d/e/1FAIpQLSdSCfl2l2sV2jo-vFfym-VPpzyEs5M0cRRPY5TmBIZ-nR6gSQ/viewform" target="_blank">Feedback</a></div></center>
